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Abstract 
This study has examined complement component six (C6) 
protein alleles and restriction fragment length 
polymorphisms (RFLP) in Caucasian systemic lupus 
erythematosus (SLE) patients and healthy individuals. The 
protein studies showed that SLE patients and the healthy 
group had very similar protein allele distributions . Four 
rare-protein types in five patients were f ound and one in 
the healthy group . Both groups showed allele frequencies 
very similar to pooled published Caucasian data and allele 
frequencies did not differ from Hardy-Weinberg equilibrium 
values. Therefore there was no evidence that deficiency 
or partial deficiency of complement component six is a 
major contributor to inherited predisposition to SLE . 
SLE patients and healthy individuals showed identical 
Taq I RFLP phenotypes. Allele frequencies for this 
polymorphic site were very similar in the SLE patients, 
healthy group and published Spanish data and these did not 
differ from Hardy-Weinberg equilibrium values. No maj or 
gene rearrangements were indicated in any of the samples 
examined. Three heterozygous rare-protein typed samples; 
BM91, BB2 and AB1 were Taq I RFLP typed and these showed 
identical patterns to common protein types. 
The protein and Taq I RFLP alleles were not 
concordant , demonstrating that C6 Taq I RFLP analysis is 
not an adequate predictor of C6 protein type. Three 
methods of linkage disequilibrium estimation were utilised 
and all three demonstrated a significant association 
between the C6*A protein allele and RFLP 8 . 0 allele, as 
well as between the C6*B protein allele and RFLP 7.0 
allele However, measurements o f linkage disequilibrium 
are of conflicting validity and a discussion of the 
arguments is presented. 
The C6 protein has been known to be 
electophoretically polymorphic for more than ten years. 
The present study was aimed at determining the molecular 
basis of the common A/ B protein allelism and four protein 
variants; Al, B2, M91 and B21. The technique of single-
stranded conformation polymorphism analysis (SSCP) was 
chosen as a mutation screening method f or the present 
study because of its simplicity, inexpense, sensitivity 
and the availability of information relating to 
~l 
intron/exon boundaries . The entire C6 coding region was 
screened for polymorphisms using this technique and 
variant SSCP patterns were investigated by cloning and 
sequencing the variant samples . 
A base difference between the two published C6 cDNA 
sequences was found to affect a Dde I restriction enzyme 
site, allowing investigation of this site using PCR and 
digest analysis . A perfect correlation between the common 
C6 protein allelism and Dde I pattern was found. Protein A 
alleles have an additional Dde I site, resulting from the 
sequence GAG at amino acid 98, a negatively charged 
glutamic acid residue, while B alleles lack this site and 
have a GCG codon , resulting in a non-polar alanine 
residue. The computer program, Isoelectric, was used to 
predict pI values for these alleles based on these 
sequence changes . C6*A alleles have a predicted pI of 
6 . 64 and C6*B alleles 6 .7 1 . This is in good agreement 
with isoelectric focusing (IEF) results. 
SSCP analysis resulted in seven variant patterns . 
One of these appeared to be an artifact. Five others, in 
exons; one , three, 10 , 12 and 13 correlated with altered 
DNA sequences . A further variant did not correlate with a 
specific DNA change but four polymorphisms were sequenced 
from that exon . Three polymorphisms were not identified 
with SSCP , these related to protein alleles; Al, B21 and 
M91. Two variant SSCP patterns correlated with protein 
alleles , exon three with the common C6 A/ B allelism and 
exon 12 with the B2 allele . The exon 12 polymorphism was 
identified as an A to G substitution, affecting amino acid 
630 . This causes an acidic, glutamic acid residue to be 
replaced with a polar , glycine molecule. The predicted pI 
for this protein allele is 6 . 71, assuming an A allele 
background, and 6 . 77 assuming a B allele background. 
These estimates are in good agreement with IEF results. 
Four DNA changes ; three in exon 11 and one in exon 13 
resulted in amino acid substitutions that altered the 
charge of the C6 protein . These however were not 
indicated with IEF, highlighting the complexities of 
predicting protein structure from DNA sequence data. 
The level of polymorphism found in the C6 DNA 
sequence appears to be considerably greater than that 
known from C6 protein studies . A significant clus ering 
of mutations was found in the C6 gene. Seven of nine 
V ll 
polymorphisms identified were located between exo n s 1 0 and 
13. Exon 11 appears to be a particularly polymorphi c 
region with f our polymorphisms sequenced in this area and 
a further two indi cated with PCR-digest analysis . This 
non-random distribution o f polymorphisms may result from 
several genetic mechanisms, f o r example gene conversion, 
differential mutati on rates and template mutagenesis. 
Five C6 DNA p o lymorphisms, in exons; three 10, 11, 
and 13 were examined in several population groups ; 
Aboriginal Australians , Caucas ians, Mi c r onesians and 
Polynesians. All of these polymorphisms were f ound in the 
groups examined, demonstrating that they predate emergence 
of these ethnic groups. Two of these polymo rphisms were 
found in a small sample of chimpanzees indicating they 
were likely to be ancient mutational events, occurring 
prior to human-chimpanzee divergence around five milli on 
years ago . The occurrence and transmission of these 
polymorphisms across species boundaries provides further 
evidence for the multiple-origin and trans- spe cies 
hypotheses of evolution . These theories suggest that the 
shared polymorphisms existed in a populatio n o f common 
ancestors that gave rise to the present-day species and 
that the polymorphisms have been maintained through 
selection , often up to millions of generations . 
Definition of the molecular basis of C6 polymorphisms 
and the identification of further sequence changes enables 
the C6 gene to be utilised as a useful, p o l ymorph i c marker 
in population, evolution, disease - susceptibility and 
linkage studies . 
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Chapter 1 
Chapter 1. 
General Introduction 
1.1 Function of the Complement System 
The complement system is a maj o r effector mechanism 
in humoral immunity and is also capable of lysing cellular 
antigens directly. Complement is activated by the 
presence of circulating immune complexes and also by less 
specific nonimmunoglobulin activators such as bacterial 
components , microbial particles and cell wall 
polysaccharides from other antigens (Bentley 1988) It 
consists of ; 1) the classical pathway, 2) the alternative 
(or properdin) pathway , 3) the terminal membrane attack 
complex , into which 1) and 2) feed, and 4) complement 
regulators and receptors . These pathways are made up of 
approximately 30 distinct plasma proteins (Cooper et al 
1988) . Figure 1 . 1 shows the complement cascade 
diagrammatically . 
1.1.1 Classical Pathway 
Components of the classical pathway are Cl, C2 and 
C4 . Cl consists of three subunits Clq , Clr and Cls which 
are held together by calcium (Schumaker et al 1987) . 
Activation of this pathway is through binding of immune 
complexes IgG or IgM to Clq, causing a conformational 
change within the Cl complex . This allows autoactivation 
of proenzyme Clr (Arlaud et al 1986) which in turn 
activates Cls (Valet and Cooper 1974) . Down-regulation of 
this step is by Cl inhibitor, which binds tightly to 
activated Cl and its derivatives (Sim et al 1979, Ziccardi 
and Cooper 1979). The Cl complex then activates C4 to 
form C4b which attaches to the surface of the initiating 
immune complex . Utilising another site C4b interacts with 
the inactive form of C2 . This interaction is Mg 2+ 
dependent (Sitomer et al 1966) and probably involves the 
N-terminal domain of C2 (C2b) (Nagasawa and Stroud 1977, 
Kerr 1980). C2 is then activated by Cl to form the 
classical pathway C3 convertase . This molecule can then 
activate C3 by cleaving a polypeptide bond to yield two 
fragments; C3a and C3b. C3 convertases are subsequently 
modified by binding of further C3b so that they become CS 
convertases (Medicus et al 1976, Vogt et al 1978). CS 
2 
Figure 1.1 The Complement Cascade . Major activation steps 
in the classical and alternative pathways are shown . 
Activation of the classical pathway is thought to be 
triggered primarily by immune complexes while the 
alternative pathway is initiated by a wide range of 
compounds and surfaces . These two pathways lead into the 
terminal cascade and cell lysis . Reproduced with 
permission, from Reid 1989, fig 1 . 
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convertases cleave CS v i a proteolysis yielding CSa and 
CSb , thus initiating the terminal portion of complement ; 
the membrane attack complex. 
1.1.2 Alternative Pathway 
The alternative complement pathway is usually 
triggered nonimmunologically by complex polysaccharide s , 
certain viruses, virus infected cells , lipopolysacchar i des 
and other diverse substances (Cooper and Nemerow 1983). 
Activation can also occur via certain immune complexes . 
Initiation is through binding of either a chemi cally 
altered form of C3 or C3b to the surface o f an activator. 
Bound C3 or C3b then binds the terminal domain of fact o r B 
(homologous to C2) in a Mg 2+ dependent interaction (Vogt 
et al 1977). Factor B can then be cleaved into fragment s 
Bb and Ba by factor D, a plasma proteolytic enzyme. The 
resultant complex is an indigenous proteolyti c enzyme (C3 
convertase) which is stabilised by binding of a non-
catalytic component, properdin (Medicus et al 1 980) . 
Subsequent steps are similar to the classical pathway as 
desscribed above. 
1.1.3 Complement Inactivation 
Both classical and alternative pathway C3 convertases 
are inactivated by dissociation of the components and then 
proteolytic degredation of C3b and C4b. Dis sociation o f 
C2a from C4b is accelerated by C4b -binding protein (C4BP) 
which competes with C2a for binding sites on C4b (G igli 
et al 1979) . C4BP acts then as a co-factor rendering C4b 
susceptible to cleavage by serine protease fact or I 
(Fujita et al 1978, Fujita and Nussenzweig 1979) . Factor 
H similarly dissociates Bb from C3b (Gigli et al 1979) as 
well as acting as a co -factor for cleavage o f C3b by 
factor I (Whaley and Ruddy 1976, Weiler et al 1976) . Two 
additional complement regulat o rs; complement receptor type 
1 (CRl) and decay-accelerating factor (DAF ) functi on to 
accelerate dissociation o f both c lassical and alternative 
pathway C3 convertases . CRl and another regulator called 
membrane cofactor protein, MCP ( formerly; glycoprotein 45-
70 or gp45-70) act as cofactors for cleavage of C4b and 
C3b by factor I . Clearance of C3 b /C 4b coated immune 
complexes and microorganisms occurs via int eraction o f CRl 
5 
and a second receptor, CR2 with the C3 b and C4b fr agmen ts 
(Holers et al 1985 ) . 
1.1.4 Membrane Attack Complex (MAC) 
The terminal complement pathway is quite rema rka ble 
in that the water soluble hydrophilic component s CSb t o C9 
undergo a hydrophilic-amphiphilic transiti on vi a a non-
enzymatic self-assembly mechanism to form the MAC c omplex. 
This structure creates transmembrane channels by 
displacing lipid molecules and plasma membrane 
constituents, resulting in disruption of the phospholipid 
bilayer of target cells. Cell lysis and death f o llow thi s 
disruption (review Muller-Eberhard 1986). The MAC pathway 
is initiated after proteolysis of CS by CS convertase 
(both classical and alternative pathway forms) resulting 
in CSa and b . The activated CS ; CSb , loosely bound to 
C3b , develops a transient binding site for C6 leading to 
formation of a stable CSb-6 dimer . Subsequent binding of 
C7 results in formation of a CSb - 7 complex . This complex 
appears to unde r go a hydrophilic - amphiphilic transition 
resulting in the expression of a high affinity lipid 
binding site that mediates a strong , non-covalent 
interaction between the developing complex and target 
membranes (Muller-Eberhard 1986) . The CSb-7 complex then 
dissociates from C3b . Failure of the CSb-7 complex to 
bind a membrane surface at this stage results in the loss 
of its potential cytolytic activity . Self aggregation o f 
the complex then takes place in the fluid phase (Figure 
1 . 2) . Binding of the three subunit protein C8 to the CSb-
7 complex , utilising one subunit, the C8 ~ chain, (Monahan 
and Sodetz 1981) is thought to bring about a 
conformational change in C8 . This change allows the 
disulfide-linked a and possibly y chains to penetrate the 
hydrophobic core of the lipid bilayer of the membrane to 
which the CSb-7 complex is attached . The exact functi on 
of C8y , however remains unclear (Haefliger et al 1991 ) . 
The CSb-8 complex is capable of slowly lysing erythrocytes 
and some nucleated cells however it primarily fun c ti on s as 
a receptor for C9 . CSb-8 binds C9 and in so do ing 
catalyses polymerisation of C9 resulting in typi ca l 
membrane lesions as s een in target cells. The MAC i s 
composed of one molecule of each of CSb, C6, C7, C8 a nd 
somewhere between one and 18 C9 molecules (review Reid 
6 
Figure 1.2 Assembly of the Membrane Attack Complex. 
Components five to nine self-aggregate to form 
transmembrane channels, causing cell lysis . Control of 
this process is via S-protein. The asterisks ( * ) denote 
metastable forms of C5b and C5b-7, respectively . 
Reproduced, with p~rmission, from Muller-Eberhard 1986, 
fig 1 . 
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1988) . Binding of the first molecule is through the C8 
component but how the binding of one C9 molecule then 
allows high affinity C9-C9 interactions is not clear. It 
is thought that the relatively hydrophobic C-terminal half 
of each C9 molecule is inserted into the phospholipid 
membrane during lesion formation. The availability of 
monomeric C9 determines the type of lesion found, if 
sufficient C9 is present then discrete cylinder like 
membrane lesions are seen (Figure 1.3). Low levels of C9, 
relative to CSb-8, effectively prevent the formation of 
typical membrane lesions , however membrane damage can 
occur without the cylindrical lesions (Dankert and Esser 
1985). It appears then that formation of the cylindrical 
complex is not a prerequisite for cell lysis. 
It is becoming clear that the MAC can cause some 
subtle and transient changes in nucleated cells without 
irreversibly damaging the cell . Several studies have 
shown that most cell types are relatively resistant to 
lysis by the MAC because of the presence of protective 
.mechanisms (Koski et al 1983, Ramm et al 1983, Morgan 
et al 1984) . MACs in the neutrophil are removed from the 
cell surface by endocytosis and vesiculation (Campbell and 
Morgan 1985, Morgan et al 1987) which allows these cells 
to recover from complement attack. Cell lysis is however 
not the only effect of the MAC since non-lethal amounts of 
the complex can cause activation of cellular processes, 
often resulting in production and release of toxic 
reactive oxygen metabolites and metabolites of 
arachiodonic acid (Morgan and Campbell 1985, Imagawa et al 
19 8 7 ) . 
1.1.4.1 Regulation of the MAC 
A single chain plasma glycoprotein, called S-protein 
is thought to be the primary regulating protein of the 
CSb-9 complex . Up to three molecules of S-protein (or 
vitronectin) can bind to the CSb-7 complex, preventing the 
complex from binding to cell surfaces which protects 
neighbouring cells from lysis by the MAC. The resultant 
free S-C5b-7 complex can bind C8 and then C9, forming S-
CSb-9, however polymerisation of C9 does not follow. Two 
possible mechanisms for S-protein regulation include; 1 ) 
preventing the conformational change in C9 that is 
9 
Figure 1.3 Models for CSb-9 and the fluid phase SCSb-9 
complexes. Diagrams (a) to (c) represent the assembly of 
MAC CSb-8 complex in association with poly C9 . Panels (d) 
and (e) represent models f o r SCSb-9 containing C9 in 
globular (d) , or partially unfolded form (e ) . Reproduced, 
with permission, from Podack et al 1984, fig 7 . 
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apparently a prerequisi te for polymerisation, o r 2) 
allowing conformation changes to occur but causing steric 
hindrance of the polymerisation process (Podac k et al 
19 84) . 
1 . 1.5 Complement Regulators and Receptors 
Activation and control o f the complement system is 
mediated in several different ways , some o f which have 
been mentioned above. The C3 and CS convertases have a 
short half life due to dissociation o f C2a and Bb . 
Additionally the activity of C3 and CS convertases is 
regulated by a number of plasma proteins and membrane 
bound receptors (Reid et al 1986, Kristensen et al 1987 ) . 
Table 1 . 1 summarises the role, specificity and geneti cs of 
these factors. 
1.2 Genetics of the Complement System 
The molecular cloning of most of the components, 
regulatory proteins and membrane receptors of the 
complement system has provided information about the 
structure , function, biosynthesis and genetics o f these 
glycoproteiris . Such studies have also emphasised the 
similarities and differences between components which 
allows them to be divided into families of st ructur ally 
and functionally related proteins . Campbell et al (1988) 
describes six distinct groups whereas additional work has 
separated some of these families into smaller groups 
(Hobart et al 1993a, Kaufmann et al 1993). This study 
will divide the components into eight families; 1) Cl 
complex and Cl-inhibitor, 2) Components C2, fact or B and 
C4 - the HLA class III complement genes, 3) Components C3 
and CS , 4) Factor I and the regulati on o f complement 
activation cluster ; C4BP , fact o r H, CRl , CR2 , DAF, MCP, 5) 
Cell adhesion glycopro tein family; CR3 , plS 0 , 95 , and other 
recept o r proteins, 6) Properdin, 7) MAC cluster I; C8a, 
esp (C8y) , and 8) MAC cluster II; C6 , C7 and C9 , 
1.2.1 Cl Complex and Cl Inhibitor 
1.2.1.1 Clq 
The Cl complex consists o f subcomponent s Clq , Clr and 
Cls. Molecular cloning o f Clq A (Sel lar et al 1987), B 
(Reid 1985) and C chains (Selle r et al 1991) has provided 
cDNA probes which have been used to identify monocyte s and 
C''J 
r--1 
Table 1 . 1 Regulat ory plasma proLeins and membrane recept o rs of the complement system 
Protein 
Cl -INH 
C4BP 
MCP 
( CD 4 6) 
Dl\F 
Mo l ecular Specificity 
weight 
Chromosome 
location 
Amino 
acids 
Gene 
(kb) 
( in kd) 
110 Clr , Cls llpll.2 -ql3 478 17 
540 C4b lq32 3843 30 
(7 X 549) 
45-70 C4b , C3b lq32 384 43 
70 C3 convertase lq32 440 /38 1 40 
Properdin 220 C3bBb XplL . 2-Xpll.3 442 6 
(monomer) 
Factor H 155 C3b lq32 1213 90 
Exons 
8 
18 
14 
11 
10 
? 
Number 
SCRs 
0 
56 
4 
4 
6 
20 
Role 
Inactivation of 
Clr and down 
regulation of 
complement 
activity 
Co factor for C4 
degradation by 
factor I 
Similar cofactor 
activity to C4bp 
Regulati on of C3 
convertase 
Up regulation of 
C3bBb 
(C3 convertase) 
Accelerates decay 
of C3bBb , acts as 
a cofactor for 
factor I 
Cl-INH = complement component l inhibitor, C4bp = complement component4 binding protein, MCP 
= membrane cofactor protein, OAP= decay accelerating factor, 
(', 
.-j 
Table 1.1 continued 
Protein 
CRl A 
B 
C 
D 
CR2 
CR] 
CR 4 
S-protein 
Molecular Specificity 
weight 
( in kd) 
250 ] 
290 J C3b , C4b 
330 ] 
210 ] 
145 C~dg , C3d 
165 i C3b 
95 
? C3dg 
80 CSb-9 
(v itronectin) 
Chromosome 
location 
1q32 
lq32 
~; 21 
a; 16p 
? 
? 
CRl I 2, 3 / 4 - complement r ecepto r type 1, -
Amino 
acids 
1800 
1013 
p;7 69 
? 
Gene 
(kb) 
13]-
1 6 0 
30 
? 
') 
2 / 3 / and 4, ? = 
Exons 
39 
47 
55? 
'1 1 ? 
_J • 
19 
? 
Number 
SCRs 
28 
l_ 6 
') 
? 
Role 
RegulaLi o n of C3b 
breakdown,binding 
immune complexes 
to erythrocytes 
phagocyt os is,decay 
acceleration of 
C:3 , C5 convectases 
Regulation o f B 
cell functions, 
Epstein-Barr 
virus receptor 
Aids cellular 
destruct ion of 
pathogens,enhances 
ingestion,possibly 
memory related 
Binds C3 dg /C3 d on 
neutrophils a.nd 
platelets 
Regulation of 
cytolytic 
damage by MAC 
as yet unknown. 
"'11 
' ~ 
Table 1.1 continued 
Protein 
Factor I 
factor D 
plS0 , 95 
CS a 
C3e 
receptor 
C3a 
receptor 
Factor H 
receptor 
Molecular Specificity Chromosome 
weight location 
(in kd) 
88 C4b, C3b 4q25 
24 Fa ctor B-CJ ? 
150,95 iC3b ? 
45 CS a ? 
? C3e ? 
? C3a, C4a ? 
so factor H ? 
? = as yet unknown. 
Amino 
acids 
583 
228 
? 
350 
? 
? 
') 
Gene 
(kb) 
25 
? 
? 
? 
? 
? 
? 
Exons 
~ 
? 
? 
? 
? 
? 
') 
Number Role 
SCRs 
0 
? 
? 
? 
? 
? 
? 
Inactivates 
C4b /C3b 
convertase of 
alternative 
pathway 
Activates CJ 
Augments 
phagocytos is 
Secretion, 
ce llular 
a ct ivation, 
c hemotaxis 
Leucocyt osis 
Secretion, 
c ellular 
activation 
Fa ctorI secretion 
blastogenesis, 
induction of 
respiration 
bursts 
Data taken from review by Reid 1ogg and a range of mo re recer1t research publications in te x t . 
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macrophages as the probable major source of serum Clq . 
Also arising from this work is the ability to identify 
mutations causing Clq deficiency . Clq deficiency can be 
classified into three f o rms ; 1) partial, 2) complete and 
3) complete functional deficiency (Loos and Heinz 1986, 
Reid 1989) . A study by McAdam et al (1988) has identified 
the defect causing the deficiency in one case but it 
appears that Clq deficiency has several different causes . 
The genes for the A, Band C cha ins are in the order A-C-B 
on a 24 kb stretch of DNA on chromosome lp. The A, B, and 
C chain genes are 2 . 5, 2 . 6 and 3 . 2 kb long respectively 
and each contains one intron . Sellar et al (1991) reports 
that there is only one gene per chain and no major gene 
rearrangements were found after RFLP analysis of Clq 
deficient individuals . 
1.2.1.2 Clr and Cls 
The Clr and Cls 
of an A and B chain . 
cloned (Leytus et al 
proteins are 166 kDa and are composed 
The genes for Clr and Cls have been 
1986 and Tosi et al 1987) and 
localised to a 50 kb stretch of DNA on chromosome 12p13 
(Tosi et al 1987) . These proteins posess interesting 
repeating sequences , called short consensus repeats (SCR), 
which are found i n a number of other complement components 
and regulators. These SCRs consist of approximately 60 
amino acids and are characterised by a consensus of four 
conserved cysteine residues , highly conserved praline and 
glycine residues , a tryptophan residue and a tyrosine or 
phenylalanine residue . 
Deficiencies of Clr and Cls have been reported 
(review Reid 1989) but are quite rare . As yet no genetic 
studies have described a mutation which may account for 
these deficiencies. 
1.2.1.3 Cl Inhibitor (Cl-INH) 
Cl-INH is a regulatory glycoprotein which has 
considerable homology with members of the serpin family of 
inhibitors of serine esterases . Genetic characteristics 
of Cl-INH are listed in Table 1 . 1 . 
1.2.2 Components C2, Factor Band C4 - HLA Class III 
Complement Genes 
1 6 
C2, C4 and factor B genes form a tight cluster along 
with the 21-hydroxylase gene in the HLA region on 
chromosome 6p13 (Franke and Pellegrino 1977 , Carroll et al 
1988) . The class I and II HLA genes on chromosome six 
code for highly polymorphic cell surface antigens involved 
in the immune response, the class III proteins C2, C4 and 
factor Bare also polymorphic but show no structural 
similarity to class I and II gene products . 
1.2.2.1 Complement Component Two (C2) 
C2 is a 102 kDa serine protease consisting of 734 
amino acids . The gene for C2 is approximately 18 kb 
(Campbell 1987) and consists of 18 exons (Ishii et al 
1993) . C2b possesses three SCR modules which are encoded 
by single exon s . Def i ciency of C2 is one of the most 
common human complement component deficiencies (Glass 
et al 1976) a n d more than half of the C2 deficient 
individuals have rheumatological disorders such as SLE, 
Henoch-Schonlein purpura and polymyositis. Johnson et al 
(1993) report that one common type of C2 deficiency is 
caused by a 28 bp genomic deletion that causes skipping of 
exon six during RNA spl i c i ng and subsequent generation of 
a premature termination codon . As yet the DNA mutation 
givi ng rise to the second type of C2 deficiency has not 
been identified . 
1.2.2.2 Factor B 
Factor Bis a 92 kDa serine protease consisting of 
739 amino acids . It is highly polymorphic with up to 18 
alleles defined by differences in electrophoretic mobility 
in agarose gels (Alper et al 1972) . Two of these alleles 
are common while the remaining 16 are rare . Campbell 
(1987) reports that there is only one amino acid residue 
difference between che two common alleles, consisting of a 
glutamine (F allele) to arginine (S allele) substitution 
at residue seven . The gene for factor Bis six kb, cDNA 
2388 bp and consists of 18 exons (Campbell et al 1985) . 
Like C2, factor Bis a mosaic structure made up of three 
domains apparently derived from three distinct gene 
superfamilies . Three exons exactly encode the three SCR 
modules within the Ba fragment . The middle domain of 
17 
factor B (residues 235-457) is structurally similar t o t he 
type A domain of von Willebrand factor (vWF ) (Manc u so e t al 
1989) . The carboxy terminal domain of fact o r Bi s 
structurally similar to serine proteases and contains 
eight exons which encode the active centre of the C3 and 
CS convertases of the alternative pathway. 
The homology of structure and function in the C2 and 
factor B proteins plus the close linkage of the genes 
suggests they arose from an ancestral gene by duplicati on. 
Despite these apparent similarities there is a ten fold 
difference in amounts of these proteins in plasma and a 
three fold difference in gene length. Homozygous 
deficiency of factor B has not been reported in man or 
other species , suggesting that it may be a lethal 
condition (Reid 1988) and reports of heterozygous 
deficiency are rare. 
1.2.2.3 Complement Component Four {C4) 
The C4 protein occurs as two isotypes, C4A and C4B 
which are distinguishable by their electrophoretic 
mobility on agarose gels and their relative hemolytic 
activity (Awdeh and Alper 1980) . C4A and Bare more than 
99 percent homologous (Belt et al 1984) and the main 
difference between them appears to be the reactivity of 
their thiol esters (Bentley 1988) . Four amino acids are 
responsible for this difference . The C4A and C4B proteins 
are highly polymorphic with at least 35 different alleles 
described (Mauff et al 1983) . C4A and C4B are coded for 
by two genes in tandem , approximately 10 kb apart . 
Comparison of the C4A and C4B cDNA sequences revealed only 
14 nucleotide differences (Belt et al 1984 , 1985), and of 
these 12 were found in the C4d region , containing the 
potential thiolester site. These nucleotide changes give 
rise to nine amino acid substitutions (Belt et al 1984) . 
One further difference in the C4d region (Belt et al 1985, 
Yu et al 1986) and six others determined by protein 
sequencing (Chakravarti et al 1983, 1987, Law and Gagnon 
1985) suggest that 18 positions in the C4 molecule show 
amino acid substitutions . A nine bp deletion coding f o r 
residues 1397-1399 (Belt et al 1984) has been described in 
both C4A and C4B (Law and Gagnon 1985), but it is not 
clear whether this is real or a cloning artifact (Campbell 
l 
et al 1990) . These amino acid changes relate t o anti geni c 
differences among allotypes, in addition t o allelic 
differences. DNA sequencing of C4 alleles has shown tha t 
o\le.Jes 
there are more than was indicated with protein typing. 
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For example two different C4A3 allotypes have been defined 
(Belt et al 1984, 1985, Yu et al 1986) which differ at 
position 1267 due to an alanine to serine substituti on. 
Likewise two different C4Bl allotypes have been defined 
which differ at position 1157, due to an asparagine-serine 
substitution (Belt et al 1984, 1985) 
An interesting feature of the C4 genes is that they 
can differ in size . The gene at the first locus (C4A) is 
approximately 22 kb, whereas the gene at the second locus 
(C4B) can be either 22 kb or 16 kb in length (Yu et al 
1986 , Prentice et al 1986 , Palsodittir et al 1987). This 
length difference is due to the presence or absence of six 
to seven kb of nucleotide sequence in an intron 
approximately 2 . 5 kb from the 5 1 end of the gene . 
A further phenomenon in the genetics of C4 is the 
exceptionally high frequency of silent or null alleles. 
These null alleles (QO) result in the deficiency or 
partial deficiency of C4A or C4B protein. The frequency 
of the nulls in the population is around five to 15 
percent for C4AQO and ten to 20 percent for C4BQO 
(Schendel et al 1984 , Tokunaga et al 1985 , Partanen and 
Koskimies 1986) . The molecular basis of the null allele 
has been defined in several cases (Yu and Campbell 1987, 
Hauptmann et al 1987) and may help in our understanding of 
some autoimmune disease which are associated with this 
deficiency. 
Cases of duplication of the C4 genes have also been 
reported (Rittner et al 1984a, Raum et al 1984, Uring 
Lambert et al 1984) at an estimated frequency of one to 
two percent, although this is probably an underestimate a s 
three new kinds of C4 gene duplication have since been 
identified from protein and RFLP analysis (Schneider et a l 
19 8 6 ) . 
1.2.3 Complement Components Three and Five (C3, CS) 
C3 is the most abundant complement protein and it 
plays a major role in the activation of the system since 
it participates in both the classical and alternative 
pathways. The complete amino acid sequence has been 
deduced from the cDNA sequence (de Bruijn and Fey 1985) 
The C3 protein consists o f two polypeptide chains , a; 992 
residues and p; 645 residues . 
The C3 gene is 41 kb and consists of 41 exons (Fong 
et al 1990) . The C3 P chain spans 13 kb from exon one to 
exon 16 . Exon 16 encodes both a and P chains . The a 
chain is 28 kb and contains 26 exons including exon 16 . 
The C3 gene has been localised to chromosome 19 (Whitehead 
et al 1982) 
C3 protein exhibits two common allotypic variants 
that are separated by gel electrophoresis and are called 
C3 fast (C3 F) and C3 slow (C3 S) . In addition to these 
forms at least 20 rare allelic variants have been 
described . Botto et al (1990) report that the two alleles 
differ by a single change at nucleotide 364 with S alleles 
posessing an arginine and F alleles a glycine residue at 
this site . The molecular basis of a second structural 
polymorphism, defined by a monoclonal antibody (Koch and 
Behrendt 1986) was also characterised by Botto 1 s group . 
This change occurred at codon 314 in exon nine of the P 
chain where a leucine residue was substituted for a 
proline molecule . Three RFLPs have also been mapped to 
introns in the C3 gene, but no allelic association between 
them has been found (Botto et al 1990) . Homozygous 
deficiency of C3 in humans is relatively rare and is 
associated with pyogenic infections and nephritis . 
Like C3 , mature CS is a disulphide linked dimer 
consisting of an a and p chain . Components C3 , C4 and CS 
along with a-macroglobin show a high degree of homology 
on comparison of amino acid sequences (Sottrup Jensen 
et al 1985) . CS however, differs from the others since it 
does not contain an internal thiolester bond and therefore 
lacks the covalent binding properties associated with 
activation . 
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The human CS gene is 79 kb, cDNA 3309 bp, and is 
comprised of 41 exons (Carney et al 1991). The gene has 
been localised to chromosome 9q32-34 (Wetsel et al 1988) 
Comparison of CS with C3 and C4 revealed strong 
similarities in exon size and number. The 5 1 flanking 
region of the gene contains sequences homologous with 
interferon, interleukin-6, gluccocorticoid, estrogen, NF-
kB and HNF-1, all of which are known responsive elements. 
The CS protein is not polymorphic in Americans, 
English , Portuguese or West Africans (Hobart et al 1981, 
Rosenfeld et al 1977) but is in Melanesians (Vaz-Guedes et 
al 1978). CS deficiency has been reported in at least 19 
individuals most of whom had recurrent infections (review 
Hauptmann 1989 , review Morgan and Walport 1991) . CS 
deficient individuals lack bactericidal activity and have 
severely impaired ability to induce chemotaxis (Miller and 
Nilsson 1970 , Nilsson et al 1974 , Rosenfeld et al 1976) . 
As yet no studies have determined the molecular basis for 
the CS polymorphism or deficiency . 
1.2.4 Factor I and Regulation of Complement 
Activation Group (RCA) 
Factor I is a serine protease involved in the 
degredat i on of complement component three . Like the 
majority of complement proteins it is composed of a number 
of protein modules ; two low density lipoprotein (LDL) 
receptor class A and B repeats, a factor H like SCR, and a 
CDS module. Further genetic characterisics of factor I 
are listed in Table 1 . 1 . 
The proteins of the RCA family are all C3b/C4b 
binding proteins which share a structural organisation. 
These proteins are characterised by having their entire or 
almost their entire sequence composed of SCRs (Chung et al 
1985, Kristensen et al 1986, Klickstein et al 1987, Caras 
et al 1987, Medof et al 1987, Weis et al 1988). These 
proteins are encoded by linked genes which have been 
assigned to chromosome lq32 (Rodriguez de Cordoba et al 
1984, 1985, Rey-Campos et al 1987, Weis et al 1987, Lublin 
et al 1987) The order of the genes is MCP, CRl, CR2, 
DAF, C4BP while the factor H gene is 6.9 cM away from 
these . Table 1 . 1 lists their genetic characteristics. 
1.2.5 Cell Adhesion Glycoprotein Family and other 
Complement Proteins 
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CR3, p15 0 ,95 and LFA-1 are all members of a family 
of cell surface antigens that share a common 95 kDa p 
chain which is non-covalently linked to a distinct a 
chain. Each ap complex participates in some f o rm of cell 
adhesion activity (Springer et al 1987 ) . The cDNA 
sequence o f the common P subunit has been cloned and 
sequenced, showing that it is composed of 747 residues 
(Law et al 1987, Kishimoto et al 1987). The gene for this 
p chain i s approximately 32 kb (Kishimoto et al 1987) and 
has been mapped to chromosome 21 (Marlin et al 1986). A 
DNA polymorphism has been described using RFLP analysis o f 
Bgl II digests . Deficiency of these cell adhesion 
molecules usually includes all three members, suggesting a 
defect in the common p chain . Patients deficient in these 
molecules often experience recurrent bacterial and fungal 
infections (Spr inger et al 1987) . Other less well 
characterised complement factors are also listed with 
available information in Table 1.1 . 
1.2.6 Properdin 
Properdin is a glycoprotein which circulates in the 
blood in the form o f oligomer s of a 56 kd chain . (Smith 
et al 1984) . The primary amino acid sequence o f properdin 
is composed mainly of six SCRs . Genetic features o f 
properdin are listed in Table 1 . 1 . Deficiency o f 
properdin is rare and is inherited as an X-linked 
recessive disorder . Deficient individuals are predisposed 
to life-threatening bacterial infections (Figueroa and 
Densen 1991) however early detection, utilising a linked 
polymorphic dinucleotide repeat, and immunisation are 
helpful . 
1.2.7 Membrane Attack Cluster I - ca (MAC I CS) 
C8 is a 151 kDa glycoprotein constituent of the C5b-9 
complex. C8 along with C9 has the ability to circulate in 
plasma as a hydrophilic protein but undergoes a 
hydrophilic to amphiphilic transition leading to 
interaction with target membranes . C8 has an unusual 
subunit structure consisting of three comp onent s ; a (6 4 
kd), P (6 4 kd ) and y (22 kd) (Kl ob and Muller-Eberhard 
1976, Steckel et al 1980). These are arranged as a 
disulphide-linked a-y dimer that is noncovalently 
associated with p. 
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The asymmetrical arrangement of noncovalent and 
covalently associated C8 subunits is unusual f or a serum 
protein but is consistent with the fact that each subunit 
arises from a separate gene (Ng et al 1987, Howard et al 
1987 , Rao et al 1987) . The amino acid sequence of subunit 
a was derived from cDNA analysis and consists of 553 
residues plus a leader sequence of 30 amino acids. The N-
and C-termini are both cysteine rich while the central 
region is relatively free of cysteines . The N-terminus 
exhibits strong homology to the 40-residue repeat sequence 
found in the LDL receptor . The C-terminus exhibits 
homology to epidermal growth factor (EGF) precurser and 
several other proteins including urokinase, blood 
coagulation factors FI X and FX and tissue plasminogen 
activator (Rao et al 1987) . It also has striking overall 
homology to human C9 . 
Amino acid sequence of C8 p was derived from a 2 . 0 kb 
cDNA sequence (Howard et al 1987 , Haefliger et al 1987). 
This subunit has a 54 amino acid leader sequence, followed 
by 536 residues co r responding to mature p. Like C8 a the 
N- and C-terminii of C8 P are cysteine rich while the 
central region is poor in cysteines . The LDL receptor and 
EGF precursor consensus sequences are again present as are 
other segments o f homology to a. 
The C8 y ami no acid sequence has been derived from a 
718 bp cDNA clone (Ng et al 1987) . It consists of 182 
residues preceeded by a 20 amino acid signal peptide . The 
sequence contains three cysteines, only one of which is 
linked to a (Haefliger et al 1991) . C8 y displays a 
striking amino acid sequence similarity to a group of 
proteins called lipocalins (Pervaiz and Brew 1987) The 
common feature of all lipocalin proteins is their 
molecular mass of around 22 kd and their ability to 
transport small ligands, suggesting a similar role for 
C8 y. 
As noted above the three subunits of C8 are coded for 
by three separate genes . The initial idea that this was 
the case arose from studies of the C8 a- y polymorphism 
(Raum et al 1979 , Rittner et al 1984b) and the C8 p 
polymorphism (Alper et al 1983, Rogde et al 1985). In 
Caucasians C8A*A (previously named C8l *A ) and C8A*B 
(C8l*B) occur at frequencies of approximately 0 . 588 and 
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0 . 374 respectively (Rittner et al 1993) . The C8B*l 
(previously C82*1) and C8B*2 (C82*2) alleles in Caucasians 
occur at frequencies of approximately 0 . 952 and 0 . 044 
respectively (Alper et al 1983). Rare alleles for these 
loci also exist, with 12 being identified f or C8A , mostly 
occurring in Japanese groups , and one for the C8B locus, 
designated C8 B*Al (C82*Al) (Alpe r et al 1983). Two major 
types of C8 deficiency are known at the protein level 
(Tedesco et al 1983) . These two types are restricted to 
different ethnic groups with C8 a-y deficiency found in 
Blacks while C8 p deficiency is found in Caucasians (Ross 
and Densen 1984) . C8 deficient individuals often suffer 
from recurrent neisserial infections such as meningitis. 
The genes for C8 subunits are designated C8A for a, 
C8B for P and C8G for y. C8A and Bare closely linked on 
chromosome lp32 (Theriault et al 1992) while C8G is 
located on chromosome 9q (Kaufman et al 1989). The gene 
for C8B is approxi mately 40 kb , and consists of 12 exons 
rang i ng in s i ze from 69 to 347 bp (Kaufmann et al 1993) . 
All intron-exon junctions follow the GT-AG rule. Two 
RFLPs have been reported for the C8B gene (Hermann et al 
1989 , Rogde et al 1989a) , neither of which correlates with 
the protein polymorphisms . Kaufmann et al (1993) study 
reports that the polymorphic Taq I site occurs in intron 
11 . A further study by the same group (Kaufmann et al 
1993) describes a DNA mutation which is a major cause for 
C8 P deficiency. A single substitution of a thymine for 
cytosine in exon nine results in a premature stop codon . 
This mutant allele was observed in all C8 p deficient 
families investigated . 
The genomic organisation of the C8A and C8G genes has 
not yet been reported . The C8A gene shows a Taq I RFLP 
and a possible polymorphic variable number of tandem 
repeats (VNTR) has been suggested (Rogde et al 1991a). 
1.2.8 Membrane Attack Cluster II (C9, C7, C6) 
1.2.8.1 Complement Component Nine 
24 
C9 is a single chain, 70 kDa, glycoprotein o f 537 
amino acids (Discipio et al 1984) . It consists o f three 
cysteine rich domains; a thrombospondin (TSP ) repeat and a 
LDL receptor domain at its N-terminus plus an EGF domain 
at its C-terminus . The central regi on o f the C9 sequence 
has strong sequence similarities with perfo rin, a pore 
forming protein secreted from cytotoxic T lymphocytes 
(Shinkai et al 1988). This central region appears to 
possess some specific hydrophobic properties . 
The C9 protein is not polymorphic, but deficiencies 
of C9 are well known . Japanese groups have been shown to 
have a high incidence of C9 deficiency, approximately 
0 . 045 to 0 . 104 percent (Akagaki and Inai 1985 as reported 
by Nagata et al 1989) . There is an association between C9 
deficiency and meningoccocal meningitis , but it is not as 
strong as that for other MAC component deficiencies. 
The C9 gene has been cloned (Discipio et al 1984, 
Marazziti et al 1988) and found to have 11 exons. 
Analysis of the intron/exon boundaries showed good 
correlation between splice sites and surface feature s of 
the protein but not with the protein homology structures 
(Marazziti et al 1988) . This was considered surprising 
since the same sequence in the LDL receptor i s precisely 
bound by introns , suggesting that this sequence i s present 
in both proteins as a result of exon shuffling. 
The gene for C9 has been localised t o chromosome 
Spl3 , along with the C6 and C7 genes (Abbott et al 1989 , 
Rogne et al 1989b) it is however located more than 2 . 5 Mb 
from these genes (Setien et al 1993). Several Taq I RFLPs 
have been described for the C9 gene (Rogne et al 1990, 
Coto et al 1990a) . As yet the sites determining these 
RFLP patterns have not been located . 
1.2.8.2 Complement Component Seven (C7) 
Complement component seven is a 120 kDa single chain 
glycoprotein . The complete primary structure of C7 has 
been derived from the cDNA sequence (D isc ipio et al 1988 ) 
C7 is a mosaic protein consisting of 821 amino acids , the 
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carboxy terminal third contains four cysteine-rich 
segments. The protein has 28 d isulfide bonds and is 
glycosylated at two sites. Almost all o f the cysteines 
are found in small units of 35 -77 amino acids, these 
regions are homologous with var i ous proteins including LDL 
receptor, EGF precursor, TSP, f actor I-like domain (FIM) , 
and C4 and blood coagulation factors IX and X. 
The C7 protein was first found to be p olymo rphi c in 
1976 (Hobart and Lachmann) with three structural forms 
being identified . These were found to be controlled by 
three codominant alleles ; C7*1, 2 and 3 (Hobart et al 
1978) . Four more alleles were soon identified; C7 *4 
(Nakamura et al 1984a ) , C7*6 (Zeng et al 1 986) , C7 *7 
(Washio et al 1986) and C7 *8 (Komatsu et al 1989). Allele 
C7*5 was described by Nishimukai and Tamaki (1986) but was 
later shown to be identical to C7*3 (Washio et al 1986) 
All of these alleles were identified using isoelectric 
focusing and since then further polymorphisms (C 7*9, C7*M 
and C7*N) of the C7 protein have been identified using 
monoclonal C7-allospecific antibody in an ELISA assay 
(Wurzner et al 1990, 1992b). Caucasian groups show one 
common autosomal codominant allele (C7*1) and two rare 
alleles with a frequency of less than 0 . 01 (Hobart et al 
1978) . In Japanese three common C7 alleles are f ound 
(Nakamura et al 1984a) and these correspond to those f ound 
in Caucasians. However the two rare alleles were f ound at 
higher frequencies (0 . 15) in Japanese . In Chinese one o f 
the rare alleles C7*2 is also more frequent than in 
Caucasians (York et al 1986) . Hobart (1990) reports that 
Oriental populations have both a higher frequency of 
variants and a greater range o f protein allotypes compared 
with Caucasians . 
Deficiency of the C7 protein has been reported in at 
least 20 families (review Wurzner et al 1992a) . 
Neisserial infection is the most common cl inica l 
manifestation, however deficient individual s may be 
healthy. C7 deficiency has been seen to co - occur with C6 
deficiency in two families (Lachmann et al 1978, Morgan 
et al 1989) and with C4B deficiency in f our further cases 
(Chapel et al 1987, Lopez-Trascasa et al 1988, Wuillemin 
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et al 1991, Segurado et al 1992) . As yet there has been 
no DNA mutati on reported which explains the C7 deficiency . 
The complete cDNA encoding the C7 protein was 
sequenced in 1988 (D i sc ipio et al) . The genomic 
organisati on o f the C7 gene was investigated by Hobarc 
et al ( in preparation ) . The C7 gene i s approximately 8 0 
kb in length and consists o f 17 exons, ranging in size 
from 86 to 244 bp . The intron sizes range from 0 . 5 to 8 . 5 
kb . The C7 gene is very similar to that f o r C6 , C8B and 
C9 . All intron / exon boundary phases are identi cal for C6 
and C7 . 
A Taq I RFLP f o r the C7 gene has been described (Cot o 
et al 1990b) and identifies two alleles 4 . 2 a nd 4. 0 kb . 
The estimated frequencies of the two alleles in a Spanish 
group are 0 . 32 and 0 . 68 for the 4.2 and 4. 0 kb alleles 
respectively. 
1.2.8.3 Complement Component Six (C6) 
C6 is a single chain glycoprotein with a molecular 
weight of approximately 120 kD. The polypeptide chain 
contains 913 amino acids with a 21 residue s igna l peptide 
(Discipio and Hugli 1989, Haefliger et al 1989) . C6 is a 
mosaic protein which is composed of nine distinct modules . 
These homology units include three TSP type I, an LDL type 
A receptor, an EGF precursor, two SCRs and two FIM 
modules . The C6 polypeptide chain i s cross-linked by 32 
disulfide bonds which occur in short discrete segments . 
Like C8 , C7 and C9 the C6 protein has a central cyste ine-
poor region . 
The C6 protein was first f ound to be polymorphic in 
1975 (Hobart et al) and has been shown to be so in all 
maj o r ethnic groups. Nineteen different allotypes besides 
the two common ones have been described (review Tokunaga 
et al 1990) . Table 3 . 1 (Chapter 3) gives the frequencies 
of the common alleles plus the combined frequency of the 
rare protein alleles in all the groups examined . As 
discussed in Chapter 3 deficiency o f C6 i s well documented 
and is o ften associated with recurrent neisserial 
infections, however several cases o f an association with 
autoimmune diseases have also been reported (Tedesco et al 
1981, Trapp et al 1987, Reinitz et al 1986, Wisnieski 
et al 1985) . As yet there has been no report of the 
mechanisms determining C6 deficiency at the DNA level. 
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The gene for C6 was cloned and sequenced in 1989 
(Haefliger et al 1989, Discipio and Hugli 1989). The cDNA 
sequence is 3 . 3 kb while the genomic DNA covers 
approximately 85 kb (Hobart et al 1993a) . The C6 gene is 
located on chromosome 5p13 (Jeremiah et al 1990, Abbott 
et al 1989) and is closely linked to C7 and C9 (Hobart 
et al 1978, 1993b, Tokunaga et al 1986, Abbott et al 1989, 
Rogne et al 1991b , Setien et al 1993) . The intron-exon 
boundaries have been defined (Hobart et al 1993a) with the 
gene consisting of seventeen exons ranging from 91 bp to 
774 bp , most being around 165 bp . Two RFLPs for the C6 
gene have been described ; one involves a polymorphic Taq I 
site (Coto et al 1991a) while the second occurs at an Msp 
I site (Coto et al 1991b) . The Msp I RFLP has been 
associated with C6 deficiency (Fern i e et al 1994) . Two C6 
and C7 sub-total deficient (SD) families , plus two 
families with C6 subtotal deficiency only, appear to 
possess an exon three (protein allele site) A allele, Msp 
I positive, and C6SD haplotype, while 16 of 17 C6QO 
individuals possessed an exon three B allele, Msp I 
negative , C6QO haplotype . It appears then that the C6QO 
and C6SD mutations arose independantly on two different 
allelic backgrounds (Fernie et al 1994) . 
1.3 Evolution of the Complement System 
The complement system in mammals is a highly 
successful recognition and effector system . The classical 
pathway of complement can be triggered by antibody-antigen 
complexes and the alternative pathway has a major role in 
recognition of foreign organisms . While the complement 
system is highly effective in eliminating antigens, unlike 
immunoglubulin-type genes which have a vast array of 
possible rearrangements, the complement system is not able 
to quickly adapt or memorise antigens . This is a severe 
limitation in an environment where many antigens are 
evolving faster than their potential host. Thus it 
appears that the combination of systems would greatly 
enhance the survival of the individual, suggesting ha 
presence of both facets of immunity represents a highly 
evolved system. 
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There is some evidence that suggests primitive parts 
of the complement system occur in some invertebrates while 
vertebrates possess a more developed system. It is 
generally agreed that invertebrates do not possess 
rearrangeable immunoglobulin genes while all vertebrates 
examined do (Litman and Kehoe 1978). Therefore it appears 
that the ancestral complement system evolved before the 
adaptive immune recognition mechanisms (review Farries and 
Akinson 1991). 
1.3.1 Alternative and Classical Pathway Evolution 
A form of the alternative pathway has been found in 
several invertebrate phyla, including Arthropods, 
Echinoderms and Annelids (Ballow 1977) . An equivalent 
protein to the alternative pathway component C3 has been 
found in birds (Kai et al 1983 , Laursen and Koch 1989), 
reptiles (Petrella et al 1989), amphibians (Grossberger 
. et al 1989, Avila and Lambris 1990), bony fish (Nonaka et 
al 1984b), sharks (Jensen et al 1981) and lampreys (Nonaka 
et al 1984a) . Conserved features of this protein are the 
chain structure and internal thioester bond (Alsenz et al 
1984) . Thus it appears that the first functi onal 
complement component could have been an ancestral version 
of C3 (review Farries and Atkinson 1991) . At some later 
time it is thought that a gene fusion event created a 
protease, a primitive factor B protein, with a binding 
site for activated C3 . Evolution of the other components 
then allowed amplification and specificity of this pathway 
to develop . 
Several studies show that plasma of birds, reptiles, 
amphibians and fish possess antibody-dependent cytolytic 
activity similar to the classical pathway of complement 
while the nurse shark possesses components equivalent to 
Cl, C2 and C4 (Jensen et al 1981, Ross and Jensen 1973) . 
Farries et al (1990) suggest that Clq evolved first as the 
link between antibodies and effector cells . Possibly an 
ancestral Clr-Cls complex then arose with the function of 
binding Clq to C3 . Duplication of the C3 gene may then 
have occurred allowing specialisation of C4 and Cl . 
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Duplication o f the fa c t o r B gene could ha ve g i ven ri se to 
C2 allowing further divergence and s pec iali sa ti on. 
1.3.2 Evolution of the Terminal Components 
Sharks have a lytic system which includes C8- and C9 -
like components (Jensen et al 1981), while CS has been 
identified in trout (Nonaka et al 1981). Farries and 
Atkinson (1991 ) suggest this terminal cascade evo l v ed 
around the same time as the classical pathway, more tha n 
400 miliion years ago (Hobart et al 1993a). C6 a nd C7 
have not been detected in the nurse shark and are thought 
to have evolved later (Discipio and Hugli 1989, Hobart 
et al 1993a). 
1.3.3 Genetic Mechanisms of Evolution of the Early 
Components of the Complement System 
Insights into the origin of complement components can 
be gained from homologies with other proteins. Like 
numerous other proteins many complement components are 
mosaics and are made up of structural units similar t o 
parts of other proteins . These individual module 
structures are usually encoded for by one or several exon s 
with intron/exon boundaries coinciding with protein unit 
boundaries in the majority of cases (review Patthy 19 87 ) . 
Patthy (1985) suggests that exon shuffling is an important 
mechanism in the reassortment of these modules ac r oss 
different protein groups and these insertion / deleti on 
events are facilitated if intron/exon boundaries 
correspond to protein module boundaries . This phenomenon 
is thought to be further facilitated if exons are in the 
same phase at their 5' and 3' ends (Patthy 1987 ) . Through 
this mechanism of exon shuffling proteins with novel 
combinations of domains, and thus new functi ons, a re 
thought to have been created. Since these ba s i c uni ts a r e 
so ancient and widespread it is not possible t o dedu c e 
which recombinations have produced the new pro t e in s . Some 
genetic events however, are simpler to reconstruc t, f o r 
example gene duplication by unequal crossing over (Farries 
and Atkinson 1991) probably explains the similarities a n d 
linkage between factor Band C2, plus C4A and C4B, Cl r and 
Cls and possibly the RCA genes. C3, C4 and CS al so s ha r e 
considerable structural similarities indicating gene 
duplication despite their lack of linkage . 
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Intragenic duplication is also thought to be an 
important mechanism in the evolution of this system, 
particularly for the RCA group. All these proteins 
contain tandem arrays o f short consensus repeats and 
analysis of intron /exon boundaries indicates intragenic 
duplication of blocks of four SCRs from an ancestral four 
SCR structure (Fujisaku et al 1989). 
1.3.4 Genetic Mechanisms in the Evolution of 
Components of the Membrane Attack Complex 
The common structural features of the terminal 
components suggest they evolved from a common ancestor. 
The structural arrangement of these proteins is shown in 
Figure 1.4 . In general these proteins differ in their 
complexity with C6 being most complex and C9 least. All 
of these proteins possess a central cysteine-poor region 
which has similarities with perforin, a pore-forming 
protein that acts as an effector molecule for killer T-
cells and natural killer (NK) cells (Shinkai et al 1988, 
Lichtenheld et al 1988) . Terminal complement proteins 
also possess cysteine rich areas which have similarities 
with modules in the low density lipoprotein receptor type 
A and B, thrornbospondin and the epidermal growth factor 
receptor (Discipio et al 1984, Stanley et al 1985, Howard 
et al 1987, Rao et al 1987, Chakravarti et al 1988, 1989, 
Discipio and Hugli 1989, Haefliger et al 1989) . C6 and C7 
also have SCR 1 s . Another homology module occurring in the 
C6 and C7 proteins is the FIM domain (Discipio and Hugli 
1989, Haefliger et al 1989, Discipio et al 1988) . C6 i s 
one of the most complex of known mosaic proteins with 
great diversity in constituent protein homology units 
(Hobart et al 1993a) . 
The mechanism of exon shuffling is thought to be 
important in evolution of the MAC components, but 
characteristics facilitating this mechanism are uncommon 
. ~ in the C6 and C7 genes (Hobart et al 1993a). In these 
genes only one of the protein elements (SCR2) follows the 
cotermination convention and phases of intron / exon 
boundaries are not consistent at their 5 1 and 3 1 ends. 
Comparison of the intron /exon structures of the C6, 
C7 and C9 genes shows them to be very highly conserved 
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Figure 1 . 4 A c omparative map of the genetic o rganisati on 
o f C6 , C7 , C9 and perfo rin. Amino acids and exo n nwnbers 
f o r C6 are given. Pro tein h omo logy units are depicted as 
op e n-boxed or circled regions. In general exons do no t 
c o rrespond to proteiri unit structu res. Reproduced, with 
permissi on, from Hobart et al 1993a, fig 2. 
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(Hobart et al 1993a) and perhaps suggests alternative 
mechanisms of exon shuffling , not reliant on cotermination 
of DNA and protein units o r phase con s i sten cy . For 
example these genes may have arisen from a common ancestor 
which had a similar genomic boundary structure . 
Based on the genomic structure o f C6 and comparisons 
with what is known of the other terminal complement 
component genes Hobart et al (1993a) believes that the 
common ancestor for these genes was similar to C6 at the 
5 1 end since C6 , C7 and C9 share a similar TSP and LDL 
receptor module structure and genomic arrangement in this 
area. A similar comparison of intron phase types between 
these genes shows consistency and this suggests that on ly 
very restricted changes have occurred since the present 
intron/exon structures were established (Hobart et al 
1993a) . 
This discussion of evolution of the complement 
component proteins is based on data which is as yet 
incomplete and therefore cannot be definitive. However it 
appears clear that the modern human complement system 
evolved from ancient constituents through a process of 
feasible genetic changes . 
1.4 Complement and Disease 
The study of complement deficiencies and disease has 
provided useful information about the physi o l og i cal role 
of the complement system in vivo . Many individual s with 
complement deficiencies have normal health, s howing that 
there is some redundancy in human defence me c hani sms . 
Disease associations with complement deficiencies can be 
grouped into two categories ; 1) susceptibility to pyogenic 
infections and 2) increased susceptibility t o immune 
complex disease, particularly SLE . Pyogenic infections 
can take two forms, the first is an increase in infections 
by pyogenic o rganisms such as Staphylococcus and 
Streptococcus whose pathogenesis is v ia prevention of 
phagocytosis and intracellular killing. The second form 
is through susceptibility to Neisseria infection . Table 
1 . 2 summarises the reported cases of complement 
deficiencies and their disease associations . Complement 
deficiencies are uncommon yet their study has increased 
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Table 1.2 Inherited compl e me nt compo nent d e fi c ienc ies: c hr omosomal l ocati o n o f the genes and 
disease associa ti o ns . 
Complement Chromosome Number 
component location of cases 
Clq A c hain lp >40 
B c h a in lp 
C c hain lp 
Clr , Cls 12pl3 Clr / Cls 16 
Clr a nd Cls 4 
C2 6pl 3 >100 
C3 19 16 
C4 A 6pl3 35% pop . lack 1 allele 
B 6p l 3 8- 1 0% lack 2 alleles 
1 % lack 3 alleles 
17 cas es lack 4 alleles 
cs 9q32-]4 30 
C6 Spl3 >100 
C7 Spl3 >80 
Reported associated disease 
SLE ir1 majority, SLE - like diseas e , DLE, 
pyogenic infections including 
meningitis 
SLE - like disease, pyogenic infections, 
often recurrent 
2 DLE and arthritis, 2 healthy 
SLE, SLE - like disease, DLE, pyogeni c 
infections, glomerulonephritis, 
rheumatoid purpura, vasculitis, healthy 
Pyogenic infections, glomerulonephritis, 
SLE 
SLE, SLE-like disease, DLE, vasculitis, 
Rheumatoid purpura. 
SLE, DLE, SLE and infect ions, 
SLE and glomerulonephritis, 
Neisserial infections, SLE 
Neisserial infections, SLE-like disease, 
or healthy 
Neis serial infections, SLE, healthy 
schleroderna, Rheumatoid Arthritis, 
,n 
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Table 1.2 continued 
Complement 
component 
C8 a 
C9 
~ 
y 
Fa c t o r B 
Fa c t o r D 
Cl - INH 
Fa c t o r I 
Fa c t o r H 
Properdin 
Chromosome 
location 
1 
1 
9p 
5p13 
6p13 
?X 
11pll.2 - q13 
4 
lq32 
X 
NUmber 
of cases 
>80 
a-y < 2 o 
5 (Caucasians) 
>500 (Japanese) 
0 
2 
many, 
>500 
15 
12 
>50 
Reported associated disease 
Neisserial infection, SLE-like disease, 
Usually healthy 
Healthy, Neisserial infections 
Recurrent bacterial infections 
Hereditary angioneurotic edema, 
SLE-like disease (rare) 
Pyogenic infections, glomerulonephritis 
SLE 
Pyogenic infections, glomerulohephritis 
SLE, haemolytic uraemic syndrome 
Neisserial infections, rarely o ther 
pyogenic infections 
\_() 
<"l 
Table 1 . 2 
Complement Chromosome 
component location 
-
C4bp lq32 
DAF lq32 
CR3 21 
Number 
of cases 
3 
2 
complete 4 
partial 15 
Reported associated disease 
Atypical Behcets disease 
Deficiency on erythrocytes; paroxysmal 
nocturnal hemoglobinuria with defi c iency 
of the CRl receptors 
Increased susceptibility to bacterial 
infections 
SLE = systemic lupus erythematosus, DLE = discoid lupus erythematosus , 
Data fr om Mo rgan and Walpo rt 1991 , Hauptman 1989 and references in text . 
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the knowledge of the role of complement in the human body . 
The importance of the membrane attack complex in host 
defense against Neisseria has been highlighted and a 
greater understanding of mechanisms of infection has 
developed . 
The mechanism underlying the association with immune 
complex disease is not well established, however 
complement promotes the removal of immune complexes from 
the circulation and tissues . Deficiency of this function 
may allow accumulation of immune complexes causing 
inflammation and release of autoantigens . This in turn 
stimulates the production of autoantibodies and more 
immune complexes (Lachmann and Walport 1987) . While 
homozygous complement deficiency is a rare cause of SLE it 
represents the strongest susceptibility genotype 
identified thus far with more than 80 percent of cases of 
homozygous deficiency of Clq and C4 having SLE(rev1ew Mo ~on 
ond Wa\pod I q1) 
1.5 Systemic Lupus Erythematosus 
Systemic lupus erythematosus (SLE) is a multisystem 
autoimmune disease of unknown etiology . It is 
characterised by excessive quantities of autoantibodies 
and immune complexes , leading to inflammation in many 
different organs (Steinberg 1985) . The lupus 
erythematosus cell (LE cell) phenomenon was discovered in 
1948 by Hargraves and was later shown to represent an 
antibody to deoxyribose nucleoprotein (DNP). Many other 
autoantibodies, particularly against nuclear antigens, 
have since been found in the sera of SLE patients. 
Consequently the fluorescent antinuclear antibody (ANA ) 
test was developed and has been used as a routine 
diagnostic test for SLE since the late 1950 1 s . 
1.5.1 Incidence 
SLE is a disease that primarily affects women, with 
90 to 95 percent of patients in their teens, twenties and 
thirties being female . It can occur at any age, however 
70 percent of patients experience onset of disease between 
ages 13 and 40 years (Steinberg 1985). SLE has been 
reported to occur in approximately one in 2000 Caucasoids 
(Engleman and Shearn 1983) while Meddings and Grennan 
(1980) report an incidence of one in 6780 New Zealand 
38 
Caucasoids. The disease is significantly more common in 
black Americans than American Caucasians and North 
American indian tribes the Sioux, Crow and Arapahoe show 
an even greater predisposition to SLE (Steinberg 1985). 
Estimates of the incidence of SLE are somewhat variable 
and possibly reflect both the heterogeneity of the disease 
and the ethnicity of populations from which samples were 
taken. As yet there is no large scale survey of the 
prevalence of SLE in the Australian population. 
1.5.2 Etiology 
The etiology of SLE is unknown, however the symptoms 
are thought to be due to excess autoantibodies that react 
with self components leading to inflammation. Initiation 
of this process may involve many factors both genetic and 
environmental and may differ substantially between 
patients. 
Genetic factors in SLE have been implicated 
particularly through studies of family aggregation of the 
·disease (Arnett 1987), twin studies (review Block et al 
1975) and inherited disorders of the complement system 
(review Morgan and Walport 1991). Possible genetic 
contributors to the disease include genes that allow 
excessive antibody response after stimulation, genes that 
predispose to particular antibody responses, hormonal 
regulatory genes and genes governing metabolic control . 
Several studies (DeHoratius and Messner 1975, 
DeHoratius et al 1975, Arnett and Schulman 1976 ; Kaplan 
1984) have also shown that environmental fact ors 
contribute to the disease process. Suggested contributory 
environmental agents include certain foods, drugs, UV 
light and infections. These factors appear to act on the 
genetically determined immune system to predispose or 
protect an individual from SLE expression. 
1.5.3 Diagnosis of SLE 
SLE is a heterogenous disease in its expression 
varying from a mild cutaneous problem to a severe, life 
threatening, multi-organ disease . It may also involve 
stages of active disease and remission with a wide range 
of clinical symptoms. The diversity of symptoms seen in 
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SLE patients makes diagnos i s difficult , parti c ularly as 
many are non-specifi c and s imilar to manifestations of 
other connective tissue diseases . It i s possible that SLE 
is a collection o f several diseases and does not represent 
a uniform group of patients . 
SLE patients examined in this study were diagnosed 
according to the criteria o f Tan et al (1982) . 
Antinuclear antibodies , anti-DNA antibodies, complement 
levels and complement activity have been shown as highly 
specific for the diagnosis of SLE (Passas et al 1985) . 
Table 1.3 shows the classification criteria as taken from 
Tan et al (1982) . For diagnosis of SLE, patient s in this 
series had any four of the criteria either serially or 
simultaneously during the course o f obse rvati on . These 
criteria are exclusive rather than inclusive and a re 
designed to exclude other autoimmune connective tissue 
diseases, arthritides and systemic illnesses, 
unfortunately also excluding some individuals who are 
likely to have SLE (Tan et al 1982). 
1.5.4 Clinical Manifestations of SLE 
Clinical features o f SLE are diverse , Tabl e 1 . 4 shows 
a number of the symptoms seen and their incidence, these 
frequencies can vary between studies and may be influenced 
by how the patient was ascertained . Cutaneous disorders 
include malar rash, discoid lesions, photosensitiv ity and 
mouth and nasal ulcerations, these features are common 
with approximately 85 percent of SLE patients having a 
dermatological disorder (Rothfield 1985) . Patient s are 
particularly affected by the typical 11 butterfly 11 rash 
across the cheeks and nose a nd sensitivity to sunlight 
which may exacerbate the malar rash . Systemic 
manifestati ons of SLE invo lve the joints, lungs, kidneys, 
liver, central nervous system, spleen and gastrointestinal 
tract . 
1.5.5 Pathogenesis 
SLE is usually classified as an immune complex 
disorder, however this is thought to be an over 
s implification (Ste inberg 1985) . SLE is mediated 
primarily by antibodies but details o f pathogenesis are 
not well proven . The production o f inj urious 
Table 1.3 The 1982 revised criteria for classification of 
systemic lupus erythematosus. 
Critenon 
I . MaJar ra~h 
2. Dis.coid rash 
3. Photosens11ivity 
4. Ora.I ulce~ 
5. Arthritis 
6. Serosit1~ 
7. Renal disorder 
8Seurolo~1c d1,order 
9 Hema1olog1c d1<,orde ; 
10 lmmunolng, c d1<;ord~r 
11 Antinuclear ant ibod y 
a) 
Ddin ition 
Fixed eryt~ma . flat or rdised . over the malar emi-
nences. tending to ~pare the nasolahial fold~ 
Erythematous rdi~ed patches with adherent keratotic 
scaling ,:tnd follicular plugging. : atrophic scarring ma~ 
occur in older lesions 
Skin rash as .t result of unusual reaction to sunlight. 
by patient histo~ or physician obser,.ttion 
Oral or nasopha~·ngeal ulceration. usually pajnle~~ -
obscrved by a ph~·sician 
Nonuosive arthritis involving 2 or more peripherii l 
joints . characterized by tenderness. swelling. or eff u· 
s1on 
Pleuritt~onvinc1ng history of pleuritic pain or rub 
heard by .t physician or evidence of pleural eff us1on 
OR 
bl Pericarditis~ocumented by ECG or rub or evidence 
of pencardial effusion 
al Persistent proleinuna greater than 0 .) rrams per da~ 
or greater than 3- if quanti1at1on not peforrned 
OR 
b) Cellular casts--ma, ~ red cell. hemoglobin . g.ranu · 
lar . tubular . or m1\ed 
a) s~1zures-m the ah-.en(e of offending dru)? , or ~n,, .... n 
meiaoolic derdn~cmenh . e.g __ uremia . ke1uac1d1,,1 , 
or elec1rolyte imbalance 
OR 
bl Ps~chos1s--1n the ab')ence of off ending drug, or 
known metabolic derangements . e g. .. urem ia . ke 1oac-
1dos1s . or electroh te imbalance 
a) Hemolvt1c ancm1a-1,1, 1th re11 culocvlo'>1'> 
. -
OR 
t-) Lc uKv~ni:;-lcss thJn J _( )()() mm· 101al l,n 2 rir rn 0re 
ti.::,-.,,,un , 
OR 
,) Ly':1rhopcni.,-tess ih A~ I .500 mrr:" 1.'n 2 c,r mr, r, IX · 
OH 
d) Tnr,1mt>,:,q,1u~n1d-kS~ ihan IO< l, OCX1 r.in/ i r. 1nr ii:> 
sence <'f 0ffcnd1n!! druf> 
a) 
b) 
C) 
d) 
Pc,~11,, e LE cell rrq)<1 r;111dn 
OR 
-\nl 1· D'--\ ..1nl1h1.-d , 1,, n., : 11.t l)'\-\ in ..ii'!l , 1 r11.d 111c 
OR 
-\n11 -Sm rre'!>cncc o! .int1r,,1J , 1n Sm nu:k..t : .,n1,cs:r 
O R 
Fal.-.e ro'>1t11,e scr1,1<.,~1c te-..1 f1H ,, rhil1, kn,,v. n lt ' t°' :' 
pos1t 1v e for at le,hl ti month, anJ (0nf.rmed r, , 
Trcp o ncmu {'1.tll,J11m 1mm1,hilizZit H1 n or ftu ,1rc,:en1 
lrcponcmal antit--0,j~ ab~0rr11,1n tc,t 
An atinormal titer of .,n11nuclea r Jnt1tx)J , h·, 1mmun0 
ftuorec;cence or .tn equ1, :.ilcn1 J~,a, at Jn, r01n1 1n 
time .. nd 1n the ar,,cnce of dru!! , ~n,,1,1,n I<' he J)'-<X I· 
atcd with "drug -indu,·eJ luru," ~ynd r0rne 
• The proro!-cd cl as ,1 f1Cdi1on 1, h;i,cd on 11 c.ntcria Fur the puqx, ,c of 1<.kn11f , in!, rJt1cn h 1n cl1n1:.ti 
stud1c'> . a r<r~or c;hall lx , .iid 10 h,l\e s,·c;tcm1C luru, en·thc· mal ,",U' 1f c1n, 4 nr m,1rc 1.)f 1h.- 11 cr,1er1.; 
are prc~en t. scr,:.ill~ or <,1rnultiineou~I~ during ;.in, interval uf oh~en Jl1on 
Reproduced, with perm1ss1on, from Tan et al 1982, table ., L 
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Table 1.4 Frequency of cl inical features in SLE. 
Feature Percent 
Fever 83 
Weight loss 62 
Arthritis, arthralgia 90 
Skin 74 
Butterfly rash 42 
Photosensitivity 30 
Mucous membrane lesions 12 
Alopecia 27 
Raynaud's phenomenon 17 
Purpura 15 
Uriticaria 8 
Renal 53 
Nephrosis 18 
Gastrointestinal 38 
Pulmonary 47 
Pleurisy 45 
Effusion 24 
Pneumonia 29 
Cardiac 46 
Pericarditis 27 
Murmurs 23 
ECG changes 39 
Lymphadenopathy 46 
Splenomegaly 15 
Hepatomegaly 25 
Central nervous system 32 
Psychosis 15 
Convulsions 15 
From Schur (1982) . 
aut oantibodie s i s we ll demonstrated i n the a ssoc i a ti on o f 
renal di s ease where t h e deg r e e o f pa thology i s largely 
determined by the extent o f antibody depos ition a n d the 
magnitude of the resultant inflammat o ry proc e ss . 
Continuous depositi on a nd inflammati on leads to 
irreversible tissue damage . Antibody depos ition however 
can o c cur in other tissues without induc ti on o f a n 
inflammat o ry respon s e. Thus the affinity , i sotypes and 
charge o f an antibody al ong with the s ize a n d 
c onfiguration o f the a ntigen are c riti ca l to d i sea s e 
pathogenes is . 
Antibodies i n SLE patients also bind cell surfac es . 
Antibodies to erythrocytes , granulocytes, lymphocytes a nd 
macrophages are produced by SLE patients . These 
antibodies cause the cells t o be removed from c irc ul at i on 
o r killed (Steinberg 1985) . The inflammat o ry l es i on s 
characteristic of SLE are initiated by antibody a nd occur 
primarily in s mall vessels . Other problems o f SLE 
patients; CNS disorders, hematologic, dermal and ca r d i ac 
dysfunction have addi tional pathogenic mechanisms, as yet 
not all are well understood . 
Richardson et al (1990) reports that DNA methyl a ti on 
in T-cells is impaired in patients with SLE a nd rheumat i c 
arthritis (RA) . They suggest a model in whi c h T- ce ll DNA 
hypomethylation alters gene expression and genera t es 
autoreactive T-cells which then parti c ipate in t h e 
pathogenesis of SLE and RA . 
1.5.6 Diagnostic Tests 
As yet there is no perfect test f o r SLE h owev er the 
presence of large amounts o f antibodie s t o na tive DNA i s a 
v ery useful diagnosti c finding. Sev era l o the r tests ; the 
lupus band test , LE cell test and fluore s cent a ntinuc l ear 
antibody te s t (ANA ) have s ome usefulne s s in SLE d i agnosis 
despite their c oncurrent detec tion o f o ther di so r ders . At 
present it is possible to measure antibodies s pec ifica l ly 
reactive with various antigens, a procedure with 
potentially greater diagnosti c use than o lder methods . 
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1.5.7 Treatment 
The variable severity of SLE requires an 
individualised treatment. The disease is usually handled 
by treating symptoms as they arise. Management of major 
organ involvement is aimed at preservation of function and 
prevention of failure. Drugs such as corticosteroids, 
prednisone , methylprednisone, cyclophosphamide, 
azathiopine and several others have some use in specific 
circumstances ( Lockshin 19 91) . 
1.6 Aims 
The aim of this study is to examine the complement 
component six protein allele distribution and C6 Taq I 
RFLP allele frequencies in Caucasian patients with SLE as 
compared to a healthy group of Caucasians . The pro ~e1n 
nd RfLP polymorp\11S1ns will be analysed for a possible 
association to determine whether l~F L P +yp·m3 can replace 
protein typing . C6 is a polymorphic protein and the 
molecular basis for the common and four rare protein 
alleles will be investigated . The presence of these DNA 
polymorphisms will be examined in several population 
groups from the Pacific region , to establish whether these 
polymorphisms arose prior to emergence of these ethnic 
groups . A small group of chimpanzee samples will also be 
examined for the presence of these polymorphisms in order 
to determine whether these sequence changes predate 
speciation . 
Chapter 2 
2.1 Materials 
Chapter 2 
Materials and Methods 
2.1.1. Chemicals, enzymes, radioisotopes 
The materials used in this proj ect were obtained from the 
following suppliers: 
Ajax chemicals - Auburn, NSW Australia 
NaOAc, MgC1 2 , HCl, KCl, NaCl, MgS04 , EDTA, 
isoamyl alcohol, ethanol, CH3COOH, is opropanol , 
bromophenol blue, (NH 4 ) 2s2o 8 , Na 2HP03 , boric acid, 
KH 2 Po4 , 1-butanol 
Amersham International - North Ryde, NSW, Australia 
Multiprime labelling system, Nick translati on kit 
Amresco - Gymea , NSW, Australia 
Acrylamide 
Applied Biosystems (a division of Perkin Elmer 
Corporation) - Burwood, Vic , Australia 
Dye labelled primers , deoxy / dideoxynucleot ide 
triphosphate mixes 
Australian Medical and Scientific (distributors o f Amicon 
products)- Chatswood, NSW , Australia. 
Microconcentrators 
Bacto Laboratories - Liverpool, NSW, Australia 
Tryptone , yeast extract, agar 
BDH Chemicals - Melbourne, Victoria, Australi a 
Sodium dodecyl sulphate ultra pure, NH 40Ac , 
polyethylene glyco1 6000 , dichloromethylsil ane 
solution, amyl alcohol, tri - sodium citrate, 
Bio-Rad Laboratories - North Ryde, NSW, Australia 
N,N 1 -methylene-bis-acrylamide 
Boehringer Mannheim - Castle Hill, NSW, Australia 
Alkaline phoshatase, X-gal, Hae III, M buffer, Msp I, 
L buffer, Mae II, dNTPs 
Bresatec - Adelaide, SA , Australia 
a 3 2 P dATP, lambda Hind III / Hind III Eco RI 
geneclean kit 
Calbiochem Novabiochem - Alexandria, NSW, Australia 
C6 monoclonal antibody 
Fluka Chemische Fabrik - Gymea, NSW, Australia 
Formamide, dimethylformamide, taurine, riboflavin 
Hanimex - Brookvale, NSW, Australia 
X-ray film 
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Immunodiagnostics (distributors of Atlantic Antibodies) -
Camperdown, NSW, Australia 
Alkaline phosphatase - anti goat IgG (H + L ) 
Linbrook International (distributors for LKB-Bromma) -
Crows Nest, NSW, Australia 
Ampholine pH 5-7 and pH 7-9 
Mallinckrodt - Victoria , Australia 
Glycerol , glucose, Cac l 2 
May and Baker Limited - Victoria , Australia 
Na2C04, NH4Cl2, CHCl3 
Merck - Kilsyth, Vic, Australia 
NaOH, NaBH4, gelatin 
New England Biolabs - Arundel, Qld, Australia 
Dde I, Bsm I, Aci I, Ser FI, Ace I, Mnl I, Bsr I, 
Novachem - South Yarra, Vic, Australia 
phenol 
Pharmacia Biotechnology - North Ryde, NSW, Australia 
Dextran sulfate , T4 polynucleotide kinase, T4 DNA 
ligase, dNTPs, ATP, Ml3mpl8 RFl DNA , lambda 
Hind III, One-phor-all-buffer-plus, Sma I, pBR322 
Polaroid Australia - North Ryde, NSW, Australia 
Polaroid film 
Promega - Sydney, NSW, Australia 
Thermus aquaticus (Taq ) DNA polymerase, Taq I 
Sigma-Aldrich Chemical Company - Cas tle Hill, NSW, 
Australia 
Bovine serum albumin (BSA), Tris, agarose type II, 
proteinase K, mineral oil , DTT, ethidium bromide, 
IPTG, salmon sperm DNA, Tween 20, formaldehyde, 
nitro blue tetrazolium (NBT), AgN03 , thiamine, 
5-bromo-chloro-3-indoyl phosphate (BCIP ) , 
N-lauroyl sarcosine, MnC1 2 
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2.2 Methods 
2.2.1 C6 isoelectric focusing gels 
Native serum samples were subjected to i soelectric 
focusing (pH 5-9) in flat bed polyacrylamide gels (Hobart 
et al 1975) followed by immunob l o tting (Whitehouse and 
Putt 1983). Proteins were transferred to polyvinylide 
difluoride membrane by capillary transfer f o r 2 hr. 
Membranes were then blocked with 0 . 5% (w/v) bovine serum 
albumin (BSA)-phosphate buffered saline (PBS) at 4° C 
overnight and then rinsed twice in 0.025% (v/v) Tween2 0-
PBS . The first antibody, goat antihuman C6 diluted one in 
700 with 2% (w/v) BSA-Tween20-PBS, was added and incubat ed 
for 90 min at room temperature . Membranes were washed 
with 0 . 025% (v / v) Tween20-PBS five times followed by 
incubation for 90 min at room temperature with the second 
antibody, anti goat IgG alkaline phosphatase conjugate 
diluted one in 1000 with 2% (w/v) BSA-Tween20-PBS. 
Membranes were stained using the 5-bromo-chloro-3-indoy l 
phosphate (BCIP) and nitro blue tetrazolium (NBT) 
detection system (Blake et al 1985 ) 
2.2.2 DNA extractions 
Genomic DNA was prepared from peripheral blood 
leucocytes , buffy coats and haemolysates . Most samples 
analysed in this study were prepared in previous studies 
using the routine method of phenol / chloroform extraction 
(Maniatis et al 1982) . Additional samples were prepared 
using a salting - out procedure (Miller et al 1 988) . Ce ll s 
were pelleted and resuspended in tris EDTA (TE) (10 mM 
Tris 1 M EDTA). Haemolysates required 4-6 washes in PBS 
before being pelleted and resuspended. 1 % (w/v) SDS and 
0.1 mg / 100 µL proteinase K were added to the cells and 
incubation was at 37°C overnight . Saturated sodium 
acetate (250 µL/ mL) was added and tubes were vortexed for 
15 sec to allow precipitation o f proteins. Samples were 
then centrifuged and supernatants trans ferred to fresh 
tubes . DNA was precipitated by addition o f an equal 
volume of isopropyl alcohol, transferred to microfuge 
tubes, dried and resuspended in double distilled water 
( ddH20) . 
2.2.3 Estimation of DNA concentration and purity 
4~ 
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The concentration of DNA preparations was estimated 
using a Gilford spectrophotometer at 260 nm assuming that 
a 50 µg/mL solution o f double-stranded DNA has an 
absorbance o f 1.0 at 260 nm in a 1 . 0 cm path length cell . 
The purity of the DNA preparation was judged by examining 
the ratio of absorbance at 260 nm and 280 nm. Pure DNA 
has a 260 : 280 absorbance ratio of 1.8 . 
2.2.4 PCR amplification of DNA 
The polymerase cha in reacti on (Sa iki 1985) was used 
extensively in this study to amplify C6 exons fr om genomic 
DNA and cDNA fragments from a lambda clone containing C6 
cDNA (from R Discipio CA , USA). Reactions were carried 
out according to the Taq polymerase manufacturers 
recommendations (Promega) in volumes from 1 0-1 00 µ L, 
overlayed with mineral oil in 0 . 5 mL micro fuge tubes . 
Radiolabelling PCR reacti ons were done in an Ericomp 
Twinbl oc k (™) Thermal cyc ler (San Diego, USA ) and non-
radioactive PCRs were perfo rmed on an Innovonics Gene 
Machine (Bartelt Industries, Melbourne, Australia). 
Optimal reaction CDnditions f ~r amplification with each (scq_ue,,ce.. cl '"'h,c.\r'\ are. I <..,Cc\i'<2c '" 1 A~ ef'\Cl, ><-) 
primer pairAwere determined experimentally. Cycles 
consisted of an initial denaturation at 96°C f or 4 min 
with subsequent cycles 1 min, annealing f or 1 min at the 
appropriate temperature and extensions at 72° C f or l min . 
Annealing temperatures were calculated f or each primer 
pair (Suggs et al 1981) and the l owe r temperature was 
chosen initially . Thirty five cyc les were routinely 
performed . Monitoring of contamination was done by 
including a negative control in all sets of 
amplifications. This cont r ol conta ined all reacti on 
components except template DNA . Reaction mixture s 
excluding DNA were set up in a DNA-free area that was 
regularly illuminated with lN radiation to reduce 
contamination risk. 
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2.2.5 Restriction endonuclease digestion of DNA 
For restri ction fragment length polymorphism (RFLP ) 
analysis, approximately 10 µ g of DNA was digested in a 
50 µL volume containing 5 µ L of stock buffer (supp lied ) 
and 50 units of the appropriate restriction endonuclease 
according to the manufacturers protocol for incubat i on 
time and temperature . 
Digestion of PCR products was carried out as above 
but in a 10-20 µ L volume using approximately 250 ng of · 
amplified DNA and 1-5 units o f enzyme. The restriction 
enzyme Aci I required the addition of 1% gelatin t o the 
reaction mix and replacement o f the recommended New 
England buffer 2 with New England buffer 4. Under these 
altered conditions the enzyme proved more reliable. 
2.2.6 Gel electrophoresis of DNA 
Agarose gels were prepared by dissolving the 
appropriate amount of agarose in Tris-acetate-EDTA (TAE) 
buffer (0 . 04 M Tris /acet ic acid , 0 . 002 M EDTA pH 7 . 8) . 
Ethidium bromide was added to a final concentration o f 
0 . 5 µ g / mL . 
The percentage of agarose in gels varied depending on 
the size of DNA fragments being examined . Small 
fragments , for example 100 - 300 bp , were run on 2% (w/v) 
gels . Total genomic digests were electrophoresed on 0 . 7 % 
(w/v) gels in order to separate the larger fragments . 
To examine PCR amplified C6 exons 5 µ L o f each 
reaction product plus 2 µ L of loading dye (30% v/v 
glycerol, 0 . 25% w/v bromophenol blue) was electrophoresed 
in a 2% (w/v) agarose gel at 120 V for 30 min. After 
electrophoresis fragments were made visable using a UV 
transilluminator at wavelength 254 nm . 
Acrylamide solution (40% w/ v) was made up to a ratio 
of 19 : 1 acrylamide to N,N-methylene-bis-acrylamide. The 
solution was de-ionised by stirring with mixed bed resin 
then filtered to remove resin particles. It was then 
degassed under vaccuum, pro tec ted from light and stored at 
4·c. Armnonium persu lphate solution (10% w/v) was made 
fortnightly and stored at 4· c . 
Polyacrylamide gels were made by diluting the above 
acrylamide solution with TBE then polymerising it by 
addition of 0 . 625% (v/v) ammonium pers ulphate and 0 . 075% 
(v/v) Terned. Digested PCR products were separated on 
160 x 160 x 1.5 mm polyacrylamide gels using Hoefer 
supplied plates and tank apparatus in TBE buffer. Gels 
were run at 30 mA for 2 to 4 hours , then stained with 
ethidium bromide and photographed. In cases where band 
sizes were very small it was necessary to silver stain the 
gel instead. The method used was an adaptati on o f Merril 
et al 1981 and involves soaking the gel in 10% 
ethanol /0 . 5% acetic acid for 3 min twice f o llowed by 10 
min in 0 . 1% AgN03 . The gel was then washed twice in ddH 2o 
and soaked in 1.5% NaOH, 0.01% NaBH 4 , 0.15% formaldehyde 
until bands became visible. The reaction was then stopped 
by a 10 min incubation in Na 2co3 . Gels were pho t ographed 
and if desired dried and stored . 
2.2.7 Southern blot and restriction fragment length 
polymorphism analysis 
2.2.7.1 Transfer of DNA on to membrane 
Digested DNA was transferred from the agarose gel 
onto nylon membrane (Biotrace HP) according to the method 
of Southern (1975) with modifications by Reed and Mann 
(1985) . Prior to transfer, gels were de-purinated in 
0 .25 M HCl for 10 min to facilitate transfer of large 
fragments. Membranes were rinsed in ddH 20 then alkali 
transferred using capillary blotting. Gels were blotted 
overnight and then rinsed in 2 x SSC (0 . 3 M NaCl, 0 . 03 M 
sodium citrate [pH 7. 0]) air dried, fixed under UV light 
(254 nm) for 3 min then dried for 2 hr at 65°C. 
2.2.7.2 Hybridisation of DNA on nylon membranes 
According to the protocol of Nasmyth (1982) three 
membranes and a nylon sheet were soaked in 2 x SSC, rolled 
so 
and placed into glass bottles. Pre-hybridisati on mix 
containing 50 µg/mL o f pre-boiled sonicated salmon sperm 
DNA, 10 mL Nasmyth solution and 10 mL ddH 2o, was added t o 
the hybridi sa tion bottles. Membranes were pre-hybridised 
at 65°C for approximately 18 hours on first use, 
subsequent pre-hybridisation periods were 2 hr. Nasmyth 
so luti ons (1.1 M NaCl ; 0 . 333 M Na2HP04; 0 . 111 M EDTA 
[pH 6 . 2] 1 . 85% N-lauryl sa r cos ine and 18 . 5% dextran 
sulfate) were made f o rtnightly and sto red at 4°C. 
Hybridisation solutions were essentially identi cal to 
pre-hybridisation solutions . Sonicated salmon spe rm DNA, 
10 mL ddH2o and labelled probe were boiled f o r 10 min. 15 
mL of fresh, warmed Nasmyth solution was then added to the 
probe mix . The pre-hybridisation mix was discarded and 
hybridisation mix was added quickly to the bottles. 
Membranes were incubated at 65°C for 12 to 48 hour s in a 
Hybaid oven. 
Hybridisation solutions were discarded f ol l owing 
incubation and membranes were washed first at r oom 
temperature for 10 min in 2 x SSC , 0 . 1% SDS . Consecutive 
washes in 1 x SSC , 0 . 1% SDS and 0 . 5 x SSC 0 .1 % SDS were 
carried out at 65° for 1 0-30 min depending on 
radioactivity levels . Membranes were checked a ft er each 
wash step . When counts reached approximately 2-20 cps the 
membranes were briefly air dried then wrapped in plastic . 
X-ray film was exposed to the membranes for 2-14 days at -
70°C . Intensifying screens, Lighting Plus (Du Pont) were 
included in the cassette to enhance results . Development 
was done in a Kodak X-Omat M20 automatic processor. 
Membranes were st ripped using 0 .1 % (w / v) SDS and 
0 . 1 x SSC . 500 mL of solution was boiled and poured over 
membranes . When the so lution coo led to room temperature 
the procedure wa s repeated until counts were reduced to 
background . Moist membranes were stored in plastic wrap 
and used several times. 
2.2.7.3 Radio-labelling of DNA 
Probes were PCR-amplified fragments of C6 cD A and 
were prepared using random priming (Feinberg and 
Vogelstein 1983,1984) . Reactions were performed using the 
Arnersham Multiprime DNA labelling systems following the 
supplier 1 s protocol . Reaction mixes contained 0 . 25 µ g PCR 
product (boiled for 2 min and then kept on ice ) ,4 µL of 
each unlabelled dCTP, dGTP, dTTP, 5 µLa 3 2 P dATP 
(3000 mCi/mM) 5 µ L reaction buffer, 5 µ L hexanucleotide 
primer buffer, 2 units DNA polymerase I - Klenow fragment 
and ddH 2o to 50 µL. Reaction mixes were incubated at 37°C 
for 1 hr. Labelled probes were then precipitated by 
addition of 2 volumes of ethanol, 0 . 1 volumes NH 4Ac and 
resuspended in 250 µ L TE . 
2.2.7.4 Molecular weight DNA marker preparation 
Radio-labelled markers were added to hybridisation 
mixes for RFLP analysis and loaded on to SSCP gels for 
orientation and size comparisons . Lambda phage DA cut 
with Hind III/Eco RI and Hind III was labelled with a 32 P 
by nick translation (Kelly et al 1970) using the Arnersham 
nick translation kit according to the suppliers 
specifications : 0 . 25 µg DNA, 3 . 3 µ L of each o f dCTP, dGTP, 
dTTP, 2 . 5 µ L a 3 2 P dATP, 5 µ L (2 . 5 units) DA polymerase 
made up to 50 µ L with ddH 2o . Reactions were inc ba ed ac 
15°C for 1 hr, ethanol precipitated and resuspended 1 
250 µL TE then stored at -2 0°C until needed. A volume 
with approximately 200 cps at a distance of 2 cm fr om a 
radiation monitor was used in each hybridisacion. pBR322 
cut with Hae III was radiolabelled using T4 polynucleo ide 
kinase : 1 µg pBR322 Hae III, 2 . 5 µ L one -phor - al -buffer-
pl s, 2 µ L (20units) T4 polynucleocide kinase, 2 µLy 32 P 
dA P, and ddH 2o o 25 µ L incubated at 37°C for 30 mi . 
The mixture was then diluted 1 in 25 with ddH 2o and stored 
at -2 o·c until needed . 
2.2.8 Single-stranded conformation polymorphism 
analysis (SSCP) 
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SSCP analysis was carried out according to Orita et al 
(1991) with modifications by Triggs Raine et al (1991). 
Specifically; radio-labelling of each C6 exon was done by 
incorporation of a 32p dATP in the PCR amplification 
reaction. On completion of PCR reactions the mixes were 
diluted 1 in 50 with 0.1% (v/v) SDS, 10 mM EDTA. 10 µL of 
the diluted product was mixed with 10 µL of formamide 
loading dye (95% formamide, 20 mM EDTA, 0.25% w/v xylene 
cyanol, 0.25% w/v bromophenol blue), boiled for 2 min then 
chilled on ice before loading. Samples were run on a 6% 
polyacrylamide gel (33 cm x 42 cm x 0.35 mm) containing 
10% (v/v) glycerol as well as on a second gel without 
glycerol. Electrophoresis of glycerol gels was at 
40 watts for 4.5 hr in a 4 ~C room and non-glycerol gels 
were run at 30 watts for 2.5 hr also in a 4 °C room. On 
completion of electrophoresis, gels were fixed in 10% 
(v/v) methanol, 10% (v/v) acetic acid for 10 min, 
transferred to 3MM Whatman paper and dried at 80° C under 
vacuum. Autoradiography was carried out from 4-24 hr at 
room temperature without intensifying screens. Films were 
developed as described previously. 
2.2.9 Cloning of DNA fragments 
2.2.9.1 Preparation of insert DNA fragments 
PCR products were extracted with a phenol, chloroform 
mixture (50 % phenol) and then ethanol precipitated using 
2 volumes of 100% ethanol and 0.1 volumes of 2 M NaOAc at 
-20 ~C overnight. The DNA was pelleted in a 
microcentrifuge for 15 min then resuspended in 13 µL 
ddH20. This product was phosphorylated using 9.2 units of 
polynucleotide kinase, 2 mM ATP and kinase buffer (50 mM 
Tris/HCl [pH 7.5], 20 mM MgC1 2 , 2 mM DTT). The mix was v incubated at 37 C for 45 min. Products were purified and 
concentrated to 5µL using microconcentrators (Amicon). 
1 µL of this was run on a 2% (w/v) agarose gel to estimate 
concentration. Products were then appropriately diluted 
or used directly in ligation reactions. 
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2.2.9.2 Preparation of blunt ended vector 
Two µ g M13mp18 RFl DNA was digested with 30 units o f 
Sma I in a 50 µ L volume containing one-phor-all-buffer 
plus and ddH2o at 30°C for 1 . 5 hr. The DNA was 
dephosphorylated with l unit of calf intestinal alkaline 
phosphatase and CIP buffer (supplied) in a final volume of 
100 µ L . Incubation was carried out at 37°C for 30 min . 
The vector was then treated with proteinase K (100 ng / µ L ) 
in the presence of 0 . 25% (w/v) SDS and 5 mM EDTA at 56°C 
for 30 min. The DNA was next extracted with 
phenol/chloroform and ethanol precipitated (as described 
above). The DNA was pelleted in a microcentrifuge and 
resuspended in 20 µL ddH 2o , such that the final 
concentration was approximately 150-200 ng/ µ L . 1 µ L of 
digested vector was run on a 1% (w/v) agarose gel along 
with a sample of undigested M13mp18 to check digestion and 
concentration . 
2.2.9.3 Blunt end ligation of insert and vector 
100 ng of linearised M13mp18 was incubated with 
approximately 30-50 ng of fragment DNA overnight at room 
temperature in a reaction mixture containing 50 mM 
Tris/HCl [pH 7.6], 10 mM MgC1 2 , 5% (w/v) polyethylene 
glycol (PEG )6000' 1 mM ATP, 1 mM DTT and 1 unit of T4 DNA 
ligase . 
2.2.9.4 Preparation of E.coli TGl competent cells 
A single colony of E coli TGl cells was inoculated 
into 10 mL Luria broth (1% (w/v) tryptone, 0 .5 % (w/v) 
yeast extract, 0 .5 % NaCl) and shaken overnight at 37°C. 
The overnight culture was then diluted one in 100 into 
200 mL of fresh sterile Luria broth and shaken at 37° C 
until the absorbance at 260 nm was 0 . 5. Cells were 
collected by centrifugation at 7000 rpm for 5 min in a 
pre-cooled centrifuge then resuspended in 40 mL CM 
solutionl (10 mM NaOAc, 50 mM Mnc1 2 , 5 mM NaCl). Cells 
were again centrifuged at 7000 rpm for 5 min then gently 
resuspended in 4 mL CM solution2 (10 mM NaOAc, 5% 
glycerol, 70 mM Cacl 2 , 5 mM MnC1 2 ). The mixture was 
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incubated on i c e f o r 20 min and then 100 µ L aliquots were 
placed into cold tubes and stored at -7 0°C until needed. 
2.2.9.5 Transformation and plating of competent cells 
Competent cells were removed from -7 0°C and placed on 
ice to thaw slowly for 20 min. Ligation mixtures were 
then added to 100 µ L of competent cells and incubated on 
ice for a further 45 min . Cells were heat shocked f o r 2 . 5 
min at 42°C and then kept on ice. To each sample 200 µ L 
o f fresh exponentially-growing TGl ce lls, 0 . 3 mM IPTG, 
0 . 02% (w / v) X-gal and 3 mL o f warmed H-t op agar (1 % w/ v 
tryptone , 0 . 5% w/v yeast extract , 0 . 8% w/ v NaCl, 0 . 8% w/ v 
agar) were added . The mixtures were gently rolled between 
palms to mix, poured onto minimal media plates and grown 
overnight at 37°C 
2.2.9.6 Screening clones and orienting fragments 
Clear plaques were grown in 2 mL Luria broth with 
20 µ L of fresh exponentially-growing TGl cells f or 
approximately 7 hr in a shaking 37°C incubator. Cultures 
were then decanted into microfuge tubes and centrifuged 
for 5 min to form a pellet of cells . To check f o r the 
presence of inserts 20 µ L of the supernatant and 5 µL DIGE 
dye (3% w/v SDS, 30% v /v glycerol , 0 . 25% w/ v bromophenol 
blue) were incubated at 6S°C f o r 10 min . Samples, along 
with control cultures, were run on a 0 . 7% (w/ v) agarose 
gel at 60 V for 4-6 hr until the bromophenol blue had run 
off the end of the gel . Clones containing insert s run 
more slowly than those without. Positive cultures were 
then tested for orientation of the insert using the 
complement test (C-test) method . 10 µ L of supernatant 
from two clones was mixed with 5 µL o f C-test dye (3% w/ v 
SDS, 30% v / v glycerol, 1 . 25 M NaCl, 0 . 25% (w/v) 
bromophenol blue) and incubated at 65°C f o r 50 min . 
Samples were then run on a 0 . 7% (w/v) agarose gel at 100 V 
for 1 hr . Clones with inserts in different orientations 
ran as two bands while inserts in the same orientation ran 
as one band . 
2.2.10 Automated DNA sequencing 
2.2.10.1 Preparatation of single-stranded DNA 
template 
M13 single-stranded DNA was prepared from DIGE and c -
tested clear plaques . 1.2 mL of plaque culture 
supernatant was removed and incubated with 300 µ L PEG /NaCl 
solution (20% w/v PEG 6000 , 2 . 5 M NaCl) on ice for 30 min. 
Tubes were then centr ifuged for 15 min and all traces o f 
PEG/NaCl solution were removed . The pellet was 
resuspended in 100 µL TE and extracted with equal volumes 
of phenol and chloroform-IAA . DNA was precipitated fr om 
the aqueous phase by addition o f 2 volumes of 100% ethanol 
and 0 . 1 volumes of 3M NaOAc (pH 5 . 3) . The pellet was 
recovered after centrifugation and rinsed in 70% ethanol 
before being vacuum dried and resuspended in 8 - 15 µL 
ddH20 . 
2.2.10.2 Estimation of single-stranded DNA 
concentration 
Yields o f single-stranded template were estimated by 
running 1 µL o f the DNA on a 1% (w/v) agarose gel along 
with 100 ng / µL of single-stranded M13mp8 . Band 
intensities were compared and usually yields of single-
stranded DNA were in the range 100-250 ng / µ L . 
2.2.10.3 Sequencing protocol 
Approximately 600 ng of single - stranded DNA template 
was sequenced using an automaced DNA sequencing system 
(ABI) . Reactions for each A and C base involved PCR 
cycling 100 ng of template, 1 µL Taq buffer (supplied), 
1 µ L M13 dye primer Joe or Fam (0 . 4 pmol / µL), 1 µL d/ddATP 
or d/ddCTP and 1 . 25 units Taq polymerase . G and T bases 
required M13 Tamra and Rox dye labelled primers 
respectively and twice the volume of all react i on 
components. Tubes were then overlayed with approximately 
10 µL of mineral oil and placed in a PCR cycling machine . 
Denaturation at 95°C for 3 min (cycle 1), and 30 sec 
(cycles 2-30), annealing at 55°C f or 30 sec and extension 
at 70°C for 1 min for 30 cycles . After PCR cycling was 
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complete the four A,C,G,T reactions were pooled and 
precipitated using 2 . 5 volumes of 100% ethanol and 0 . 1 
volumes 3 M sodium acetate (pH 5 . 3) at - 20°C for several 
hr. DNA was pelleted in a microfuge for 30 mins, rinsed 
in 70% ethanol and vacuum dried . The pellet was 
resuspended in 5 µ L deionised f o rmamide, 1 µL 50 mM EDTA 
(pH 8. 0) heated for 2 min at 90°C and electrophoresed on a 
6% denaturing polyacrylamide gel, using an ABI 373 
automated DNA sequencer . The ABI version 1.3 software was 
used to perform the automatic fluoresence analysis and 
base calling . 
2.2.11 Statistical and computing methods 
Restriction digest analysis of C6 exons was carried 
out using the software package PC / Gene (™ , Intelli-
genetics Inc., U. S . A. ) . Primers were designed using the 
PCR primer selection software (Epicentre Software, 
Pasadena, U. S .A. ) . Ca lculation of protein pI values was 
carried out using the Isoelectric computer program 
(Genetics Computer Group Sequence Analysis Software 
package version 7 . 2) . Statistical analyses were performed 
using the INSTAT computer program, P values o f 0 . 05 or 
smaller were accepted as significant. Linkage 
disequilibrium estimates were calculated using three 
methods , these are described further in chapters 3 and 6 . 
One method utilised log linear modelling techniques with 
the program GLIM 3 . 77 update O (copyright) 1 985 Royal 
Statistical Society, London . A second method used Baur 
and Danilovs (1980) equation for linkage, and a 
specifically written computer program (X Gao, Human 
Genetics Group, John Curtin School of Medical Reseach) for 
the calculation , this method incorporated both possible 
haplotypes for double heterozygotes. 
Chapter 3 
Chapter 3 
C6 Protein Typing and Taq I RFLP analysis 
3.1 Introduction 
Complement component s ix wa s first f ound to be 
polymorphic in 1975 (Hobart et al) using i soe lectric 
focusing (IEF) . Three common patterns are seen and 
designated A, Band AB, the A pattern being the more 
anodic . Additionally rare patterns occur which are 
characterised by strong bands at some fracti on o f the 
normal band interval . To date there are at least 19 
variant allotypes (review Tokunaga et al 19 90) . 
The inheritance of these patterns conforms to an 
autosomal codominant model (Hobart et al 1975). It was 
suggested by Alper et al (1975) that the A and B patterns 
differed by a single unit of charge causing a frameshift 
of the A pattern and this has since been proven (Fernie 
et al 1993, Chapter 4, Dewald et al 1993). Since the 
initial report of C6 IEF polymorphisms many population 
groups have been studied . Table 3 .1 shows a summary o f 
these findings. The main difference appears to be that 
the C6 A allotype is the more common form in Caucas ians, 
while C6 Bis more common in Oriental groups who are also 
characterised by a relatively high frequency o f the II rare 11 
C6 *B2 allele . In all studies the gene frequen c ies conform 
to Hardy-Weinberg expectations, suggesting that there is 
little o r no selective pressure on C6 alleles (Hobart 
et al 1975). 
Several studies have shown that C6 and its 
functionally sequential component C7 are structurally and 
biochemically very similar (Podack et al 1979, Discipio 
and Gagnon 1982), and that the genes for these proteins 
are closely linked (Hobart et al 1979, Tokunaga et al 
1986), along with C9 on chromosome 5pl3 (Jeremiah et al 
1990) . Many animal studies have shown that C6 is 
polymorphic and inherited as an autosomal codominant gene, 
in rabbits (Kunstman and Mauff 1980, Goldman et al 1982, 
oo Table 3.1 Published C6 pro tein allele frequencies tor various racial groups. u, 
C6 Protein Allele Frequencies Sample 
Number Population - Country(group) A B Rare 
Cau c asian - England , USA 0 . 610 
USA 0 . 646 
England , USA 0 . 621 
Norway 0 . 610 
West Germany 0.613 
West Germany 0 . 601 
Germany 0 . 646 
Australia (IDDMl 0 . 590 
Australia (NIDDM) 0 . 612 
Australia 0 . 642 
Norway (Lapp s ) 0 . 530 
Norway (Non-Lapps) 0 . 590 
England 0 . 683 
ItaJy 0 . 657 
Sardinia 0 .7 06 
Russia 0 . 625 
A 
Combined Caucasian data 
Range 
0 .624 
0 .~30-0 . 706 
(0 . 041) SD 
0.370 
0.333 
0 . 360 
0 .3 90 
0 . 379 
0 . 388 
0 . 3 4 6 
0 . 404 
0 . 362 
0 . 345 
0 .47 0 
0 . 410 
0 . 307 
0 . 334 
0 .2 94 
0.350 
B 
0 . 01S 
0 . 021 
0 . 018 
0 . 000 
0.008 
0.011 
0.008 
0.006 
0 . 025 
0.013 
0 .00 0 
0 . 004 
0.010 
0 . 009 
0 . 000 
0 . 010 
99 
264 
189 
81 
194 
709 
254 
162 
178 
116 
167 
1623 
202 
439 
240 
? 
0 . 366 
0.294-0 .4 70 
(0 . 0 43) 
Rare 
0 . 010 
0 . 000-0 . 025 
(0.007) 
Reference 
Hobart and Lachmann 1975 
Alper et al 1975 
Hobart amd Lachmann 1976 
Olving et al 1977 
Rittner et al 1979 
Kunstmann et al 1980 
Kuhnl and Kreckel 1980 
Kirk et al 1980 
Kirk et al 1980 
Kirk et al 1980 
Olving et al 198 0 
Olving et al 1980 
Whitehouse and Putt 1983 
Scacchi et al 1992 
Scacchi et al 1992 
Kucher et al 1993 
Total Number 
>4917 
m 
Ul 
Table 3.1 continued. 
C6 Protein Allele Frequencies 
Population - Country (area) A B Rare 
Oriental - N. Ameri c a 
l.Japan 
Japan 
Japan 
Japan 
China (Beijing) 
China (Guangzhou) 
Japan (Ibaraki) 
0 . 590 
0.427 
0 . 423 
0.432 
0 . 467 
0 . 416 
0 . 445 
0 . 450 
Japan 0.446 
Korea ( Seol) 0 . 433 
China (Fujiang) 0 . 463 
China (Si c huan) 0 . 498 
China (HeiJ o ngjiang)0 . 471 
China (Zhengzho Han)0 . 452 
China (Lanzho u Han) 0 . 461 
China (Huhho t Han) 0 . 445 
China (Xi' an Han) 0 . 4 9 0 
China ( Guangd ong) 0 . 4 5 7 
China (Liaoning) 0.470 
Combined Oriental data 
Range 
Standard deviation 
A 
0 . 460 
0 . 416-0 . 590 
0 . 038 
0 . 3 50 
0.483 
0.510 
0 . 503 
0 . 481 
0 . 532 
0 . 518 
0.477 
0.466 
0 . 523 
0 . 500 
0 . 448 
0 . 522 
0 . 523 
0 . 522 
0 . 529 
0 . 487 
0 . 515 
0.505 
B 
0.050 
0 . 090 
0 . 067 
0 . 065 
0 . 052 
0 . 052 
0 . 037 
0 . 073 
0 . 088 
0 . 044 
0 . 037 
0 . 055 
0 . 007 
0 . 025 
0 . 017 
0 . 026 
0 . 023 
0 . 028 
0 . 025 
0 .4 9 4 
0 . 350-0 . 532 
0.0 4 2 
Sample 
Number 
5 J. 
288 
495 
565 
135 
155 
255 
351 
278 
490 
') 
') 
') 
') 
') 
') 
') 
') 
203 
Rare 
Reference 
Hobart and Lacrunann 1975 
Tokunaga et al 1983 
Tokunaga et al 1984 
Nakamura et al 1984 
Nishimukai et al 1985 
Zeng et al 1986 
Zeng et al 1986 
Washio et al 1986 
To kunaga et al 1986 
Park et al 1988 
Zhang and Du 1990 
Zhang and Du 1990 
Zhang and Du ]990 
Hu and Du 1992 
Hu and Du 199') 
Hu and Du 1992 
Hu and Du 1992 
Hu and Du 1992 
Ts u nenari et al 1992 
0 . 03 8 
0 . 007-0 . 090 
0 . 023 
Total number 
>3266 
( 'I 
' (' 
Table 3 .1 continued . 
Population - Country 
Blacks -
N. America, W. Indes, Nigeria 
Indians - India 
Fiji 
India , 
Micro nesians - Nauru 
Polynesians - W.Samoa 
Rarotonga 
New Caledonia 
Melanesia - New Caledonia 
Uvea 
Fiji 
Aust-ralia - N . W. Aborigines 
C . Aborigines 
New Guinea - E . Highlands 
New Britain 
Rhesus Monkeys 
C6 Protein Allele Frequencies 
A B Rare 
0 . 560 
0.551 
0 . 500 
0.612 
0 . 633 
0 . 446 
0.375 
0 . 629 
0.708 
0 . 600 
0 . 638 
0 . 650 
0 . 637 
0 . 693 
0 . 679 
0 . 5 4 6 
0 . 481 
0 . 578 
0 . 624 
0 . 592 
0 . 380 
0 . 403 
0 . 500 
0 . 388 
0 . 366 
0 . 452 
0 . 568 
0 . 359 
0 . 287 
0 . 396 
0.347 
0 . 336 
0 . 345 
0.307 
0 . 315 
0.404 
0 . 420 
0 . 402 
0.376 
0 . 354 
0 . 060 
0.045 
0 . 000 
0 . 000 
0 . 000 
0 . l O £• 
0 . 055 
0 . 006 
0.005 
0 . 004 
0 . 015 
0 . 014 
0 . 018 
0 . 000 
0 . 006 
0 . 050 
0 . 09 
0 . 020 
0 . 000 
0 . 005 
(' l ,,(1mp P 
NumbPt Refe1·ence 
c; 9 
165 
13 
115 
86 
180 
440 
245 
g4 
120 
852 
70 
139 
180 
319 
9 
106 
97 
105 
103 
Ho bar 
Hobar 
nd Lachmann L975 
and Lachmann 1976 
Hoba rt and Lachrnann 197 
Ranford et al 198 
Co rbo et al 1991 
Ranford et al 198 
Ranford 198 9 
Ranford et al 1982 
Ranford et al 198 
Ranford et al 198 
Ranford 1989 
al 198 Ranford ~-
Ran ford e 
Ranford et 
Ranford 1989 
Ranford 198 
Ranford 198 9 
Ranford 198 9 
Ranford 1989 
J 198 
1 l 9 8 £, 
Holl a11ci AJoer 1977 
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Rother 1986), rats (Granadose et al 1984), manx shearwater 
(Whitehouse 1982), pigs (Shibata et al 1993), and rhesus 
monkeys (Hall and Alper 1977). The close genetic linkage 
of C6 and C7 seen in man has also been found in marmoset 
(Whitehouse 1984), mouse (Orren et al 1985), dog (Eldridge 
et al 1983) and opposum (van-Oorschot et al 1993) This 
suggests that C6 and C7 are strongly conserved throughout 
species and probably of great antiquity. 
Genetically controlled deficiency states have been 
identified for C6 , firstly by Leddy and coworkers in 1974; 
by 1992 more than 100 C6 deficient individuals had been 
identified (review Wurzner et al 1992a) . Work by Orren 
et al (1992) suggests that there may be two groups within 
the C6 deficiency category . In one group individuals have 
very low levels of C6 ; 0 . 3-3 µ g/mL compared with the 
normal range of 20-80 µ g/mL . The C6 protein in these 
samples is hemolytically active , able to incorporate into 
the terminal complement complex , has a molecular weight 
79-86 percent o f normal C6 and has only one weak·anodal 
IEF band . I n d i v i duals with this C6 pattern are termed C6 
subtotal deficients (C6SD) . Samples in the second group 
show no detectable levels of C6 protein in their sera and 
are termed C6QO for quantitative zero. 
At least 17 studies have suggested that deficiency of 
C6 (C6QO) or C7 may lead to increased susceptibility to 
neisserial infection (partial review Hauptman 1989, Potter 
et al 1990 , Densen 1991) . In addition meningococ caemia 
has been reported in a case of acquired complement 
component deficiency (C3-C5 , C8 , C9 and fact or Band I ) 
due to hepatic failure (Ellison et al 1986) . 
Interestingly Wurzner et al (1991) study o f C6SD 
individuals showed them to have no history o f susceptibity 
to neisserial infections . Therefore it appears that even 
very low levels of functionally active C6 and C7 may 
provide protection against these infections . 
Reports of an association between toxoplasma and C6 
deficiency (C6QO) have also been described (Feldman and 
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Schreiber 1977, Delage et al 1979, Morgan et al 1989) as 
has an association between hyperthyroidism and C6 
deficiency (Trapp et al 1987, Morgan et al 1989) and 
recurrent bronchopulmonary infections (Glass et al 1978). 
C6 deficiency (C6QO) has not been limited to 
associations with infec tive disease states but also with 
autoimmune disorders. Individual cases of C6 and C7 
deficiency have been found in patients with systemic 
(Tedesco et al 1981, Zeitz et al 1981) or discoid lupus 
erythematosus (Trapp et al 1987), Sjogrens syndrome (Trapp 
et al 1987), rheumatic illness (Boyer et al 1975), 
arthritis with antinuclear antibodies (Reinitz et al 
1986), haematuria (Sakano et a l 1988) and other diseases. 
A significant association between the C6 *B2 allele and 
glomerulonephritis has also been reported (Nishimuka et al 
1985) . To date two studies (Kirk and Ranf o rd 1980, 
Yukiyama et al 1985) have examined C6 protein associations 
in autoimmune disease patients. Kirk and Ranford (1980) 
showed that 340 Caucasian diabetes patients had C6*A and 
C6*B frequencies similar to contro l s . Yukiyama and 
coworkers (1985) showed that Japanese SLE patients had 
reduced C6*A and C6*B2 frequen c ies compared with controls . 
Complete and partial deficiencies of 
complement components C2 and C4 are associated with 
systemic lupus erythematosus (SLE) (Glass et al 1976, 
Schur 1978, Fielder et al 1983, Chr i stiansen et al 1983, 
Dunckley et al 1987) with C4A deficiency being a genetic 
determinant of the disease in approximate ly one third of 
SLE patients (Dunckley et al 1987). It is of interest 
then to determine whether complete or partial deficiencies 
of C6 are similar genetic determinants o f SLE in 
Caucasians, as C4A deficiency. 
Additionally a C6 DNA polymorphism, a Taq I 
restriction fragment length polymorphism (RFLP) has been 
reported (Coto et al 1991a) but not extensively studied in 
either patient groups or healthy controls . Prior to 
widespread implementation of the polymerase chain reacti on 
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(PCR), DNA analysis u s ing RFLP was used t o d e tect p r o tein 
polymorphisms, often relying on linkage di s equilibri um as 
well as direct detecti on o f the p o lymo rphi s m. J a zwin s ka 
et al (1988) showed that the s erologically detectable Gm 
allotypes could be confidently defined by RFLP analysi s . 
Similarly a study by Kohonen-Corish and Serjeantson (1 98 6 ) 
showed that HLA-DR protein phenotypes correlated with the 
HLA-DRP/Taq I RFLP. The present study examines whether 
Taq I RFLP analysis could replace traditi onal C6 pro t e in 
typing . 
In this study C6 protein analysis was carried out on 
403 Caucasian SLE patients and 50 healthy Caucasian blood_ 
donors and laboratory staff using the conventional IEF gel 
technique (Hobart et al 1975) followed by passive transfer 
of protein to a membrane (Tokunaga et al 1984) and 
immunological detection (Whitehouse and Putt 1 983 ) . Thi s 
combination of methods was chosen for its simplicity and 
availability of reagents . Taq I RFLP studies were carried 
out on 99 SLE patients and 46 healthy blood donors and 
laboratory staff . Numbers for RFLP analysis were much 
reduced in the SLE patient group due to the limited supply 
of large amounts of DNA , but numbers were considered 
adequate for the identification of an abs o lute correl a ti on 
with protein data . 
3.2 Aims 
To examine complement component six protein and Taq I 
RFLP phenotypes and allele frequencies in a Caucasian SLE 
patient group and healthy white Australians. 
3.3 Materials and Methods 
3.3.1 SLE Patients 
The SLE group examined consisted o f patients wh o had 
been diagnosed with SLE according to the 1982 rev i s e d 
criteria for classification of SLE (Tan et al 1982 ) . 
Patients came from Sydney where they had been reviewed by 
Dr Paul Gatenby (Clinical Immunologist, Royal Princ e 
Alfred Hospital) Serum samples had been sto red a t - 70°C 
for up to eight years. DNA wa s extrac ted f o r p rev i ous 
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studies between 1985 and 1989 using the s andard 
phenol /chloroform method (Maniat i s et al 1984) and st o red 
at 4°C since then . 
3 . 3.2 Controls 
Serum samples were stored at -70°C . DNA was 
extracted for previous studies from healthy Canberran 
blood donors , laboratory staff and students and kept at 
4·c. 
3.3.3 Methods 
Serum samples were C6 protein typed and DNA samples 
RFLP typed according to the methods described in Chapter 
2 . Some Taq I RFLP results were obta i ned by probing pre-
existing nylon filters from previous studies by E 
Jaz ~: inska and H Dunkley . This was done to conserve the 
limited supplies of DNA . Statistical analysis methods and 
linkage disequilibrium estimation methods are described 
and referenced in Chapter 2 . 
3.4 Results 
3.4.1. Frequency of protein types 
Figure 3 . 1 shows a C6 protein gel with the three 
common patterns AA , AB, BB and the heterozygous rare 
protein types found in this study ; AlA, ABl, BB2, AB21 and 
BM91 . C6 protein phenotypes and allele frequencies o f SLE 
patients and controls are shown in Table 3 . 2 . SLE 
patients and healthy controls showed very similar C6 
protein allele frequencies (X2 = 0 . 002 , P = 0 . 990). Both 
patient and control group C6 allele frequencies did not 
differ from expected Hardy - Weinberg equilibrium values (X2 
= 0 . 160, P = 0 . 997 , x2 = 0 . 005 , P = 0.997 respectively ) 
The SLE patients were European Caucasians as were the 
healthy control group and as such a comparison with pooled 
published Caucasian data was appropriate . No significant 
difference between the groups was found (SLE vs publi shed 
mean ; x2 = 0 . 769, P - 0 . 768 , Healthy vs published mean; x2 
= 0 . 755 , P = 0 . 686) 
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Figure 3.1 A C6 protein gel showing the three common and 
four rare protein types. Lane 1 AA, lane 2 and 16 BM91, 
lanes 3 and 11 AB, lanes 4, 5, 6 and 14 BB, lane 7 AB2, 
lanes 8 and 12 BB2, lane 9 ABl, lanes 10 and 15 AlA, lane 
13 AB21. 
Schematic Representation of C6 Protein Gel 
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Table 3 . 2 The distributi o n o f C6 phenotypes and C6 allele frequencies in an SLE patient 
group and a healthy Cau c asian group. 
C6 Protein Phenotype 
A AB B Arare 
Population Obs Exp Obs Exp Obs Exp Obs Exp 
( % ) ( % ) ( % ) ( % ) 
SLE - Caucasian 135 132.3 189 194.4 74 71.4 3 2 . 8 
(33.5) (46.9) (18 . 4) ( 0 . 7) 
Healthy - Caucasian 15 15.7 25 24.1 9 9.2 1 0.6 
(30.0) (50.0) (18.0) ( 2 . 0) 
Population C6 Allele Frequencies 
C6*A 
SLE - Cau c asian 0.573 
Healthy - Caucasian 0.560 
Poo led Published 
Cau c asian datac 0 . 615 
Obs= observed sample number s , 
a x2 = 0.160 df = 4 P = 0. 9 9 , 
c See Table 3.1 for referenc es 
C6*B C6*R Number Tested 
0.421 0.006 403 
0.430 0.010d 50 
0.374 o.011e,f 4968 
Exp= expected sample numbers 
b x2 = 0.005 df = 3 P = o . 997 
d C6 allele frequencies SLE vs Healthy x2 = 0.002 df = 2 P = 0 . 990 
e C6 allele frequencies SLE vs Published x2 = 0 . 769 df = 2 P = 0 . 768 
f C6 allele frequencies Healthy vs Published x2 = 0 . 755 df = 2 P = 0 . 686 
Brare 
Obs Exp 
( % ) Total 
2 2.oa 403 
( 0 . 5) 
0 ob 50 
( 0. 0) 
b 
Four rare protein types in five patients were found 
and one in the control group. These variants were 
tentatively named using published patterns as a reference 
and later confirmed by Y Tokunaga, Blood Transfusion 
Service, University Hospital, Tokyo, Japan. 
3.4.2 Frequency of RFLP patterns 
RFLP phenotypes of SLE patients and controls as well 
as calculated allele frequencies are shown in Table 3 . 3 . 
The two polymorphic bands detected with a 3 1 1.28 kb 
fragment of C6 cDNA (R Discipio, Research Institute of 
Scripps Clinic, La Jolla, California, USA) are an 8 . 0 kb 
and a 7 . 0 kb fragment (Figure 3.2) . SLE and healthy 
control data show very similar RFLP allele distributions, 
(X2 = 0.002, P = 0.990). Insufficient quantities of DNA, 
or absence of pre-existing membranes, prevented RFLP 
analysis of three of the six rare-protein type samples. 
However the remaining three rare-protein type samples were 
RFLP typed . BM91 was an 8 . 0/7 . 0 kb RFLP heterozygote , BB2 
was a 7 . 0 kb RFLP homozygote and ABl was an 8 . 0 kb 
homozygote. RFLP patterns for these individuals were 
identical to patterns found in samples with common-protein 
phenotypes. RFLP allele frequencies of SLE, healthy 
Caucasians and published Spanish data are similar (S LE vs 
Spanish ; x2 = 0.412 P = 0.814, healthy vs Spanish; x2 = 
0 . 212 P = 0 . 899) and do not differ from expected Hardy-
Weinberg equilibrium values (SLE ; x2 = 0.009, P = 0.955 , 
Healthy; x2 = 0.186, P = 0.911) 
3.4.3 Association of protein and RFLP types 
No absolute correlation between protein and RFLP 
types was found . Analysis of this data involves some 
degree of uncertainty since haplotypes of double 
heterozygotes cannot be definitively identified . Three 
methods of examining the data are available; 1) exclusion 
of double heterozygotes, 2) double heterozygotes counted 
twice, ie both possible haplotypes included and 3) double 
heterozygotes distributed among the possible haplotypes 
based on the allele frequencies o f the two sites. Tables 
3.4 (a-c) show the haplotype frequencies for the three 
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Figure 3.2 C6 1 . 28 kb cDNA (1689-2971 bp ) hybridisation 
o f Taq I digested genomic DNA . Lane l homozygote 7 . 0 kb , 
lane 2 heterozygote 7 . 0 and 8 . 0 kb, and lane 3 homozygote 
8.0 kb. 
C6 - 1.28kb cDNA (1689-2971bp) x TaqI 
1 2 3 
kb 
-8.0 
-1.0 
' 4 
r 
Table 3.3 C6 Taq I RFLP phenotypes and aJ lele frequ e n c ie s in cu 1 SLE patient group and 
!JPalthy Ca u c asian group 
Population 
S LE - Ca ucasian 
HPaJthy - Ca ucasian 
Population 
SLE - Ca 1-1casian 
Healthy - Caucasian 
Spanish dataf 
C6 Taq I RFLP Type 
8.0 8.0 / 7.0 
Obs Exp 
( % ) 
15 13.8 
(15 . 2) 
7 7.8 
(15 . 2) 
Obs Exp 
( % ) 
44 46 . 3 
(44 . 4) 
24 22 . 3 
(52.2) 
(kb) 
7 . 0 
Obs Exp 
( % ) 
40 38.8a 
(40 .4 ) 
15 ls.oh 
( 3 2 . 6) 
C6 Taq I RFLP Allele Frequencies 
C6 * 8 . 0 C6 *7.0 
0 . 374 
0 .4 13 
0 . 400 
0 . 626 
0 . 587c 
0 . 6ood,e 
Obs = o bserved sample numbers , Exp= expected sample numbers 
a SLE , testing Hardy -Weinberg equilibrium x2 = 0 . 009 df = 2 
Total 
Total 
99 
4 6 
62 
99 
4 6 
P = 0 . 955 
b Healthy, testing Hardy - Weinberg equilibrium x2 = 0.186 df - P = 0 . 911 
P = 0 . 710 C6 RFLP allele frequencies SLE vs Heal thy x2 = 0 . 688 df = 2 
d C6 RFLP allele frequencies SLE vs Spanish x2 = 0 . 412 df = 2 
e C6 RFLP allele frequencies Healthy vs Spanish x2 = 0 . 212 df 
f Coto et al (1991a) 
r = 0 .814 
= 2 P = 0 . 899 
N 
r--
* 
Table 3.4a C6 proteLn and C6 T'aq I RFLP data pooled fr u m tlH, .r:; 1,i-,: pat1enr group and healthy 
Ca u c asians. 
Method l; Hapl otyres o [ combined SLE and h ec:1lt.. hy Cr1uc ,-:i s ietn ~:; pr ,,LP. 111 and Taq J RFLP dc1ta 
e x cl uding d o uble l1elerozygotes and rar·e - protei n all e les. 
Genotypes Observed (N) 
1\A : 
8.0 / 8 . 0 (15) 
8.0/7.0 ( .! 9 ) 
7 . 0/ 7.0 (lL) 
AB : 
8 . 0/8.0 (4) 
8.0/7.0 (43) 
7.0 / 7.n (22) 
BB : 
8 . 0/8.0 (2) 
8.0 / 7.0 (4) 
7.0/7.0 (20) 
To t a 1 ( 14 0) 
Haplotype frequen cies 
hapl ot ypes not dis c ernable 
A-8.0 
10 
l q 
4 
* 
r- 3 ) _ 
0 . 273 
Haplotype Assignment 
B-8.0 A-7.0 B-7.0 
4 
4 
4 
* 
12 
0 . 062 
I Y 
. ) 
• L, 
... 
2 ). 
h 3 
) ])r: l . - ..., .) 
-
22 
4 
40 
* 
,6 
0 .340 
Linkage disequjlibrium ; oa = (freq o f A - H . O) (freq of 8 - 7 . 0) 
Da = 0 . 075 
(freq of A - 7 . 0) (freq o f B -8 . 0) 
C6 *A and C6 * 8 . 0 
C6 *B and C6 *'7 . 0 
uh 
ob 
Db= Baur and na n ilovs me h od 
= 0.077, X;, = 21 . 73 , P, 0 . 00 1 
2 
-= 0.063, X = 14 . 08 , P = 0 . 035 
(1980) 
Table 3.4b C6 protei11 and C6 Taq I RFLP data pooled from the SLE patient group and l1edlthy 
Caucasians. 
~ Method 2; Haplotypes o f combined SLE and healthy Caucasians protein and Taq I RFLP data 
including double heterozygotes, counted twice for both possible hapl otypes and excluding 
rare-protein alleles 
Haplotype Assignment 
Genotypes Observed (N) A-8.0 B-8.0 A-7.0 B-7.0 
AA : 
8.0/8.0 (15) 
8 . 0 / 7 . 0 (19) 
7.0/7.0 (11) 
AB: 
8 . 0/8 . 0 (4) 
8.0 / 7 . 0 (43) 
7 . 0 / 7 . 0 (22) 
BB : 
8 . 0/8 . 0 (2) 
8 . 0/7 . 0 (4) 
7 . 0/7 . 0 (20) 
Tota l ( 140) 
Haplotype frequency 
* . . haplotypes n ot discernibl e 
Linkage disequilibrium; oa = 0 . 03 46 
30 
19 
4 
43* 
96 
0 . 262 
4 
4 3 * 
4 
4 
55 
0 .15 0 
C6 *A and C6 * 8 . 0 ob= 0 .11 9 x2 = 64 .4 1, P < 0 . 001 
C6 *B and C6 *7. 0 ob~ 0 .1 01 , x2 = 47.00, P < 0 . 001 
19 
22 
43* 
22 
106 
0 . 290 
43 
22 
4 
40 
* 
109 
0 .298 
'sjt 
r---
Table 3.4c C6 protein and C6 Taq I RFLP data pooled from the SLE patient group and healt l iy 
Caucasians . 
Method 3 ; Predicted haplotypes of combined SLE and healthy Caucasians p1-otein and Taq I RFLP 
data using gene counting f o r all but the double heterozygotes, with these distributed 
according to allele frequen c ies for the two sites, rare-protein alleles excluded. 
Haplotype Assignment 
Genotypes Observed (N) A-8.0 B-8.0 A-7.0 B-7.0 
AA : 
8.0/8 . 0 (15) 30 
8 . 0/7.0 (19) 19 19 
7 . 0 / 7 . 0 (11) 22 
AB : 
8 . 0/8 . 0 ( 4) 4 4 
8 . 0/7 . 0 (43) 18.43* 30 .8 5 * 13 . 54 * 22.66 * 
7 . 0/7 .0 (22) 22 22 
BB : 
8 . 0/8 . 0 ( 2 ) 4 
8.0 / 7.0 ( 4) 4 4 
7 . 0/7 . 0 ( 2 0 ) 40 
--
Total (140) 71 4 3 77 89 
Haplotype frequencies 0 . 254 0.154 0 . 275 0 . 318 
* haplotypes not discernibl e 
Linkage disequilibrium using the conventional equation; 
oa = 0 . 038 
methods described . Analysis o f these results (Table 3 . 5) 
shows there 
( 1 vs 2; x 2 
df = 3 , P = 
to be no significant difference between them; 
2 
= 4 . 38 , df = 3 , P - 0 . 223 , 1 vs 3; X = 4.4 0 , 
2 0 . 230, 2 vs 3 ; X = 0 .1 02, df = 3, P = 0 . 992 ) 
Numerous methods for estimation of linkage 
disequilibrium (D) between two loci are available, the 
simplest being; 
Da = (freq A-8 . 0) (freq B-7.0) - (freq A-7.0) ( freq B- 8 . 0) 
Results of this calculation for the three different 
haplotype distribution methods are given in Tables 3.4 (a-
c) . This linkage disequilibrium calculation for method 1) 
(discarding double heterozygotes) gives a value of Da = 
0 . 075, suggesting linkage disequilibrium between these 
sites. The alternative methods 2) and 3) give Da = 0 . 035, 
and 0.038 respectively, concluding a random association. 
A second linkage disequilibrium estimation method (Baur 
and Danilovs 1980) is considered better as it attempts to 
normalise the equation for allele frequencies which the 
equation given above does not . This calculation however 
could only be carried out for the exclusion of double 
heterozygotes and double-counting methods because the 
computer program used to calculate this linkage 
disequilibrium value was designed for the double - counting 
method of haplotype analysis. The linkage values 
estimated for both of the haplotype methods showed a 
significant association between the protein A and RFLP 8. 0 
alleles as well as between the protein Band RFLP 7.0 
alleles (Tables 3 . 4 a and b). 
A third and further refined method of measuring an 
association between two loci is a log-linear model (Weir 
and Wilson 1986). This method discards double 
heterozygotes where the haplotypes can not be determined , 
since the authors believe their inclusion introduces 
ambiguities in the data. The result obtained from this 
analysis gives a scaled deviance of 35 . 713 , df = 4, P < 
0 . 001, showing that there is significant deviation from 
random association of the alleles . The conclusion reached 
\.0 
r---
Table 3.5 Comparis o n o f haplotype distribution methods for analysis of double hetero zygo l e s 
f o r the C6 pro t e in determining J o ci and the C6 Tag I RFLP site . 
% Haplotypes 
Method A-8.0 B-8.0 A-7.0 A-7.0 Comparisons x2 df p 
1. Discard d o uble 27.3 6.2 32 . 5 34 . 0 1 vs 2 4.38 3 0 . 223 
hetero zygotes 1 vs 3 4 . 40 3 0 . 230 
2 . Double c o unting 26 . 2 1S.O 29 . 0 29 . 8 2 vs 3 0 . 102 3 0 . 992 
3 . Distribute using 25.4 15.4 27.5 31.8 
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from these linkage disequlilibrium analyses suggests there 
is linkage disequilibrium between the C6 protein and Taq I 
RFLP alleles. 
3.5. Discussion 
Results in this study contrast with Yukiyamas results 
in that there is no difference in distribution of C6 
protein alleles between a large Caucasian SLE group, 
control group and published Caucas ian data. The 
difference in these two studies probably arose from 
differences in sample s ize and diversity within SLE 
patients . Additionally there was no evidence that any 
patients or controls were C6 deficient . C6 protein allele 
frequencies for both SLE patients and controls are in good 
agreement with Hardy-Weinberg equilibrium thus indi cat ing 
that all genotypes were distinguished and in particular 
that null alleles and heterozygous null samples were not 
missed . The C6 monoclonal antibody used in the C6 protein 
typing reacts with the end portion of t he factor-I-like 
module II (FIM II) of C6 (Wurzner et al 19 93) which i s 
encoded by exon 15 (Hobart et al 1993a) . While this 
analysis did not determine whether the protein in these 
samples was functional , no bands outside of the normal 
migratory range were noted and no samples showed any loss 
of constant bands. Thus there was no evidence of a 
truncated or aberrantly s pliced protein in any o f the 
samples examined. In addition little variability in band 
intensity was found across the different samples and there 
was no evidence that sample s had degraded. So it appears 
that C6 is a relatively stable protein and is unaffected 
by appropriate long term storage. 
Taq I RFLP studies confirmed the protein results in 
that no association between C6 and SLE wa s evident. 
Controls and patient s had identi ca l phenotypes and similar 
allele frequencie s . Compar i sons with published data 
continued the trend of similarity. Of the 145 samples 
RFLP typed none showed unusual sized bands or were missing 
bands. Band intensiti es varied only as was expected with 
varying amounts o f DNA; band int ens ities were consistent 
within any one sample . Some partial digests were noted 
but were easily distinguished. From the results it 
appears that no maj or gene rearrangements have occurred in 
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the samples examined. RFLP analysis is a relatively gross 
level examination and from what is known of the 
conservation of C6 throughout species it was unlikely that 
a maJor gene rearrangement would be found. 
Analysis of protein and Taq I RFLP data showed there 
to be no absolute correlation between the two techniques, 
and as such Taq I RFLP studies could not replace the 
isoelectric focusing protein technique . Further studies 
(Chapter 4, Fernie et al 1993, Dewald et al 1993 ) have 
since shown that the A and B protein alleles differ by a 
single unit of charge resulting from a point substituti on 
at amino acid 98 (numbering fr om Discipio and Hugli 1989) 
This polymorphism does not affect a Taq I restriction 
enzyme site in genomic DNA and thus is 
not responsible for the polymorphic RFLP pattern. The 
amino acid 98 polymorphism causes a change from glutamic 
acid (negatively charged) to alanine (neutrally charged ) 
residue and thus determines whether the protein will have 
an A or B pattern on IEF gels. The polymorphism-affec ts a 
Dde I restriction enzyme site and had this enzyme been 
used in RFLP analysis it might have resulted in an 
informative RFLP with perfect correlation to protein 
phenotype . 
Three of the six rare-protein typed individuals were 
Taq I RFLP typed . These samples showed no differences in 
RFLP phenotype compared with other individuals. On the 
basis of the C6*A and C6 *B protein allelism it is most 
likely that these rare alleles will be determined by p o int 
mutations in the DNA . Larger DNA changes such as several 
base pair insertions or deletions could result in 
frameshift changes consequently altering protein 
translation. Fernie et al (in preparation) suggest that 
the polymorphic Taq I site maps to the intron between 
exons 16 and 17, approximately 15 kb from exon 12 ; h oweve r 
they do not rule out that the site lies beyond the 3 ' 
untranslated region. It thus appears that the Taq I 
polymorphism would not affect protein phenotype since it 
probably occurs in a non-coding region of the gene . 
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In order to determine whether there is an associati on 
between the protein and Taq I RFLP alleles, haplotypes o f 
the individuals must be determined . This is a simple 
process when samples are homozygous at either of the two 
sites but impossible when both sites are heterozygous and 
no family data are available . Many researchers advocate 
discarding double heterozygotes in this situation. This 
is considered valid although somewhat inefficient 
particularly as double heterozygotes in this study 
constitute the largest single class of genotypes in the 
data. Alternative procedures include these data either 
counting each double heterozygote twice, incorporating 
both possible haplotypes, or by allocating haplotypes 
based on allele frequencies for the two loci. Any method 
however, involves a degree of inaccuracy and a universal 
consensus as to which method is least affected by 
inacuracies has not yet been reached . Statistical 
analysis of the resultant haplotype frequencies in the 
present study for these three methods, suggests there i s 
no significant difference between them. For this data set 
it therefore appears that any of the methods will 
represent the data to a similar degree of accuracy. 
A further area of debate is which method should be 
employed to calculate a possible association between two 
loci. The simplest method, found in basic genetics texts, 
results in a conclusion of random association of these 
alleles for haplotype methods 2) and 3) but not when 
method 1) is utilised . This linkage disequilibrium 
calculation is considered overly simplified and very 
dependent on allele frequencies (Lewontin 1988), thus more 
refined statistical models have been developed. The 
further two calculations employed (Baur and Danilovs 198 0 , 
Weir and Wilson 1986) are considered better estimators o f 
linkage disequilibrium as they attempt to normalise the 
equation such that it is less affected by allele 
frequencies. The conclusion reached from these analyses 
is that the protein and RFLP alleles are not associated at 
random. The validity of measuring an association between 
two or more alleles is an issue not universally agreed 
upon and will be discussed further in Chapter 6 . 
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The occurrence of linkage disequilibrium in this gene 
is not an expected outcome . The C6 gene is not 
thought to be greatly selected for since people deficient 
in ih~CG protein are often perfectly healthy . Additionally 
po\yrno, f\W::.CYl~ 
neither -th~ pro{e~n OO( RFLP t\ are thought to alter the functional 
efficiency of the C6 protein and any specific combination 
of alleles for the two sites is not known to incur any 
advantage or disadvantage to the individual . The two 
polymorphic sites being examined are at least 60 kb aparc 
(Hobart et al 1993a) and therefore recombination events 
are possible in this region. As yet there have been no 
studies examining the Taq I polymorphism in other 
organisms and so it is impossible to determine if this 
polymorphism is as old as the C6 protein allelism, which 
has been desc ribed in other animals and i s quite ancient . 
It is possible that the Taq I RFLP site is a recent 
polymorphism and insufficient time has passed for 
recombination to produce linkage equilibrium. 
Further examination of the C6 gene (Chapter 5) shows 
that the common C6 protein allele determining site and one 
further DNA polymorphism occur in chimpanzees. This 
result implies that these polymorphisms arose prior to 
divergence of chimpanzees and humans and have since been 
maintained in the two populations. For this maintenance 
of DNA sequence to occur it is usually assumed that some 
form of selection has been involved (Takhata and Nei 1989, 
Golding 1992) . It is possible that the selective 
advantage of these sites , as well as the apparently 
associated common protein allele determining loci and RFLP 
site , is no longer present or that it has not yet been 
identified . More extensive studies examining the 
relationship between structure and functi on of C6 may 
elucidate possible advantages of particular DNA 
sequences. 
As noted earlier several studies reported individual 
cases of C6 and C7 deficiency with systemic (Tedesco et al 
1981, Zeitz et al 1981) and discoid lupus erythematosus 
(Trapp et al 1987) . The suggested mechanism by which 
complement contributed to development of SLE was in its 
affect on solubilisation of immune complexes . SLE is well 
associated with a reduced ability to solubilise immune 
complexes and it was thought that defects in the 
complement system might contribute to this. Zeitz et al 
(1981) study suggested that deficiencies of the terminal 
complement components and the resultant absence of 
functional membrane attack complex (MAC) did not prevent 
solubilisation of immune complexes . This evidence in 
addition to the present study appears to confirm that 
absence of MAC function caused , for example by C6 
deficiency, is not a characteristic of SLE patients and 
that other mechanisms must be involved in solubilisation 
of immune complexes if that is truly a contributing fact or 
to SLE development. It is likely , based on the 
heterogenous nature of SLE , that a number of factor s both 
genetic and environmental contribute more to the disease 
process than C6 . 
Considerable evidence suggests that C6 deficiency 
(C6QO) leads to an increased susceptibility to neisserial 
infection . Absence of C6 prevents the formation of the 
membrane attack complex (MAC) which consequently reduces 
bactericidal and cytolytic activity in the sera of these 
individuals (Densen 1991, Lim et al 1976). This lytic 
mechanism appears to be crucial in the immune system's 
ability to control neisserial infection . Again however 
there appears to be large heterogeneity in infective 
susceptibility as many C6 and C7 deficient individuals 
remain healthy (Lachmann et al 1978). 
3.6 Conclusions 
(1.) This study shows that neither C6 protein 
deficiency nor a specific C6 protein phenotype is 
associated with SLE . Additionally there is no evidence 
that an abnormal C6 protein occurs in any of the SLE 
patients or controls. 
(2.) No association between SLE and the C6 
polymorphic Taq I site is present since SLE patients, 
controls and published data show similar allele 
frequencies . Nor is there evidence for any major gene 
rearrangements or deletions in the C6 gene of any SLE 
patients or controls . 
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(3.) No absolute correlation between C6 protein type 
and Taq I RFLP pattern is present . Therefore Taq I RFLP 
analysis cannot replace the C6 IEF protein typing 
protocol. 
Chapter 4 
Chapter 4 
Mutation Detection In the C6 Gene using Single-Stranded 
Conformation Polymorphism Analysis 
4.1 Introduction 
The field of mutation detection is becoming 
increasingly important particularly as more disease-
causing genes and their mutations are identified. 
Restriction fragment length polymorphism (RFLP ) analys i s 
and linkage studies have been widely used over the years 
to identify possible associations between a disease and 
particular polymorphisms . One early example of linkage 
between a disease and RFLP polymorphism was for sickle 
cell anemia where the mutation was linked to a variable 
Hpa I s i te (Kan a n d Doxy 1978) . RFLP analysis is very 
useful in detecting major gene rearrangements and smaller 
mutations which alter a restriction enzyme recognition 
site . However many point mutations do not affect an 
enzyme site and thus are missed with this method, Neither 
the common C6 protein types (AA , AB and BB) nor the three 
rare-protein typed indi viduals (ABl , BB2 and BM91) found 
in this study (Chapter 3) showed any evidence for further 
polymorphi sms in the Taq I RFLP study . This demonstrates 
that the changes causing these protein phenotypes do no t 
involve a Taq I restriction enzyme recognition site. 
It is of interest to identify and characterise the 
DNA site which determines the C6 protein allelism because 
it could enable protein typing by isoelectric focusing t o 
be replaced by a more robust, faster and simpler DNA test. 
Isoelectric focusing is often inconvenient because samples 
must be carefully stored to avoid degradation of the 
labile proteins . The highly polymorphic nature o f 
complement component six makes it a very useful marker in 
population studies, particularly for comparison o f 
Oriental and Caucasian population groups . A simpler te s t 
that does not require careful storage of serum samples 
would greatly increase the usefulness of C6 as a t oo l f o r 
population studies . 
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A number o f relatively new methods of mutation 
detection are now available and most are aimed at 
detecting single base-pair changes with very high 
efficiency . Several factors must be considered before 
adopting a technique f o r a particular study . The length 
of the coding region of a gene is particularly important 
especially if the use of rnRNA-cDNA is not an option . The 
number of samples to be screened and the probability of 
heterozygosity o f mutations must be considered . Cost , 
ease of procedure, safety and time are always impo rtant 
factors for almost all laboratories . 
DNA from the rare-protein typed control was not 
available and only limited supplies of DNA from the SLE 
patients with protein variant phenotypes were available 
with no possibilty for further samples from three people 
as these patients were deceased or uncontactable. It was 
therefore not an option to use rnRNA-cDNA and the study had 
to be optimised so as not to exhaust limited DNA samples. 
A screening procedure to identify heterozygous single-base 
changes in indi vidual exons PCR-amplified from genomic DNA 
was necessary . Based on the number of exons and samples, 
the heterozygous nature of the prospective mutations, time 
and expense , sequencing every exon in each rare-protein 
typed individual, was not considered. 
Single - stranded conformation polymorphism (SSC P ) 
analysis is a mutation detection screening method which 
examines relat i vely short stretches of DNA, ideal f or 
individual exon analysis . It first requires the target 
DNA to be amplified using PCR, utilising either 
incorporation of radiolabel or labelled primers in the PCR 
reaction . The PCR product is then diluted in a denaturing 
solution and heat dissociated before being run on a non-
denaturing polyacrylamide gel (Orita et al 1989) . Under 
these conditions single-stranded DNA fragment s f o ld into 
specific conformations based on their primary sequence 
because these structures are stabilised by intramolecular 
interactions . Single-base substitutions in a PCR product 
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can induce a conformational c hange in the s ingl e - s tra nded 
DNA that is detected as an altered migrat o ry pa ttern i n a 
polyacrylamide gel . Thi s technique is simple, 
inexpensive, relatively safe and fast . Its reported 
sensitivity is between 35 (Sarkar et al 19 92 ) and 1 00 
percent (Orita et al 1989, 1990, Michaud et al 1992 ) 
depending on how vigorously parameters such as gel 
temperature, ionic strength of the running buffer and 
glycerol content are optimised for each study (Glavac a nd 
Dean 1993) . 
Alternative screening methods commonly employed 
include denaturing gradient gel electrophoresis (DGGE), 
mismatch cleavage and heteroduplex analysis. DGGE relies 
on the differing melting behaviour of various sequences 
under denaturing conditions. This method appears to have 
good sensit ivity, ranging from approximately 50 (Sheffield 
et al 1989) to 100 percent (Gottardi et al 1992) 
particularly when a GC clamp is utilised (Sheffield et al 
1989). The method is simple, safe and fast but requires 
specialised apparatus and expensive GC extended primers . 
Mismatch cleavage relies on identifying sequence 
mismatches in heteroduplexed molecules by chemical 
cleavage or enzymatic attack of the single-strand at the 
site of the mismatch. RNase A methods are less sensitive 
for particular mismatches (Myers et al 1985) , and while 
chemical cleavage methods can detect a high percentage o f 
genetic variation, they require expertise to carry out the 
biochemical steps involved (Cotton et al 1988), and great 
care must be taken with the toxic chemicals . 
Heteroduplex analysis relies on the differing 
electophoretic mobility o f perfectly matched DNA fragment s 
compared with similar fragments c ontaining a mismat c h, o r 
heteroduplex. It is a simple, fast, safe and relatively 
inexpensive method of screening mutations, but as yet only 
limited published data are available to establish its 
sensitivity. 
6 
Originally the strategy for identifying mutations 
which cause IEF prote in variants was based on the idea 
that IEF only detects charge changes in the protein being 
examined. Thus only DNA mutations caus ing amino acid 
changes which result in charge c hanges would be 
candidates. This simplifies identification should several 
polymorphisms be found. However on further invest igati on 
it appears that neutral amino acid substitutions may be 
detected with careful application of IEF conditions 
(Whitney et al 1979) as they can change the conformation 
o r folding o f the pro tein and hence alter its migratory 
pattern in a polyacrylamide gel . From this it appears 
that these protein variants may not be exclusively charge 
variants and if several polymorphisms were f ound it may 
not be possible to definitively identify which of the 
mutations contributed to the variant pattern seen on an 
IEF gel. DNA analysis of a number of samples with the 
same protein variant could however resolve this problem. 
Exon-specific PCR products from the C6 gene o f five 
rare-protein typed SLE samples and several different 
ethnic population samples were examined using SSCP 
analysis. Any sample showing an altered SSCP pattern 
compared with the majority of others was investigated by 
sequencing cloned products. Ten clones from the variant 
samples were compared with the published sequence and 
wherever the same sequence c hange occurred in mo re than 
one clone a computer-based restriction site analysis was 
carried out , usually identifying an altered enzyme 
recognition sequence . Sequence changes were then either 
confirmed or disproven after the affected PCR product was 
digested with the appropriate enzyme and examined, along 
side controls , on a polyacryalmide gel. 
4.2 Aims 
To locate the DNA site which determines the common C6 
protein alleles A and Band to examine all o f the C6 
coding exons in samples with a known rare-protein type to 
determine the DNA sequence changes that cause these 
variant protein phenotypes . 
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4.3 Materials and Methods 
The methods o f analysis used were restri ct i on enzyme 
digestion, PCR-RFLP, s ingle-stranded confo rmati on 
polymorphism analysis, blunt end cloning and automated 
sequencing. Details are outlined in Chapter 2 . Samples 
examined were (a) the five SLE patients f ound to have a 
rare-protein type, all of whom were hetero zygous f o r the 
rare allele, (b) a homozygous WP3 (B2) sample f ound in a 
previous study (Ranford 1989), (c) one AA, AB and BB 
protein typed sample from the Caucasian SLE group and (d) 
one AA, AB and BB protein typed sample from eac h o f f our 
different ethnic groups; Aboriginal Australian, Caucasian , 
Micronesian and Polynesian groups. 
4.4 Results 
4.4.1 Common protein allele determination site 
The two published C6 cDNA sequences (Discipio and 
Hugli 1989, Haefliger et al 1989) differed by a single 
base change at amino acid 98 , cDNA position 413 (numbering 
according to Discipio and Hugli 1989), of exon three 
(Hobart et al 1993a) . This change affected a Dde I 
restriction enzyme site which thus allowed PCR-RFLP to be 
employed to examine the site. The resultant digest 
patterns correlated perfectly with the common protein 
alleles. The C6 *A had an additional Dde I site compared 
with C6 *B. 
Figure 4.1 shows the results o f a Dde I digest and 
description of the DNA sequence , amino acid change and 
predicted pI values for the two pro tein alleles . Thi s 
mutation causes an amino acid change giving rise to a 
charge change in the protein. This correlates well with 
what is seen on an IEF gel because the A allele has a 
predicted pI value of 6.64, which is slightly more acidic 
and therefore will migrate to a more anodic position than 
the B allele, which has a predicted pI value of 6 . 71 . 
4.4.2 Variant SSCP patterns 
Figure 4.2 shows the SSCP patterns f ound for all of 
the C6 exons. Table 4.1 summarises the variant SSCP 
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Fi gure 4.1 l@plified restricti o n fragment length 
polymo rphi s m t yping o f the c ommon C6 protein phenotypes 
u tili s ing t he e x on 3, Dde I site a Polyacrylamide gel 
after elec tropho resis of uncut 199 bp amplification 
product ( lane 4 ) and Dde I fragments from C6 AA homozygote 
(l anes 3,6, 7 ) , AB heterozygote (lane 8) and BB hornozygote 
( lanes 2 and 5 ) . The fragment sizes, in bp of a DNA 
standard (Msp I digested pBR322 ) are sho wn in lan~ 1 . b 
Pos iti on, sequen c e, amino acid, restricti on site and pI 
value s f o r t he t wo commo n C6 pro tein types. 
C6 Exon 3 Dde I Digest 
a +l 
~ 
CJ 
B A 
Q 
AB ~ 
1 2 3 4 5 6 7 8 bp 
-
199 
147-
1 23• 
110-
-
113 
90- 86 
-76-
- 77 67-
- 36 
b 
Polymorphism at cDNA 413, amino a c id 9 8 , ex o n 3. 0 5 6 
Phenotype; 
Codon; 
Amino acid; 
Dde I site; 
pI; 
A B 
GAG GCG 
Glu Ala 
+ ( C 1 TNAG ) - (C 1 TNAG ) 
6.64 6.71 
90 
Figure 4.2 SSCP patterns for all of the C6 exons 
examined. Non-glycerol and glycerol gels shown; variant 
bands are those which differ from the pattern seen in the 
majority of other samples. In exon 11 two equally 
frequent patterns were seen, these were labelled "2" for 
the two band pattern seen and "3" for the three band 
pattern since it was inappropriate to label either as 
"variant". 
SSCP 
Exon 1. 
Non-Glycerol 
variant 
' 
10% Glycerol 
variant 
t 
Gels 
Exon 2. 
Non-Glycerol 10% Glycerol 
• Non denatured 
• 
+ 
Non denatured Non denatured 
Exon 3. Exon 4. 
Non-Glycerol 10% Glycerol Non-Glycerol 10% Glycerol 
A B AB A B AB 
' ' ' ' ' ' 
SSCP Gels 
Exon 5. Exon 6. 
Non-Glycerol 10% Glycerol Non-Glycerol 10% Glycerol 
Exon 7. Exon 8. 
Non-Glycerol 10% Glycerol Non-Glycerol 10% Glycerol 
variant variant 
+ + 
+ 
Non denatured 
SSCP Gels 
Exon 9. Exon 10. 
Non-Glycerol 10% Glycerol Non-Glycerol 10% Glycerol 
variant variant 
• 
' 
-------
+ 
Non denatured 
t t 
Non denatured 
Exon 11. 
Non-Glycerol 10% Glycerol 
2 3 
t + 
2 3 
' • 
+ 
Non denatured Non denatured 
SSCP Gels 
Exon 12. Exon 13. 
Non-Glycerol 10% Glycerol Non-Glycerol 10% Glycerol 
variant 
+ 
variant 
+ 
variant 
+ 
variant 
+ 
+ + 
+ + -
Non denatured 
Non denatured 
Exon 14. Exon 15. 
Non-Glycerol 10% Glycerol Non-Glycerol 10% Glycerol 
+ + Non denatur1ed Non denatured 
SSCP Gels 
Exon 16. Exon 17. 
Non-Glycerol 10% Glycerol Non-Glycerol 10% Glycerol 
+ + + + 
Non denatured Non denatured 
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Table 4.1 A summary of the variant SSCP patterns found in 
the C6 exons in four different protein variants and 
samples from Aboriginal Australians, Caucas i ans , 
Micronesians and Polynesians . 
Protein 
Type 
AlAa 
BB2 
B2B2(WP3) 
AB21 
BM91 
Caucasiansb 
AA 
BB 
AB 
Aboriginalc 
Micronesianc 
Polynesianc 
1 
v' 
v' 
* 
v' 
v' 
v' 
v' 
v' 
\/ 
\/ 
3 
\/ 
v' 
v' 
v' 
y 
v' 
* 
* 
* 
v' 
v' 
v 
8 
v' 
v' 
\/ 
v' 
v' 
* 
v 
v' 
v 
v 
v' 
v' 
C6 Exons # 
10 
v' 
v' 
* 
v' 
v 
v' 
v' 
v 
v' 
v' 
,1 
11 
2 
2 
3 
2 
2 
2 
2 
3 
2 
3 
# Exons 2 I 4 , 5, 6 / 7, 9 I 14, 15, 16 and 17 
variant 
Symbols : 
SSCP patterns in any of the samples 
* - unique SSCP pattern . 
v' - most common SSCP pattern . 
- no SSCP result 
2 - two SSCP bands seen . 
3 - three SSCP bands seen . 
Two individuals had protein type AlA. 
12 
v 
v' 
* 
V 
v 
v 
v 
v 
V 
\! 
v' 
showed no 
examined . 
a 
b AA, AB, and BB results are summarised from two 
Caucasian individuals . 
C Micronesian, Polynesian and Aboriginal Australian 
patterns .are combined results from three individuals . 
13 
v 
v 
v 
* 
v 
v 
v 
v 
V 
v' 
\! 
v' 
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patterns found in the samples examined and Table 4.2 s h ows 
the location, amino acid, codon sequence and protein 
phenotype of the samples from which sequence changes were 
identified. In one case a sample gave no SSCP result f o r 
two exons, that is PCR amplification failed f o r that 
sample in the radiolabelling experiment and it was decided 
to sequence these exons rather than repeat the 
radiolabelling PCRs and SSCP gels. 
4.4.2.1 AlA Protein Type 
No variant SSCP patterns were detected in these two 
samples for any of the C6 exons on either glycerol or non-
glycerol gels . Exons one and 11 failed to amplify in one 
of the two samples, but since no variant pattern was found 
in the sample which did amplify , it was not considered 
necessary to investigate these exons with sequencing . 
Therefore the mutation causing this protein type was not 
detectable with the SSCP conditions utilised in this 
study . 
4.4.2.2 BM91 Protein Type 
Only exon eight showed a variant SSCP pattern for 
this sample . It was distinguishable since it showed the 
loss of a major band. Sequencing ten clones of this 
individual yielded no sequences different from published 
data. It is theoretically possible, although 
statistically unlikely, that ten normal clones were 
inadvertently selected over mutants. The same primer pair 
was used for SSCP analysis and generation o f insert for 
cloning ; therefore it cannot be argued that the mutation 
occurred in the primer binding site thus amplifying only 
the normal allele, because in that case no variant SSCP 
pattern would be seen. It appears that either the 
mutation was missed in sequencing or the real mutation was 
undetected under the conditions used for SSCP analysis and 
the variant pattern seen was a false positive result. 
4.4.2.3 AB21 Protein Type 
Two polymorphisms or mutations were found in this 
individual . The first was indicated by SSCP analysis and 
I J 1 
Table 4 . 2 Polymorphisms detected by SSCP analysis and DNA sequen c ing. 
Amino Acid 
Exon Number Change 
.L. NA NI'. 
1 98 Glu (A) .... Ala ..J • 
1 0 . 5lR Cys ( P) .... Cys 
.l 1 . S44 Asp (A) .... Gly 
[ 544 Asp (A) ... Asp 
546 GJ. n (P) .... His 
575 Arg (8) .... G.ln 
1 2 . 6]0 Glu (A) .... GJ.y 
1 ] . 680 Arg (B) .... Trp 
(NP) 
( p) 
( p) 
(A) 
( B) 
( p) 
( p) 
(NP) 
Charge 
Change 
NA 
yes 
no 
yes 
no 
yes 
yes 
yes 
yes 
r - µula r amino a c id (neutr.·aJ c harge) 
nr = n o n polar amino acjct ( n e ur1 ·a1 c harge) 
A - acidic amino a cid ( 11ega tive c harge) 
R =- basic amino acj d (po sit· i vr::. c l1arge) 
Sequence 
Published New 
GGC 
---.. l\GC 
GAG -... ccc 
TGT -. TG C 
GAC ---. GGC 
GAC ---.. GAT 
CAG --. CAC 
CGA .... CAA 
GAA .. GGA 
CGG • TGG 
Enzyme site 
n o ne 
Ode I 
Bsm I 
Aci I 
Ac e I 
Bsr I 
Mnl I 
Ser FI 
Ma e II 
[ Denotes that these two rnut at ions invariably occurred t ogethe r . 
Protein Type 
of proband sample 
AB2J. 
A/B 
BB2 
BB2 
BB2 J 
B82 
AB21 
BB2 
B2B2 
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confirmed by sequencing; it occurred 74 bp upstream o f the 
initiation codon . It s position suggests that it has no 
effect on the mature protein. The second sequence change 
was found only after sequencing as no SSCP result was 
obtained for this individual f o r exons 11 and 12. The 
sequence change occurred in exon 11, caus ing replacement 
of an arginine residue (pos itively charged) with a 
glutamine residue (neutral ) . The sequence change a l tered 
an Mnl I restriction enzyme site and thus was able to be 
confirmed with digest analysis (Figure 4.3 ) . Using the 
computer program Isoelectric the predicted pI f o r this 
allele , assuming it has the background of a standard A 
allele, is 6 .57 (Table 4.3). The standard A allele has a 
pI of 6 . 64 and the B allele a pI of 6.71 . Thi s suggests 
that the variant protein would migrate more anodally than 
the standard A allele. However this is n o t what was seen 
on an IEF gel; this allele migrated more cathodally than 
both a standard A and B allele (Chapter 3 , Figure 3 . 1). 
This individual has been protein typed as AB21, but with 
Dde I digest analysis it appears as BB . Of all 143 Dde I 
and protein typed samples examined (Chapter 5) this 
individual is the only one in which the two tests gave 
conflicting results . The predicted pI assuming a B allele 
background is 6.64, the same as that seen f or the standard 
A allele, suggesting that this individual possesses two 
mutations . One alters a standard B allele such that it 
migrates similarly to an A allele with IEF, while a second 
mutation might cause the protein to migrate further 
towards the cathode than a standard B allele . 
4 . 4.2 . 4 B2B2 Protein Type 
This sample was o riginally f ound in a Nauruan 
population and designated WP3 f o r Western Pacific three 
allele . It was subsequently typed by Y To kunaga (Blood 
Transfusion Service, University Hospital, Tokyo, Japan ) 
and designated C6*B2 . One variant SSCP pattern was 
identified in exon 13 and ten clones o f this exon were 
examined. All sequences showed an arginine (positively 
charged ) to tryptophan (neutral) substitution at ami o 
acid 68 0 . This mutati on result s in the protein having a 
l :J 0 
Figure 4 . 3 Amplified restriction fragment length 
polymorphism typing of C6 exon 11-12, Mnl I site. a 
Polyacrylamide gel after electrophoresis o f Mnl I digested 
fragments o f C6 exon 11-12 PCR products. An individual 
heterozygous for this polymorphism (lane 2), and 
individuals homozygous f o r the published sequence (lanes 3 
and 4 ) . The fragment sizes, in bp of a DNA standard (Hae 
III and Msp I digested pBR322) are shown in lanes 1 and 5 
respectively. b Position, sequence, amino acid, 
restricti o n site and pI V3lues for published and new 
alleles . 
a 
b 
C6 Exon 11-12 Mnl 
587 -
434 -
267 -
234 -
213 -
192 -
184 -
124 -
104 -
1 2 3 4 5 
I I Digest 
bp 
- 368 
110 
115 
Po lymorphism at cDNA 18 4 5, amino a c id 575, exon 11.10 3 
Phenotype; 
Codon; 
Amino acid; 
Mnl I site; 
pI ( +A, +B ) ; 
Pub lished 
CGA 
Arg 
+ ( CCTCN., / 7 ) I , 
6.64, 6.71 
New Allele 
CAA 
Gln 
- ( CCTCN7 ; 7 ) 
6.57, 6. 6 4 
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Table 4.3 Calculated pI values# for the DNA mutati ons 
causing charge changes in the protein found in the rare-
protein typed SLE patients . 
Amino Acid 
Position Name 
98 
544 
546 
575 
630 
680 
Glutamic acid (AA) 
Alanine (BB) 
Glycine 
Histidine 
Glutamine 
Glycine 
Tryptophan 
544 Gly + 630 Gly 
544 Gly + 630 Gly 
546 His+ 630 Gly 
546 His+ 630 Gly 
pI 
6 . 64 
6 . 71 
6 . 71 
6 .77 
6.67 
6 .7 3 
6.57 
6 . 64 
6.71 
6 .77 
6 . 57 
6 . 64 
6 . 76 
6 . 83 
6 . 72 
6 .7 9 
Underlying 
protein type 
A 
B 
A 
B 
A 
B 
A 
B 
A 
B 
A 
B 
A 
B 
Change 
* pI 
0 . 07 
0 . 07 
0 . 06 
0 . 03 
0 . 02 
0 . 07 
0.07 
0 . 07 
0.06 
0 . 07 
0 . 07 
0 . 12 
0 . 12 
0 . 08 
0 . 08 
in 
* The change in pI is the difference between the standard 
A (pI = 6 . 64) or B allele (pI = 6 . 71) and the mutated 
allele . 
# pI values were calculated using the computer programme 
11 Isoelectric 11 ( see Chapter 2) . 
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predicted pl of 6.64 (Table 4 .3) , identica l t o t he 
standard A allele . This result does not c o rrelate well 
with the migration pattern o f this protein allele s een on 
an IEF gel as the sample runs more toward the cathode than 
an A allele (Chapter 3 , Figure 3 . 1 ) . 
This sequence c hange destroyed a Mae II restr i ction 
enzyme site and so the homozygous nature o f the mutation 
was confirmed with resti ct i on digest analysis (Chapter 5 , 
Figure 5 . 4) . Fortunately one o ther WP3 (B2 ) DNA sample 
was available for analysis. This sample had the WP3 (B2 ) 
allele in the hetero zygous form and after Mae II d igest 
analysis it showed this mutation , also in a heterozygous 
form . Four Nauruan individuals with the 11 Nau 11 protein 
allele , also thought to be a C6*B2 allele (Ranford 1982, 
Tokunaga et al 1990), were available for testing as was 
the BB2 phenotype SLE patient . Mae II digestion analysis 
showed that two of the Nauruan samples and the BB2 SLE 
sample had the mutation in a heterozygous f orm and two 
lacked the mutation . These results were difficult to 
resolve ; however analysis of further samples (Chapter 5) 
showed that 20 samples with common-protein phenotypes 
carried this mutation . One of these was homozygous f o r 
this change and two samples lacked the mutati on but 
possesed the C6*B2 allele. It theref ore appears that this 
mutation is not responsible f o r the B2 prote in phenotype 
but is simply a relatively common polymorphi s m that was 
coincidently found in a homozygous form in this WP3 (B2) 
protein type sample . 
4.4.2.5 BB2 Protein Type 
Two variant SSCP patterns were detected f or this 
individual. These exons were cloned, sequenced and 
compared with published data. A neutral polymorphism 
(Table 4.2) in exon 10 was detected and conf irmed with 
Bsm I digesti on (Chapter 5, Figure 5.1). Exon 12 showed a 
mutation at amino acid 630 which caused a glutamic acid 
(negatively charged) to glycine (neutral) amino acid 
substitution . This sequence change altered an Ser FI 
restriction enzyme recogniti on site and was thus able t o 
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be confirmed with digest analysis (Figure 4.4 ) . Using the 
Isoelectric program a pI of 6.77 was calculated (Table 
4 . 3) for this protein allele, assuming a standard B allele 
background . This suggests that the protein would migrate 
further toward the cathode than a standard B allele which 
is in good agreement with what was seen on an IEF gel 
(Chapter 3, Figure 3 . 1) . It appears then that this 
polymorphism is a good candidate to explain the B2 protein 
phenotype. Three Nauruan B2 protein typed samples and the 
homozygous WP3 protein typed sample were examined at this 
site in order to clarify whether this mutati o n is 
responsible for the B2 (Nauru and WP3) allele . Two 
Nauruan samples proved to have this change in the 
heterozygous form and the WP3 sample appeared to be 
homozygous for this change, which agrees with expectations 
based on their protein types . One heterozygous Nauruan B2 
sample however , lacked the mutation . 
Interestingly the BB2 sample proved to possess the 
·exon 13 mutation identified from the variant SSCP pattern 
in the WP3 (B2) sample . No variant SSCP pattern was seen 
for exon 13 of this individual and yet digest analysis 
proved its presence. It is possible that the heterozygous 
form of this mutation explains the difficulty in 
determining its variant status by SSCP analysis . 
4.4.2.6 Exon 11 
Exon 11 showed two relatively common SSCP patterns, 
one with a three band and another with a two band pattern 
(Figure 4 . 2) . Hence an example of each pattern was 
examined by cloning and then sequencing. A Nauruan sample 
with the three-band SSCP pattern and a common protein type 
(AA) was chosen for examination but after sequencing no 
resolvable changes were identified . However all clones 
contained an ambiguous base (an Non automated sequence 
data) in the codon for amino acid 557 which was either an 
adenine or guanine but was not able to be definitively 
identified from the chromatographs obtained. Should this 
change prove real it would change a negative aspartic acid 
residue to a neutral asparagine residue. This charge 
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Figure 4.4 Amplified restriction fragment length 
poly mo ~phism typing o f ~xon 11-12, Ser FI site . a 
Po :yac ~ylamide gel after electrophoresis of Ser FI 
fragments from samples heterozygous for the exon 12 
polymo rphism (lane 2 ) , samples homozygous for the 
published sequence ( lanes 3 and 4) and uncut PCR product 
(lane 5 ) . The fragment sizes, in bp, of a DNA standard 
(Hae III digested pBR322 ) are shown in lane 1 . b 
Position, sequence, amino acid , restriction site and pI 
values for the published and new exon 13 alleles . 
C6 Exon 12 Ser FI I Digest 
a 
1 2 3 4 5 bp 
-358 
-145 
- non-specific band 
64- -non-specific band 
57-
-54 51-
-40 
-23 
-22 
-primers 
b 
Polymorphism at cDNA 2010, amino acid 630, exon 12.096 
Phenotype; Published New Allele 
Codon; GAA GGA 
Amino acid; Glu Gly 
Ser FI site; - (CC'NGG) + (CC'NGG ) 
pI ( +A, +B ) ; 6.64, 6.71 6.71, 6.77 
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change was not indicated with IEF however other cases of 
charge changes not affecting IEF patterns have been 
identified (see further exon 11 results). Time 
constraints prevented further investigation of this 
sequence, so it was not equivically proven that this site 
was the explanation for the three-band pattern seen with 
SSCP. Further studies would examine this site with 
restriction enzyme Sfa NI to determine whether this 
mutation destroyed an Sfa NI recognition sequence and if 
so confirm it as real. Correlation of Sfa NI digest 
results with SSCP patterns for a number of individual s 
would identify whether this site was the explanation for 
the exon 11 two- and three-band SSCP pattern obtained in 
this study . 
Exons 11 and 12 were amplified together for sequence 
analysis because the exon 12 forward primer was 
problematic. Since this insert was already cloned for the 
BB2 protein typed individual it was logical to use it to 
examine the two -band SSCP pattern found in exon 11. 
Sequence analysis gave interesting results . Ten clones 
were examined and of these two showed no changes at all, 
four showed a change from GAC (aspartic acid) to GGC 
(glycine) at amino acid 544, and four clones showed a 
change from GAC (aspartic acid) to GAT (aspartic acid) 
also at amino acid 544 along with a change from CAG 
(glutamine) to CAC (histidine) at amino acid 546 . All of 
these changes affected restriction enzyme sites and thus 
were able to be confirmed . The GAC to GGC change at amino 
acid 544 created an additional Aci I site and proved to be 
real and not uncommon in other samples examined (Chapter 
5). The predicted pI for this change alone was 6 .77, 
assuming a standard B allele background (Table 4. 3) . It is 
possible that this mutation occurs on the same haplotype 
as the exon 12 mutation. This would give rise to the 
production of a protein with a predicted pI of 6 . 83, also 
assuming a standard B allele background. The change at 
amino acid 546 created a Bsr I site and also proved to be 
real and found in many other samples examined (Chapter 5) 
The pI value for the altered protein resulting from this 
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mutation alone was 6.73. If this mutation occurred with 
the exon 12 mutation a pI o f 6.79 for the pro tein would 
result, again assuming a B allele background. The other 
change at amino acid 544 was a neutral polymorphism which 
destroyed an Ace I site, (Figure 4.5 ) therefore the normal 
allele could be confirmed. DNA from this ind i vidua l was 
exhausted during the study and as such exon s 11-12 PCR 
product for Ace I digestion were generated from 
unsequenced M13 cultures from 10 clones. Ace I 
restriction enzyme digestion demonstrated that there was 
no wild type exon 11 allele present in this PCR product. 
It is possible that no further wild type alleles were 
present in the M13 cultures which would explain this 
negative result. Also possible is that the two clones 
which gave wild type alleles for this individual were 
either sequencing or PCR errors , or resulted fr om a 
contaminated PCR product used for generation of the insert 
for cloning . If two clones were the result of PCR error 
this would indicate an unusually high degree of error f o r 
Taq I polymerase . 
Interestingly Bsr I and Aci I digestion o f a number 
of other samples suggested that there are other mutati on s 
in this region not described above . Chapter 5 deals with 
these new alleles in further detail . Based on Bsr I and 
Aci I digest results of a number of samples (Chapter 5), 
several of which had been SSCP typed at exon 11, the two-
and three-band pattern did not correlate with either o f 
these mutations nor a specific combination o f these 
alleles . It thus appears that these mutations do not 
cause an altered migratory pattern with SSCP analysis 
under the conditions utilised in this study, and therefore 
would have been missed entirely had the unidentified 
mutation not caused a migratory change prompting sequence 
examination. The mutation causing the three-band SSCP 
pattern appears likely t o be the unconfirmed mutation at 
amino acid 557 suggested after sequence examination of the 
Nauruan sample . 
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Figure 4.5 Amplified restriction fr agment length 
p o :~·mo rphism typing o f C6 exon 11-12, Ace I site . a 
Po lyacrylami de gel after electrophoresis o f uncut 619 bp 
amplificat ion product ( lane 5) and Ace I fragments from an 
individual homozygous for the polymorphism (lane 3) and 
individuals homozygous f o r the published exon 11 sequence 
( lanes 1, 2 and 4 ) . The fragment sizes, in bp of a 
standard DNA (Hae III digested pBR322) are shown in lane 
6. b Position, sequence, amino acid, restriction site 
and pl values for the normal and new exon 11 alleles. 
a 
b 
C6 Exon 11-12 Ace I Digest 
1 2 3 4 5 6 bp 
619- -587 
-434 
269-
-267 243-
-234 
209- -213 
-192 
-194 
-124 
-104 
- 89 
- 80 
Polymorphism at cDNA 1753, amino acid 544 exon 11.011 
Phenotype; 
Codon; 
Amino acid; 
Ace I site; 
pI (+A, +B); 
Published 
GAC 
Asp 
A T 
+ (GT(CXG)AC ) 
6.64, 6.71 
New Allele 
GAT 
Asp 
A T 
- ( GT(CXG)AC) 
6.64, 6.71 
4.4.3 SSCP Detection Analysis 
It is important to note that some SSCP patterns 
showed more than the expected two bands for a homozygote 
or four bands for a heterozygote (Figure 4.2). This is a 
fairly common occurrence with SSCP gels as some single-
stranded DNA fragments may have more than one stable 
conformation under the conditions at which the gel was 
run. This problem or artifact may have been overcome if 
each SSCP gel had been optimised for each specific exon. 
Initially the SSCP conditions were optimised for the exon 
three polymorphism; identical conditions were then used 
for each exon . With hindsight this process may not have 
been optimal but less information on the parameters 
affecting SSCP was available at the commencement o f this 
analysis . 
Overall SSCP analysis in this study detected sequence 
changes in exons one, three , 10, 11, 12 and 13. One 
possible false positive was also found and at least two 
mutations, those causing the BM91 and AlA protein alleles, 
were missed with this screening study . Interestingly four 
mutations were found and confirmed in exon 11, while two 
others were indicated by digest analysis . None of these 
correlated with a particular variant SSCP pattern, 
suggesting that they did not alter the migratory pattern 
of the single-stranded DNA under the conditions used in 
this study . The mutations detected with SSCP analysis 
included both transitions and transversions and are listed 
in Table 4 . 4. 
4.5 Discussion 
Examination of the two published cDNA sequences for 
the C6 gene gave an absolute correlation between a 
sequence difference and the protein phenotypes seen with 
isoelectric focusing . This change leads to a unit charge 
change in the resultant protein correlating well with the 
difference seen on an IEF gel . It is still possible that 
this difference is not the sole cause of the protein 
polymorphism and that perhaps it is only one of a number 
of substitutions which are in linkage disequilibrium. 
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Table 4.4 A review o f the mutations detected with SSCP 
analysis 
Exon 
1. 
3 . 
10 . 
11 
11 . 
11. 
11. 
12. 
13. 
Sequence 
change 
G -. A 
A -.. c 
T -.. C 
A _. G 
C -. T 
G ....- c 
G -• A 
A -.. G 
C -.. T 
Type 
transition 
transversion 
transition 
transition 
transiti on 
transversion 
transition 
transition 
transition 
Enzyme 
site 
none 
Dde I 
Bsm I 
Aci I 
Ace I 
Bsr I 
Mnl I 
Ser FI 
Mae II 
SSCP 
Detection 
yes 
yes 
yes 
n o 
no 
n o 
yes 
yes 
- this sample failed t o amplify for the SSCP gel and 
therefore no SSCP result was available, the mutati on was 
found after sequencing. 
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This however appears unlikely based on ; (1) the absolu e 
correlation found in 143 samples examined in this study 
( Chapter 5) , ( 2) the lack of other variant SSCP pat terns 
correlating with protein type and (3) that it is the only 
difference found in two complete cDNA's . The replacement 
of protein typing with a simple and robust DNA-based 
analysis allows more convenient examination of the common 
C6 polymorphism, particularly for studies of evolution and 
differences between ethnic groups. 
Unfortunately SSCP analysis did not indicate a 
potential site for mutations responsible for the two 
protein types AlA and BM91 . No variant patterns were 
detected for the two AlA protein type samples whereas a 
variant pattern was found for the BM91 sample but 
sequencing revealed no mutation , suggesting a false 
positive result . Examples of false positives with SSCP 
have been reported (Hongyo et al 1993) but are thought to 
be rare (Gaidano et al 1991, Sarkar et al 1992) . One 
explanation is that false positives are the result of 
semi-stable transitional conformations which disappear 
when the sample is run under different conditions (Michaud 
et al 1992) . This is probably unlikely in the present 
situation since the variant pattern had lost a major band 
not gained additional bands. An alternative and highly 
possible explanation is a sequence change caused by PCR 
error . Triggs Raine et al (1991) report that errors 
incorporated into a PCR product by Taq polymerase (Tindall 
and Kunkel 1988) do not form a large enough proportion of 
the product to visibly interfere with the SSCP analysis 
whereas Hongyo et al (1993) report that mutant SSCP bands 
could be clearly discerned when as little as three percent 
of che gene copies contained the mutation o r error . This 
conflict probably arises because of the variability in 
optimisation of the SSCP gel running conditions and the 
differing nature of the sequence being examined. As such 
it remains possible that the false positive variant 
pattern arose through PCR error. Re?C~\t\ct, c\ -th , PC l 0. 11(,') 
SSC e\ I'\~ ve F<O f 1, i i~ e "S\1 (C I\- I'.::> 
·\::/ ~ LAI \~ I E, ._J 
-lhe_ s rne_., erfa- H Cl-l\G\ ,1-:::e 0 seUJf\d I'(\ e, 
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The sensitivity of SSCP analysis is well known o 
vary, commonly from around 70 to 100 percent depending on 
optimisation of gel running conditions (G lavac and Dean 
1993). The present study detected two of five mutations 
expected to contribute to protein phenotype, representing 
a 40 percent efficiency rate for detection of expected 
mutations . SSCP analysis also detected four unexpected 
mutations which therefore suggests the technique is of 
considerable value in screening for polymorphisms. SSCP 
analysis has been well utilised since initiation o f the 
present study and greater knowledge of the affect o f 
important parameters has been gained. Temperature, 
glycerol content, gel concentration , buffer ionic strength 
and fragment size are all important parameters affecting 
the sensitivity of SSCP . It was also assumed that the 
type of mutation would influence its detection rate with 
transversions expected to cause a greater alteration in 
the secondary DNA structure than transitions. This 
however appears not to be true since this and several 
other studies (Glavac and Dean 1993, Sheffield et al 1993) 
show good detection rates for both transitions and 
transversions . Glavac and Dean (1993) along with 
Sheffield et al (1993) suggest that the position and type 
of mutation are not correlated with the rate of detection 
but that the base sequence around the mutation appears to 
have a greater affect on mobility. In view of these 
findings it could be that the mutations causing the AlA, 
B21 and BM91 protein phenotypes occur in areas of the gene 
which are perhaps GC rich and may not be amenable to 
detection with SSCP analysis . Fraser et al (1992) have 
used the computer program Squiggles (University of 
Wisconsin , Genetics Computer Group) to predict secondary 
structure of single-stranded DNA , based on RNA structure. 
They have found good agreement between experimental 
findings of mobility shifts, resulting from altered 
conformation, and predicted conformation changes based on 
these models . This technology may become very useful when 
utilising SSCP for identification of known mutations as it 
may allow design of very effective PCR primers. 
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The s ample with pro t e in type AB 21 wa s s h own to have 
two mutations. One in t h e 5' untra nslated r eg i on which 
would not be expec ted t o contribute t o the va ri a n t pro ein 
phenotype while the second appeared in exon 11. Thi s 
mutation resulted in an overall c harge c hange with the 
replacement of a positively charged arginine re s idue f o r 
an uncharged glutamine residue. The predicted pI f o r thi s 
change is 6 . 57, less than a standard A allele (pI = 6. 64 ) ; 
however IEF patterns suggest it has a pI greater than the 
standard B allele (6 . 71 ) . Exon three re s ult s a r e a l so 
conflicting for this individual, suggesting it i s 
homozygous C6 *B at the DNA level . A possible explanation 
for these results is that the individual is homo zygou s B 
at the exon three site and carries two polymorphisms, on e 
as yet unidentified . The identified polymorphism change s 
a normal B allele such thats its pI is 6 . 64, identical t o 
that of a standard A allele . A second sequence change, on 
a standard B allele background, could produce an amino 
acid change resulting in a pI of > 6 . 71 . This hypo the s i s 
would result in a total protein IEF pattern identi cal t o 
that seen for this individual. Other explanations inc lude 
the possibility that exon three results are incorrect a nd 
this mutation is one of several changes in the B allele, 
the combination of which give a pI value greater than 
6 .71. This however appears unlikely since the change in 
pI would have to be greater than 0 . 14 , requiring severa l 
additional charge-changing mutations. Alterna tively t h i s 
mutation may significantly change the conf o rmati on o f the 
protein , consequently altering its migrat o ry pattern in a 
polyacrylamide gel matrix. The change from an arginine 
residue to a glutamine adds two CH 2 molecules and while 
this would not appear to greatly alter the pro tein' s 
secondary structure, it is difficult to predict the 
consequences o f this change. Pro tein struc t u re s a r e 
dependant on many chemical bonds and small c ha nge s in 
constituent molecules may alter b ond intera ctio n s 
substantially and hence markedly change the f o l d ing 
pattern of the protein . 
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No further samples with this protein type were 
available so it was not possible to examine this site in 
other individuals to determine whether this mutation co -
occurs with the var i ant protein phenotype . Future studies 
would involve obta ining a number of AB21 and BB21 protein-
typed individuals plus samples with common protein types 
and carrying out Mnl I digest analysis on exon 11 along 
with further mutation screening in the B21 sample s . 
Should B21 samples exclus ively possess the exon 11 
mutation compared with common-pro tein type samples it 
would be rea sonable to assume that it i s associated with 
this protein variant. It is anticipated that another 
change would be found for this protein variant and 
examination of this site in other B21 samples would 
confirm its contribution to this phenotype . There is 
however the possibility that a B21 protein phenotype as 
seen on an IEF gel is actually a heterogenous group o f 
proteins with very similar pI values, and that examining a 
large number o f samples would show that not all had the 
·same sequence change as the sample examined in the present 
study . 
The WP3 sample , also described as B2, was homozygous 
for a sequence change in exon 13 . This change resulted in 
an overall loss of positive residues because the mutation 
caused the substitution o f a positively charged arginine 
residue for a neutral tryptophan . The predicted p I for 
this sample ; 6 . 64 does n o t correlate with what i s 
observed on an IEF gel as the sample runs more towards the 
cathode than a normal A allele . Digest analysis of 63 
samples , (Chapter 5) including six samples with the B2 
allele , showed that this mutation occurred in samples with 
normal protein types and also that it was not present in 
some samples that possessed the B2 allele . Therefore it 
was concluded that this mutation is a common polymorphism 
o f the C6 gene and is not responsible for the 82 or any 
other rare-protein allele . 
Six mutations were found in the BB2 protein typed 
sample, with two being neutral polymorphisms. The 
117 
remaining mutations all caused charge changes. The exon 
13 mutation is described above and appears not to be 
responsible for the B2 allele . The amino acid 544 (Ac i I 
site) and amino acid 546 (Bsr I site) changes were f ound 
in relatively high frequencies in samples not showing 
variant-protein Qatterns (Chapter 5) and therefore appear 
not to be responsible for this protein allele . The exon 
12 mutation at amino acid 630 (Ser FI site) was identified 
in two other Nauruan B2 type samples , however one C6*B2 
sample did not show the Ser FI site mutation. This result 
suggests that the exon 12 mutation may be one cause o f the 
B2 (Nau , WP3) protein phenotype, but that at least one 
other mutation also results in the characteristic B2 IEF 
pattern . It therefore appears that the B2 protein 
phenotype represents a group of proteins which are 
heterogenous in their underlying DNA mutations . Similar 
findings have been reported for the C4 gene (Belt et al 
1984 , 1985, Yu et al 1986) and it therefore appears likely 
that this will also be true for C6 . 
Many of the arguments for whether a specific sequence 
change is the cause of a protein phenotype are based on 
the predicted pI value, calculated using the computer 
program Isoelectric . While these predicted values are 
thought to correspond closely with what is seen on an IEF 
gel (Assis Prof W Hildebrand, personal communications) 
they still remain estimates . Despite the large number of 
C6 protein studies reported, few have attempted to 
approximate the pI of C6 alleles. An early study by Alper 
et al (1975) gave an approximate range of 6 . 0 to 6.5 f o r 
the common protein types. The values obtained with the 
computer package give slightly higher values of 6.64 and 
6 . 71 for C6 *A and C6 *B respectively . This difference is 
considered insignificant after consideration of the error 
involved in estimating the values experimentally. It thus 
appears that the calculated pI values are in reasonable 
agreement with previous estimates and as such the 
predicted pI values for new alleles should be relatively 
accurate . 
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The cluster of mutations found in exon 11 of the C6 
gene suggests that this area is a hot spot for mutati on. 
Exon 11 codes for the entire third thrornbospondin (TSP ) 
repeat and some intervening protein sequence between thi s 
and the first short consensus repeat (SCR) in the C6 
protein molecule. Interestingly the exon three protein 
allele determining site also occurs in a thrornbospondin 
repeat module . Haefliger et al (1989) report that the CSb 
binding site on the C6 protein occurs in the carboxyl 
terminal portion of th~ protein, encoded for by the 5' end 
of exon 12 through to exon 17 . Nakano et al (1991) 
further localised the CSb binding site to within the two 
short consensus repeats , encoded for primarily by exons 12 
to 14 . This region includes the exon 12 and 13 sequence 
changes identified but not the four exon 11 changes found. 
The present study produced no evidence that these sequence 
changes alter the function of the protein because a non-
functional detection system for C6 identification was 
used . Other studies however have utilised a hemo1y+1c C6 
detection system which is a functional assay and there has 
been no suggestion that the variant protein phenotypes 
affect the function of this protein . There are no studies 
available that have examined whether these rare C6 protein 
types incorporate as normal into the MAC . It would be 
interesting to determine whether these rare-protein 
phenotypes reduce or enhance binding of CSb or C7 . 
From this study it is clear that single-stranded 
conformation polymorphism is a valuable tool for mutation 
detection; however particular care must be taken to 
optimise gel conditions as these are crucial for detection 
efficiency . Although this technique did not detect all 
DNA changes, there is no certainty that any screening 
method would. Even sequencing a number of clones from 
each exon may not detect a polymorphism present in a 
heterozygous state, as was possibly the case in one sample 
in this study. Efficiency of detection of mutations using 
the more common screening methods of SSCP and DGGE al ong 
with heteroduplex analysis will depend to a large extent 
on the sequence surrounding the mutation site. It may be 
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that some sites will not be amenable to detecti on with a ny 
one of these methods but it is possible that a combinati on 
of these techniques might consistently increase detection 
rates to 100 percent. Despite varying efficiency rates 
screening methods remain valuable as time- and money-
saving devices compared with sequencing. 
4.6 Conclusions 
(1.) The site determining the common C6 protein 
alleles A and B occurs at amino acid 98, encoded for by 
exon three. Dde I digestion of PCR amplified C6 exon 
three can be used as a simple and reliable alternative 
method for C6 protein phenotyping . 
(2.) SSCP analysis is a simple and fast method of 
screening for mutations in small DNA fragments; however 
considerable care must be taken to optimise gel conditions 
for each DNA fragment . 
(3.) A total of nine new polymorphisms were detected 
in the C6 gene but only one of these convincingly 
correlated with a rare-protein allele . This suggests that 
the C6 gene is significantly more polymorphic than protein 
data suggests . 
Chapter 5 
Chapter 5 
Population Studies of C6 DNA Polymorphisms 
5.1 Introduction 
The study of DNA polymorphisms across different 
species and populations enables workers to determine 
whether a gene is highly conserved or has diverged 
significantly since separation of the different groups. 
Golding (1992) considers it more likely that identical DNA 
sequences result from their being present in the ancestral 
group than through separate mutational events, however 
other workers (Sigurdardottir et al 1991, Anderson et al 
1991) consider convergent evolution, ie independent 
mutational events, a more likely explanation for sequence 
identity across species. Thus information about the 
presence of identical DNA sequences among different groups 
leads to theories about evolution, migration and 
divergence of these populations. 
Identification of polymorphisms shared across 
different species has led to the theory of trans-species 
evolution (Arden et al 1980, Klein 1980, Arden and Klein 
1982). These polymorphisms are inferred to have been 
present in the ancestor of the species and to have 
survived within both species throughout their divergence. 
This sharing of polymorphisms across several different 
species requires a selective explanation (Takahata and Nei 
1990, Golding 1992). 
Trans-species polymorphisms have been identified 
across different species of mice (McConnell et al 1988, 
Sagai et al 1989, Figueroa et al 1988) and rats (Figueroa 
et al 1988) and between chimpanzees and humans (Lawlor 
et al 1988, Mayer et al 1988, Gyllensten and Erlich 1989). 
Parham et al (1989) suggest that more than 50 percent of 
328 HLA substitutions may be shared by humans and 
chimpanzees. Takahata and Nei (1990) show that these 
shared polymorphisms require strong selection because the 
probability of observing this phenomenon for selectively 
neutral alleles is exceedingly small. Most neutral 
polymorphisms are retained for only an average of 4Ne 
The effect of selection is also inferred from the rati o o f 
amino acid replacements to silent nucleotide substitutions 
in comparison of alleles between species (Gyllensten and 
Erlich 1989) . A larger number of amino acid replacements 
relative to silent and intronic changes suggests that 
selection maintains these polymorphisms (Hughes and Nei 
1988, Gyllensten and Erlich 1989). The strength of the 
selection implied is surprising, particularly as many of 
the polymorphisms studied are of unknown or disputed 
selective value to the individual (Golding 1992) . It has 
been speculated that these polymorphisms may periodically 
be under strong selection , however evidence for this is 
still lacking (Golding 1992). Even with the enormous 
amount of published work aimed at identifying the 
selective force associated with the A-B-0 polymorphism, 
Cavalli-Sforza and Bodmer (1971) report that no real 
understanding of such forces has yet emerged 
A further consequence of the idea of trans-species 
polymorphisms is that there would have to have been 
ancient allelic diversity (Klein 1987). This implies that 
a large group of individuals gave rise to present day 
humans , as opposed to a single line (Klein 1987, Takahata 
1990) . If this were not the case the polymorphisms would 
have been lost by random drift in the bottleneck stage 
(Figueroa et al 1988) . 
The polymorphic nature of complement component six 
has proved useful as a tool for examining different ethnic 
human groups . A study of polymorphisms in the C6 gene, 
combined with further molecular studies, could give an 
indication of similarities and differences in the genetic 
makeup of different populations and in tracing population 
origins and movements. Examination of the C6 protein 
alleles shows that Polynesians, Melanesians and Caucasians 
have a C6*A frequency of approximately 0.60 and C6*B 0 .4 0 
(Chapter 3, Table 3.1) whereas Japanese and Chinese 
population groups have C6*B frequencies higher than C6*A . 
In Micronesians C6*B is by far the most common allele 
(Ranford et al 1982, Ranford 1989) and Australian 
Aborigines have approximately equal C6*A and B 
frequencies. C6 *B2, the most prevalent rare allele, was 
first identified by Hobart and Lachmann (1976) and was 
designated C6*B2 by Mauff et al ( 1980) . It occurs in the 
Micronesian people from Nauru with a frequency of 
approximately 0 . 07 (Ranford et al 1982) and has since been 
identified in all but one of the Pacific area populations 
that have been C6 protein typed. C6*B2 is found at 
frequencies around 0 . 05 in Aboriginal Australians and 
Japanese, while additional rarer alleles have also been 
observed in almost all populations studied, usually 
occurring at a combined gene frequency of around 0 . 05 
(Hobart et al 1993a). 
The continent of Australia has been occupied for more 
than 50 000 years (Roberts et al 1990). The origin of the 
Australian Aboriginal people is still an issue of great 
debate among anthropologists (Bellwood 1989) and has given 
rise to several possible theories. The multiple origin 
hypothesis was postulated from anthropometric and cranial 
diversification studies of both living populations and 
fossils . This hypothesis suggests that either two (Thorne 
1980) or three (Birdsell 1977) ancestral groups from the 
original people of Java and Southeast Asia settled in 
Australia . Other theories suggest a single group of 
people from Java settled in Australia, spread out and 
diversified (Habgood 1985, Brown 1987). Since the initial 
settlement in Australia the Aboriginal people have been 
isolated and have evolved into a separate race now called 
Austroloid. Prior to European settlement, around 200 
years ago, the Aboriginal people existed as hunter-
gatherer tribes and were scattered throughout the entire 
continent, including Tasmania (Kirk 1981). The estimated 
size of the Aboriginal population at the time of first 
European contact was 250 000 to 300 000 (Radcliffe-Brown 
1930). 
Other native people of the Pacific were classified by 
European voyagers according to their geographical 
distribution, thus the terms Melanesians, Micronesians and 
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Polynesians were adopted. Anthropological, arc haeo l ogi ca l 
and linguistic evidence suggests that colonisation o f 
these regions of the Pacific occurred in two waves. The 
New Guinea highland people are thought to share the same 
ancestral group as the Aboriginal Australians (Bellwood 
1989) . This founder population is believed to have come 
from Java 40 000 to 50 000 years ago and diverged once 
established in their new homeland . Approximately 4 000 
years ago a second wave of people , this time of s outhern 
Mongoloid origin, moved from Southeast Asia into the 
Pacific , spreading out to occupy regions of Micronesia and 
Polynesia (Bellwood 1989) . Genetic studies of indigenous 
people of the Pacific provide a unique opportunity to 
examine patterns of migration and the effects of isolation 
from other human groups (Serjeantson and Hill 1989) . 
Additionally the knowledge of the genetic background of 
native populations allows identification of possible 
disease-suscept i b i lity loci . 
A study of C2 , C4 , C6 and factor B, the more 
polymorphic comp lement component proteins, have been 
carried out in samples from the Pacific (Ranford et al 
1982 , Ranford 1989) and these show that the common alleles 
are the same in all populations studied . Ranford (1989) 
suggests that these groups may have evolved from a common 
ancestral origin , however differences in the frequencies 
of these common genes between the groups shows they have 
been evolving separately for considerable time . In 
general , variation in the complement proteins is 
restricted in Polynesians , Micronesians and Melanesians as 
C2 is not variable, fewer C4 alleles are found compared t o 
other populations and more than 80 percent of the factor B 
genes are the common, slow allele. Despite some 
similarities in genetic make-up of the Polynesians, 
Melanesians and Micronesian~ they are not a homogenous 
group. Micronesians lack the C4B null allele and they 
have a unique C6 gene frequency distribution (Ranford 
19 8 9) . 
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Isolation of some tribes of Aboriginal Australians 
has occurred through vast land distances and may be 
comparable to many of the remote i slands of the Pacific 
(Bellwood 1989). As a result some genetic d i versity has 
developed between them . Differences in C4Q O, C4A4 and 
C4B2 allele frequencies between some tribes has arisen 
(Ranford 1989), possibly as a result o f migrat i on by 
genetically different peop le or by divergent evolution 
through geographi c o r cultural iso lation. 
The genetics of the complement components in the 
Pacific is n o t sufficient evidence to reliably conclude 
the migrational patterns that occurred around the area. 
However, in combination with other genetic, linguistic, 
archaeological and anthropometri c studies this information 
may be useful in helping to clarify origins of the people 
of the Pacific . 
Further genetic sudies in the Pacific have utili sed 
the human leucocyte antigen (HLA) system . Conclusions 
reached in one such review (Serjeantson and Hill 1989) 
include the common ancestry of Australian and Papua New 
Guinean highlanders, evident from HLA -B, C linkage. 
Similarity in HLA distributions of Papua New Guineans and 
Melanesians suggest a common ancestry . Polynesians and 
Micronesians have a very limited number of s imilaritie s in 
the HLA system and it appears that Microne s i a has 
experienced genetic admixture not found in othe r groups o f 
the Pacific. 
Early Australian travelle rs left genetic evidence of 
their presence in Melane s ia, but did not transfer 
Melanesian genes into Polynesia (S erjeant son and Hill 
1989) . Polynesia was probably co l onised by a small number 
of settlers, since many HLA alleles are missing from the 
region . HLA allele frequencies and their linkage show 
that New Zealand Maoris, Hawaiians and Easter I slanders 
are of the same Polynesian branch. The possibility of an 
Amerindian contribution to Eastern Po lynesia is possible 
although it is probably of great antiquity. 
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The migratory pa terns and divergence dates suggested 
by the HLA system have proven remarkably consistent with 
those suggested by archaeological, linguistic and cultural 
studies of the region. This is quite remarkable given 
that this system is such a small segment of the human 
genome and it has long been subjected to forces of 
selection, mutation and drift. 
Examination of further polymorphisms in the C6 gene 
in several human groups and chimpanzees could generate 
more information about the similarites of different ethnic 
groups as well as about the evolution of C6. The common 
protein allele determining site and four polymorphisms 
identif i ed in Chapter 4 were examined in small groups of 
Aboriginal Australians (from the Kimberley region) , 
Caucasian-SLE patients , Caucasian-laboratory staff and 
students, Polynesians (from Rarotonga) and Micronesians 
(from Nauru) as well as a group of chimpanzees. Regions 
of the C6 gene were PCR amplified from these samples and 
subjected to restriction enzyme digest analysis to 
determine the presence or absence of specific 
polymorphisms . 
5 . 2 Aims 
To examine the occurrence of five DNA polymorphisms 
in the C6 gene in Aboriginal Australians, Caucasians, 
Micronesians , Polynesians and chimpanzees . 
5.3 Materials and Methods 
5.3.1 Samples 
The samples examined were Caucasian SLE patients, 
including the rare-protein typed individuals, Caucasian 
laboratory staff and students, a group of Polynesians 
(Rarotongans), Micronesians (Nauruans), Aboriginal 
Australians (Kimberley region) and a number of 
chimpanzees . The SLE patients, laboratory staff and 
students were protein typed for this study (Chapter 3) 
while the Rarotongans, Nauruans and Kimberley Aboriginals 
had been typed previously by P Ranford (1989). DNA 
extraction from the Polynesians and Micronesian samples 
126 
was carried out for earlier work while the Aboriginal 
Australian samples were extracted from hemolysates for the 
present study. Chimpanzee samples were from animals held 
under long-term observation in one of several primate 
colonies of the Laboratory of Slow, Latent and Temperate 
Virus infection of the National Institute of Health. The 
majority were captured in the wild in Africa, but a small 
number may have been born in captivity. DNA from these 
samples was extracted from hemolysates by A Browne in 
1992. Storage of all DNA was at 4°c. 
5.3.2 Methods 
All samples were examined by PCR-RFLP following 
discovery of new polymorphisms affecting restriction 
enzyme sites (Chapter 4). Exons three, 10, 11-12 and 13 
were PCR amplified then digested with Dde I, Bsm I, Aci I, 
Bsr I and Mae II respectively. Restriction enzymes Aci I 
and Bsr I were both used for exon 11 polymorphisms. Exon 
three digests were run on 15% polyacrylamide gels, exon 10 
on 10% polyacrylamide gels, exon 11-12 - Aci I 2% agarose, 
exon 11-12 - Bsr I 2% agarose, and exon 13 10% 
polyacrylamide gels. 
A minimum number of ten individuals (20 chromosomes) 
were chosen for examination, where possible. The 
probability of not detecting a given polymorphism with 
this sample size was calculated for several allele 
frequencies. For allele frequencies of 0.5, 0.25 and 0.1 
the probabilities of non-detection are 0.02, 2.3 and 24.4 
percent respectively. 
5.4 Results 
5.4.1 Exon 3 
Table 5.1 shows the results of 153 Dde I digests in 
the different groups examined. Comparison with protein 
data where available shows absolute correlation between 
the two tests except for one sample, a variant protein 
type AB21 discussed in Chapter 4. The chimpanzees had not 
been protein typed so it was not possible to compare DNA 
results but the fact that they possessed this polymorphism 
suggests the exon three substitution is the protein allele 
determining site in chimpanzees as well as humans. The 
prevalence of AA homozygotes in chimpanzees suggested a 
higher A allele frequency in chimpanzees compared with 
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Table 5.1 Genotypes and allele frequen cies of the C6 exon 3 , Dde I locus in Aboriginal 
Australians, Ca u cas ian SLE patients and l1ea;t hy individuals, Mi c ronesians, Polynesians, and 
chimpanzees. 
Genotype Frequencies 
N AA AB 
Group Obs Exp Obs Exp 
Abo riginal Aust. 40 7 8 12 9 
Ca ucasians - SLEa 104 20 19 23 25 
Ca ucasians - healthy 30 2 4 11 8 
Mi cronesians 64 1 3 17 13 
Po lynesians 48 6 7 14 12 
chi mpanzees 20 9 9 l 1 
a Rare-protein typed SL E patients n o t in c luded 
NA= not applicable. 
N = number of chromosomes . 
BB 
Obs Exp 
l 2 
9 8 
2 4 
14 16 
4 3 
0 0 
x2 p 
0 .803 0.669 
0 .168 0.920 
0.178 0.411 
1 . 667 0.435 
0.287 0 . 866 
NA NA 
Percent 
Allele Frequencies 
A B 
65 . 0 35 . 0 
60 . 6 39.4 
50 . 0 50.0 
29.7 70.3 
54 .2 45.8 
95 . 0 5 . 0 
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humans . The human population groups are all in good 
agreement with Hardy-Weinberg expectations (Table 5 . 1) 
Sample sizes are too small for accurate compar i sons of the 
allele frequencies in the different populations, however 
the Nauruan group appears to have somewhat different 
allele frequencie s to all other groups. The observed 
allele frequencies in the different population groups are 
in general quite different from those of published studies 
for larger groups (Chapter 3 , Table 3 . 1) o f the same 
population , highlighting the effect of restri cted sampl e 
size . 
5.4.2 Exon 10 
Results of PCR-RFLP digests and analysi s o f exon ten 
using the restriction enzyme Bsm I are shown in Figure 5 .1 
and Table 5.2. This polymorphism was found in the 
heterozygous form in six of the 65 human samples examined 
and is therefore not uncommon. It was not found in the 
chimpanzee group, suggesting it arose after divergence of 
chimpanzees and humans. The sequence change does not 
cause an amino acid change in the protein and i s therefore 
a silent polymorphism. This study suggests it i s a 
relatively common polymorphism, occurring in at least f our 
different population groups . It was of interest to note 
the apparent increased frequency of this polymorphi sm in 
the Nauruan group examined. 
5.4.3 Exon 11 
This exon shows four DNA polymorphisms (Chapter 4), 
possibly representing a hot spot for mutati on in this 
gene. Two of these polymorphisms were chosen f or 
examination in these population groups as it was probable 
these were polymorphisms not associated with a specific 
rare-protein type . The results of PCR-RFLP analysis are 
shown in Table 5 . 3 and 5 .4. Both of these polymorphisms 
occur relatively frequently in the samples examined . 
5.4.3.1 Exon 11-12, Aci I polymorphism 
Of 44 human samples examined two showed this 
polymorphism in a homozygous f o rm while fi ve possesed the 
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Figure 5.1 Amplified restri c tion fragment length 
pc:ymo rphism typing o f C6 exon 10 , Bsm I si te. a 
Folyo.cry-lamide gel a f ter electrophoresis o f uncut 280 bp 
amplification pro d uct (lane 5 ) and Bsm I fragments from 
individuals heterozygous f o r the polymorphism ( lanes 2 and 
6 ) and individuals homozygous for the published exo n 10 
sequence (lanes 3 and 4 ) . The fragment sizes, in bp of a 
standard DNA (Hae III digested pBR322) are shown in lane 
1 . b Position , sequence, amino acid , restriction site and 
pl values for the published and new exon 1 0 alleles . 
C6 Exon 10 Bam I Digeat 
a 
267 -
184 -
124 -
104 -
89 -
80 -
64 -
57 .-
51 -
primers 
b 
1 
Polymorphism 
Phenotype; 
Codon; 
Amino acid; 
Bsm I site; 
pI ( +A, +B) ; 
at 
2 3 4 5 6 bp 
- 280 
- 197 
- 93 
cDNA 16 7 5, amino acid 518, exon 
Published New Allele 
TGT TGC 
Cys Cys 
- ( GA.A TG I CN I ) + ( GA.A TG I CN I ) 
6.64, 6.71 6.64, 6.71 
10.15 9 
,-~ 
("Y) 
rl 
Table 5.2 Genotypes and allele frequer1cies o f the C6 exo n 1 0 , Bsm I l oc us in Aboriginal 
Australians, Ca u casian SLE patients and healthy individuals, Micr onesians, Po lynesian s , and 
c himpanzees. 
Genotype Frequencies 
Group N DD DC 
Aboriginal Aust . 20 9 1 
Ca u cas ians - SLE 30 14 l 
Ca u c asians - heallhy 30 15 0 
Mi cronesians 28 11 3 
Polynesians 22 10 1 
c himpanzees 20 10 0 
C = new exo n 1 0 sequ e nce, D = published exon 10 sequence . 
N = number o f chromosomes 
cc 
0 
0 
0 
0 
0 
0 
Percent 
Allele Frequencies 
D C 
95.0 5 . 0 
96 . 7 3 . 3 
100 . 0 0 . 0 
89 . 3 10.7 
95 . 5 4 . 5 
100.0 0 . 0 
N 
("'I 
,- -j 
Table 5 . 3 Genotypes and allele frequencies of the C6 e xon 11-12, Aci I locus in Aborigi11dl 
Australians , Ca u c:as ian SLE patients and healthy individuals, Micronesians, Polynesians, and 
c himpanzees. 
Genotype Frequencies 
Group N LL LS ss 
Ca ucasians - SLE 22 9 2 0 
Ca ucasians - healthy 18 6 2 1 
Micronesians 12 5 1 0 
Polynesians 16 7 0 1 
chimpanzees 12 6 0 0 
S = new exonll - 12 sequence, L = published exon 11-12 sequence 
N = number of chromosomes 
Percent 
Allele Frequencies 
L s 
90.9 9 .1 
77.8 22 . 2 
91.7 8.3 
87 . 5 12.5 
100 . 0 0 . 0 
1 33 
change in a heterozygous form. Six chimpanzees were 
examined and none showed this change . Gene frequencies 
were variable and probably reflect the inacuracy of small 
sample size . Interestingly eight human samples (not 
included in Table 5.3) showed a digest pattern different 
to the expected band sizes . The uncut PCR product was 619 
bp and samples possessing the identified Aci I site were 
591 bp, whereas these unusual samples showed only one band 
of approximately 560 bp (Figure 5.2). Repeated PCR and 
digest analysis of these samples did not change the 
different pattern. The undigested PCR product of these 
samples appeared to be 619 bp on examination prior to 
digestion, eliminating the possibility of a smaller 
initial PCR product due perhaps to a shorter intron 11 
sequence . This result suggests there is an additional 
polymorphic Aci I site approximately 30 bp 3' from the 
identified polymorphic Aci I site at amino acid 544 or 30-
60 bp in from the exon 12 end of the PCR product. The 
identified Aci I polymorphism causes an amino acid change 
that results in an overall charge change in the protein 
and yet these samples show no evidence of altered IEF gel 
patterns. 
5.4.3.2 Bsr I polymorphism 
The polymorphism at amino acid 546, altering a Bsr I 
restriction enzyme site was found in a homozygous form in 
two human samples and in the heterozygous form in 12 of a 
total of 45 samples examined . Gene frequencies for this 
polymorphi sm are given in Table 5 .4. Sample numbers are 
small and as a result allele frequencies are quite 
variable . Only five chimpanzees were examined at this 
site and none showed this change . Interestingly seven 
samples examined showed a digest pattern completely 
different to that seen f or homozygous normal, homozygous 
mutant and heterozygous samples . These samples were PCR 
amplified and digested several times to rule out the 
possibility o f partial digests . This finding suggests a 
further polymorphism not found in the sequenced samples 
which also affects a Bsr I recognition site . It was 
difficult to identify the exact sizes of the new fragments 
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Figure 5 . 2 Amplifi ed r est r ict i o n fr agme nt length 
polymo r ph i s m t yping o f C6 e x o n 11-1 2 , Aci I site . a 
Polyac r ylamide g e l af t er e le c tro pho re s is o f PCR amplified 
exo n 11 -12, Aci I digest ed fragment s . Homozygous 
p u bli s hed samples ( lane s 3, 4, 6 ) , a hetero zygous sample 
( lane l ) and a h omo zyg o us polymo rphic allele sample ( lane 
5 ) . Th e fragment sizes, in bp of a DNA standard (Hae III 
and Ms p I digested pBR322) are sho wn in lanes 1 and 7 
respec tively . b Position, sequence, amino acid , 
restr i ction site and pl values for published and new 
, l 1 a.1 e.Le s . 
C6 Exon 11-12 
I 
ACl. I Digest 
a 
1 2 3 4 5 6 7 bp 
619 '- - 622 
591-
560' - 527 
- 404 
- 309 
-242 
-190 
b 
Polymorphism at cDNA 1752, amino acid 544, exon 1 1.010 
Phenotype; Published New Allele 
Codon; GAC GGC 
Amino acid; Asp Gly 
Ac i I site; - ( C 1 CG 1 C ) + ( C ' CG ' C ) 
pI ( +A, +B ) ; 6 . 6 4, 6.71 6. 71, 6 . 77 
I...D 
(", 
rl 
Table 5.4 Genotypes and allele freqt1encies of the C6 exon 11 - 12, Bsr I locus in Abo riginal 
Australians, Ca u c asian SLE patients and healthy individuals, Micronesians, Polynesians, and 
c himpanzees. 
Group 
Caucasians - SLE 
Ca u c asians - healthy 
Micronesians 
Polynesians 
c himpanzees 
T = new exon 11 - 12 sequence, 
N = number of chromosomes 
N TT 
24 8 
20 4 
10 3 
18 7 
10 0 
Genotype Frequencies 
TU 
4 
4 
2 
2 
0 
U = published exon 11-12 sequence 
uu 
0 
2 
0 
0 
5 
Percent 
Allele Frequencies 
T u 
83 . 3 16 . 7 
60 . 0 40 . 0 
80.0 20 . 0 
88.9 11.1 
100 . 0 0 . 0 
but estimates of 260 bp and 180 bp were taken (Figure 
5 . 3). All of these unusual samples also possessed the 
unexplained Aci I pattern. 
5.4.4 Exon 13 
·, ~ 
I 
The polymorphism identified in this exon, at amino 
acid 680 , was initially thought to contribute to the C6*B2 
protein allele however the calculated pI for this change 
did not correspond to expectations based on IEF gel 
patterns . It was thus decided to examine this site in a 
number of other samples in order to identify whether the 
change was a polymorphism found in non-rare protein types 
or a possible cause of the B2 allele . Of 63 human samples 
examined two showed this polymorphism in homozygous form 
and 29 in the heterozygous form (Figure 5 . 4, Table 5 . 5). 
One of the two homozygous samples was the B2 (WP3) 
phenotyped sample from which the polymorphism was 
initially identified and the other was a Nauruan sample 
with normal protein type. Of the 29 heterozygous 
individuals identified 22 had common protein allele types. 
The seven heterozygous samples with rare protein types 
included four of the five rare-protein type SLE patients 
and represented three different rare alleles (Al, B2 (WP3, 
Nauru) and A?B21) which suggests this polymorphism is not 
responsible for any of them . It thus appears that this 
sequence change is a relatively common polymorphism which 
has no identifiable affect on IEF protein type. Allele 
frequencies vary considerably across the different groups 
examined , probably reflecting sample sizes. This 
polymorphi sm was found in a heterozygous form in three 
chimpanzees suggesting it is an ancient polymorphism. 
5.5 Discussion 
This study of C6 DNA polymorphisms reinforces the 
known polymorphic nature of complement component six. The 
C6 protein is well known to be highly polymorphic with at 
least 19 different alleles identified with isoelectric 
focusing . The present study shows that the polymorphic 
nature of the C6 gene is even greater than suggested by 
protein studies. Of nine identified DNA polymorphisms 
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Figure 5.3 .lunplified restricti o n fragment length 
p o :ymo rphism typing of exo n 11-12, Bsr I site . a 
Po lya c r:/lamide gel after electrophoresis of Bsr I digested 
fragme nts of C6 exon 11-12 PCR produces. Individuals 
hetero zygous for this p o lymo rphism (lanes 4 and 6 ) , 
samples homozygous published alleles ( lanes 3, 7 , 8 , 9 , 
10, 11, 14), samples homozygous for the polymo rphism 
(lanes 12, 13) . Two samples with patterns different to 
all others , representing new alleles are in lanes 5 and 
15 . The fragment sizes, in bp of a DNA standard (Hae III 
and Msp I digested pBR322) are shown in lanes 1 and 16 
respectively. b Position, sequence, amino acid, 
res t riction site and pl values for the confirmed alleles 
of exo n 11, identified with Bsr I. 
C6 Exon 11-12 Bsr I Digest 
a 
bp 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
619-
-622 
-527 
-404 
337_ r 
260!2.Z.- -309 
_242,238 233-
-190, 180 180 
-147 
b 
Polymorphism at cDNA 1759, amino acid 54 6 , ex o n 11.01 7 
Phenotype; Published New Allele 
Codon; CAG CAC 
Amino a c id; Gln His 
Bsr I s ite; - ( ACTG ' GN ' ) + ( AC'I'G ' GN ' ) 
pl ( +A , + B ) ; 6 . 6 4, 6 . 7 1 6 . 6 7 / 5. 7 3 
14 0 
Figure 5 .4 A..rnplified I.-e strict i o n fragment length 
po~ymorphism typing o f exon 13 , Mae II site. a 
Po2-yacr~rlamide gel after electrophoresis o f uncut 176 bp 
amplification product (lane 4 ) and Mae II fragments from 
samples heterozygous for the exon 13 polymorphism (lanes 2 
and 3J and homozygous for the polymorphism ( lane 5) . The 
fragment sizes, in bp of a DNA standard (Hae III digested 
pBR322) are shown in lane 1 . b Position, sequence, amino 
acid, restriction site and pI values for the published and 
new exon 13 alleles . 
a 
C6 Exon 13 Mae II Digest 
267-
234-
213-
192-
184-
104-
s9-
so-
64 -
5 7 -
51 -
1 2 3 4 5 
-176 
-158 
b 
Polymorphism at c DNA 2159, amino acid 680, exon 13.133 
Phenotype; 
Codon; 
Amino a c id; 
Mae II site; 
pI ( +A, +B ); 
Published New Allele 
c lGG T jGG 
Arg Trp 
- ( A 'CGT ) + ( A 'CGT ) 
6.6 4, 6.7 1 6.57, 6.64 
( J 
" Ji 
- ! 
Table 5.5 Genotypes and allele freque11 c ies of the C6 exo n 13, Mae II l ocus in Abo ~iginal 
Australians, Ca u cas ian SLE patients and healthy individuals, Mi c ronesians, Polynesians, and 
c himpanzees. 
Genotype Frequencies 
Group N xx XY 
Abo riginal Aust . 20 7 3 
Ca u ca sians - SLE 30 6 9 
Ca ucasians - healthy 30 12 3 
Micronesians 26 5 6 
Polynesians 20 2 8 
c himpanzees 20 7 3 
X = new exon 13 sequence, Y = pub li shed exon 13 sequence 
N = number of c hro mosomes 
yy 
0 
0 
0 
2 
0 
0 
Percent 
Allele Frequencies 
X y 
85.0 15.0 
70.0 30 . 0 
90.0 10 . 0 
61.5 38.5 
60 . 0 40 . 0 
85 . 0 15.0 
4 3 
only two correlated with an altered protein type , leaving 
seven others that were not indicated fr om protein work. 
This suggests that the C6 gene i s three o r f our times more 
polymorphic than the protein data indicates. This level 
of polymorphism in C6 could reflect a lack o f natural 
selection for the gene, in that mutati ons are tolerated 
because a functi onal C6 prote in is not essential for 
survival of the individual . Alternatively these DNA 
sequence changes may not affect the proteins funct i on . A 
report by Davies et al (1993) describes a high level of 
polymorphism in the 5 1 untranslated region o f the a -
galactosidase A gene detected with SSCP analysis . Few 
polymorphisms for this gene had previously been reported . . 
This suggests that more detailed examination of gene 
sequences in general may reveal higher levels o f 
polymorphism than was previously thought and as such what 
is found in the C6 gene may not be unusual 
The population studies were not aimed at accurately 
determining the frequency of the different base 
substitutions in the groups examined, for that larger 
numbers of samples would need to be examined. The purpose 
of this work was to indicate the presence o f these 
polymorphisms in the different groups and to g i ve an 
indication of allele frequencies . 
Many population studies have examined C6 protein 
types in different ethnic groups (summary Chapter 3 , Table 
3 . 1) . Allele frequencies for the common-protein types are 
well established and relatively similar in the major 
ethnic groups . Results in the present study show good 
agreement with published protein data f o r the Caucasian -
SLE group, but other groups appear quite different. This 
disagreement is probably a reflecti on o f the limited 
sample size in the present study . Except f or the healthy 
Caucasians, who showed an equal frequency o f Cb'r<A and Cb b 
alleles, other groups were in agreement with published 
pre i" 
data in which allele was most comomon. No published data 
A 
are available on protein allele frequencies of 
chimpanzees, but rhesus monkey studies (Hall and Alper 
144 
1977) show similar A and B allele frequencies to those of 
Caucasians. The chimpanzees examined in this study showed 
a predominance of A alleles, this however disagreed with 
similar studies on other samples carried out by Tuxworth, 
Bontrop, Fernie, Hobart, Lachmann and Mouse (personal 
communications from M Hobart) who found all 30 of their 
chimpanzee samples possessed the AB phenotype, a finding 
in conflict with Hardy-Weinberg expectations. 
Mitochondrial DNA studies of the chimpanzees used in the 
present study (personal communications C Wise) show 
remarkable diversity, ruling out the possibility of 
inbreeding in the group. Thus the predominance of A 
alleles in this study is likely to be a reflection of 
restricted sample size. 
This study highlights the accuracy of replacing the 
protein test with a DNA based analysis. Of all common-
protein typed samples examined none showed disagreement 
between the two tests. The DNA method also allows 
clarification of rare-protein samples as the background 
allele can be definitively identified. Additionally, it 
is possible that a DNA mutation could cause a common A 
allele to appear as a B allele with IEF and vice versa. 
While this occurrence is probably quite rare, based on the 
data obtained from this study, it effectively increases 
the number of possible polymorphisms that occur in the C6 
gene. 
The polymorphism identified in exon 10 was a silent 
substitution that has a gene frequency between three and 
10 percent in humans. It is therefore a relatively common 
polymorphism found in at least four different ethnic 
groups with the polymorphism arising prior to emergence of 
these racial groups. None of the chimpanzees examined 
possessed this polymorphism. Of the 14 Micronesian 
samples examined three possessed this polymorphism on one 
of their chromosomes. This suggests an allele frequency 
of around 10 percent in this ethnic group. While this 
estimation is probably not precise it does suggest 
Micronesians are more polymorphic at this site than the 
other groups examined. This result is in agreement with 
protein data for this group as Mi crone s i ans show a unique 
protein allele frequen cy distr i but i on characterised by a 
higher frequency o f rare-protein alleles (Ranford 1989) . 
This finding also coroborates the HLA data which show that 
Micronesians have only limited s imilarites with 
Polynesians . Serjeantson a nd Hill (1989) suggest that 
Micronesians have had an independent source of HLA genes 
that are not found else-where in the Pacifi c , and 
theref o re a unique distribution o f C6 DNA p o lymorphi sms is 
not unlikely. 
The exon 11 Aci I s ite polymorphism was present on 
nine human chromosomes of a total of 72 examined, 
indicating it too is relatively common in humans. It was 
not found on any of the 12 chimpanzee chromosomes 
examined . From these data it is not possible to determine 
whether the negative finding in chimpanzees i s due to the 
restricted sample size or to it being a lineage- spec ifi c 
polymorphism. This question could be answered with 
·further studies utilising a large number o f chimpanzees 
and perhaps other organsisms . The healthy Caucasians 
showed the greatest frequency of this polymorphi s m, around 
22 percent, markedly contrasting with results f o r exon 10 
where the estimated frequency for the new allele was zero . 
Micronesians did not show a higher allele frequen cy for 
this polymorphism in relation to other groups but this 
says little about the level of polymorphism in this ethnic 
group compared to others since the difference in 
occurrence was essentially a chance effect o f finding 
homozygous versus hetero zygous samples . It is worth 
noting also that the restriction enzyme Aci I is quite 
difficult to use and requires considerable care when 
estimating the amount o f PCR product to digest . 
Additionally reacti on conditions are non-standard, 
requiring the addition o f one percent gelatin and an 
alternative buffer to that recommended by the 
manufacturer. It is possible that inaccuracies occurred 
since digestion may have been inefficient and 
identification o f the 591 bp band was sometimes difficult . 
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The unusual 560 bp Aci I digest pattern was found in 
eight human samples and no chimpanzees . This finding may 
be the result of a recent mutati on affecting an as yet 
undetermined Aci I site. The recognition sequence for 
Aci I is CCGC and many sites which differ fr om this motif 
by only one base are present in the exon 11-12 PCR 
product. It is possible that a point mutati on occurs at 
one of these sites and therefore generates a new Aci I 
recognition sequence . A good candidate f o r this 
explanation occurs in exon 12 at amino acid 621 - 622 , 
position 12 . 072 . The published sequence at this site is 
CCGG but if it were CCGC in these samples, a new Aci I 
site would be generated and would give rise to a digesti on 
product of 566 bp, assuming the samples did not possess 
the confirmed Aci I polymorphism. The likelihood o f 
additional polymorphisms in the exon 11-12 regi on is not 
remote based on having found five other sequence c hange s 
in this area of the C6 gene . It is however highly unusual 
that all eight samples possess this 11 new 11 unconfirmed Aci 
I polymorphism in a homozygous form . Further studies 
would ideally involve cloning and sequencing a number o f 
these unusual samples in this region in order t o determine 
the underlying sequence of these exons and intron. 
The exon 11 Bsr I polymorphism was found on 16 o f the 
45 examined human chromosomes . Two cases of homozygosity 
were identified with the remaining 12 alleles being found 
in a heterozygous form . Interestingly the homozygotes and 
four heterozygotes were found in the healthy Caucasians 
and the next highest 11 new 11 allele frequency occurred in 
the Caucasian SLE patients, suggesting that this 
polymorphism may be more prevalent in Caucas o ids than 
Micronesians and Polynesians . 
The exon 11 Bsr I polymorphism was not iden ified on 
any of the 10 chimpanzee chromosomes, and aga in this may 
be a result of small sample size or that it i s a species 
specific polymorphism. A more extensive study could 
determine its presence or absence in chimpanzees. 
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Like the Aci I polymorphism, unusual Bsr I d ige s 
results were identified in seven samples, all o f whi c h 
also possessed the Aci I unusual pattern (the eigth sampl e 
was not tested). These digest results d i d not relate t o 
any form of the identified polymorphism and thus 
represented a new sequence change . Two possible 
explanations for the observed band sizes are; 1) amino 
acid 546-as published; no Bsr I s ite, possible 
polymorphism at amino acid 590 ; new Bsr I s it e , 
polymorphism in intron 154 bp fr om exon 11, also creating 
a new Bsr I site, and unchanged Bs r I site at amino acid 
626-627 as seen in published sequence , 2) amino acid 546-
published sequence ; no Bsr I site , possible polymorphism 
in intron 24 bp from exon 11 creating a new Bsr I site, 
possible polymorphism in intron 154 bp from exon 11, 
creating a new Bsr I site , and unchanged Bsr I s ite at 
amino acid 626-627 as seen in published sequence . Figure 
5.5 is a schematic representati on of the two possible 
explanations of the different patterns identified with the 
Bsr I digests, their approximate sizes and the 
polymorphisms needed to explain them. It was interest ing 
that this new polymorphism occurred only in a h omozygous 
form and always with the unconfirmed Aci I polymorphism. 
It never appeared with either a normal allele o r with the 
previously identified sequence change at amino ac id 546 . 
It seems highly unlikely that two further sequence changes 
could occur in this region, however if option two were the 
correct explanation both these new mutati on s would be in 
the intron and therefore somewhat more likely than further 
exonic polymorphisms. Additi onally in light of having 
found four polymorphisms in this exon already it is 
perhaps not impossible that this could occur here . It 
could be that the sequence c hange s responsible for the 
Bsr I and Aci I unconfirmed polymorphisms are not simple 
point mutati ons and may then occur at the same site . It 
is difficult to locate a site in this sequence which c ould 
be altered such that all these findings would be 
explained . 
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Figure 5.5 Schematic representation of the two possible 
explanatio ns for the unusual Bsr I digest patterns o f exon 
11-1 2 . 
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Option 1 
Mut ations r equired ; 1) amino acid 590, 11.149 TGC -- TGG, 
new Bsr I site created 
2) intron 11, 154 bp from the end of 
exon 11, TGC --- TGG, new Bs r I site 
created 
Option 2 
Mutation s required; 3) intron 11, 24 bp from the end of 
exon 11, AAT -- ACT, new Bs r I site 
created 
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ex o n 11 , TGC -. TGG , new Bs r I s i t e 
created 
2 ) 
J 
intron 
4 ) 
! 
published 
J 
r • • • • • • i,. • • • • • • • .. ..... ....... . . 
2 8 ~ ·········· i-.• ••••• ·····~·s o··· . . . . . . .. ••••• i,. • • ••. . . . . . ... - ... • • • • • •••• t-- ••••••••• 
exon 12 
published 
l 
r • • •• • .. •. • • t- •••• - ••• • ...... 
' 
;._ •. e e • • • e • e I . . . -~ 127 2 8 ~ ·.·.•····· "·'· 5 0 •,•, ~... . .. f e e e • _ I 
~ ...... ~ ....... · .. • •• e e I 
...... Ii- •••• "-'-··· 
intron exo n 12 
11111111111 
-
150 
The number of samples examined for the two exon 11-12 
polymorphisms was much reduced relative to the exon three, 
10 and 13 polymorphism studies. This was due to the 
difficulty in obtaining PCR product for many of these 
samples. The problem with amplification of this fragment 
arose because of its larger size relative to the exon 
three, 10 and 13 fragments and the quality of the template 
DNA. The age of some of the samples from which DNA was 
extracted for this study was greater then 10 years and 
many samples showed considerable degradation. This 
appeared not to be a problem with the smaller PCR 
products, but was clearly important when attempting to 
amplify the 619 bp fragments. Thus it was not possible to 
obtain a discrete band of PCR product for restriction 
digestion analysis for many of these samples. 
The exon 13 polymorphism, identified with the 
restriction enzyme Mae II, showed a high frequency in all 
groups examined, ranging from 10 to 40 percent. The 
Micronesian and Polynesian groups showed almost equivalent 
frequencies. Three of 10 chimpanzees also possessed this 
polymorphism, suggesting it may be an ancient polymorphism 
established prior to the divergence of chimps and man, 
some four to six million years ago. Alternatively it may 
have arisen independently in the two groups due to some as 
yet unidentified selective advantage. The allele 
frequencies reported here are only estimates of the 
population frequencies and may not be precise. Also worth 
noting is that the Mae II digestion analysis was sometimes 
problematic as the identification of the published allele 
sequence and the new allele relied on the enzyme cutting 
to completion. In homozygous cases it was generally clear 
that complete digestion was obtained but in some 
heterozygous cases, several digestion attempts with 
increasing amounts of enzyme failed to produce bands which 
were of equal intensity. As such the heterozygote data 
had to be interpreted and it is possible that inaccuracies 
occurred. 
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The frequencies of the exon three and 13 
polymorphisms were different in samples from four ethnic 
groups suggesting divergence between these populations. 
Differences in allele frequencies between ethnic groups 
may arise through variations in initial population size, 
the extent of migration and immigration, climatic or 
health crises and perhaps cultural factors such as the 
prevalence of consanguinous marriages. Further studies 
would utilise large samples to more precisely determine 
allele frequencies in these groups and thus allow better 
population comparisons. 
From this study of C6 DNA plymorphisms it appears 
that the exon three, common-protein allele determining 
site and the exon 13 polymorphism may have arisen prior to 
divergence of humans and chimpanzees and these have since 
been maintained through selection. Alternatively it is 
possible that these polymorphisms arose through convergent 
evolution, evolving independently in the two species after 
divergence from a common ancestor. Both theories require 
selection to be acting on the gene, and as yet it is not 
clear what advantage either polymorphism would have on the 
individual. From this study neither theory can be proven 
and the issue of selection for the C6 gene will be 
discussed further below and in Chapter 6. 
A total of five confirmed (Chapter 4) and two implied 
polymorphisms were found in the exon 11-12 region of the 
C6 gene. In proteins critical for survival a cluster of 
DNA polymorphisms such as this, could suggest that the DNA 
site does not encode a functionally important protein 
domain. An exception to this generalisation however is 
the HLA system, in which greater variability enhances 
survival as it allows a larger number of antigens to be 
recognised by the body and hence eliminated. In the case 
of the C6 protein however it is not clear whether 
increased variability has any beneficial or detrimental 
effect on the organism. It is true that many C6 deficient 
individuals are healthy implying that functional 
competence of C6 is not critical for survival, however 
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many deficient individuals experience recurrent 
infections. These infections may not be life threatening 
under present day health care, however at the time these 
polymorphisms were arising this may have been a 
significant factor. It is possible these polymorphisms 
conferred some advantage to the individual in the past and 
have not yet disappeared from the population. An 
explanation for the maintenance of these polymorphisms is 
difficult and is an issue which has been well debated. 
Fisher et al (1939) found that chimpanzees and humans 
shared an apparently neutral polymorphism for tasting PTC 
(phenyl-thiocarbamide) and this was found in the same 
frequency in both groups. The conclusion drawn from this 
was that there must have been strong balancing selection 
for this "apparently valueless" characteristic to maintain 
it for such a long time. Since Fishers study there have 
been many other cases of trans-species polymorphisms 
(Lawlor et al 1988, Mayer et al 1988, Gyllensten and 
Erlich 1989). Many examples of trans-species MHC 
polymorphisms have been examined at the molecular level 
and found to be identical suggesting a single molecular 
ancestor. Takahata and Nei (1990) report that these 
polymorphisms require selection to explain their 
existance, since the probability of observing this 
phenomenon for selectively neutral alleles is very small. 
It was not determined in this study whether any of the 
identified polymorphisms affected protein function, and 
thus it is difficult to extrapolate about the location of 
these polymorphims in regard to functionality of the 
protein domains. This cluster of DNA polymorphisms does 
suggest analogy with the C4 diversity region and genetic 
mechanisms such as gene conversion and template 
mutagenesis may have been involved in C6 evolution. 
Chapter 6 discusses these theories in further detail 
5.6 Conclusions 
(1.) The exon three Dde I digest analysis is an 
accurate, alternative method of C6 protein typing the 
common C6*A and C6*B alleles. 
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(2.) The exon 10 polymorphism was found in all four 
ethnic groups examined, with Micronesians having the 
highest incidence of this change. The exon 11, Aci I and 
Bsr I polymorphisms were found in Micronesians, 
Polynesians and Caucasians, with healthy Caucasians having 
the highest incidence of both new alleles. The exon 13-
Mae II polymorphism was found in all four ethnic groups 
and chimpanzees. 
(3.) Restriction enzymes Aci I and Bsr I identified 
further sequence changes not found previously, the amount 
of polymorphism found in the exon 11 to 12 region shows 
this to be a highly variable region of the C6 gene. 
Chapter 6 
Chapter 6 
General Discussion 
This thesis has examined complement component six 
protein types and restricti on fragment length 
polymorphisms (RFLP) in a group of Caucasian patients with 
SLE and healthy Caucasian individuals. No association 
between a specific protein type nor RFLP pattern and SLE 
was found . Samples from healthy Caucas ians showed the 
same frequency of protein alleles and RFLP alleles as the 
Caucasian SLE patients. Allele frequencies f or the 
protein and RFLP loci showed good agreement with Hardy-
Weinberg expectations in both groups . This study was 
undertaken after a review of the literature showed there 
to be some association between SLE and C6 deficiency 
(Tedesco et al 1981, Trapp et al 1987) . Of the 403 SLE 
patients examined in this study none appeared to be 
completely deficient in the C6 protein and the concordance 
with Hardy-Weinberg expectations showed that partial 
deficiency of C6 is not a major contributor to inherited 
predisposition to SLE . This suggests that the reported 
association between SLE and C6 deficiency may be an 
ascertainment artifact , a suggestion also made by Wurzner 
et al (1992a) and Sjoholm (1991) . 
Deficiency of C6 is one of the more common complement 
component deficiencies, occurring in aproximately one in 
60 000 Caucasians (review Morgan and Walport 1991). In a 
review by Wurzner et al (1992a) C6 deficiency is reported 
to be found particularly in American Blacks (Petersen 
et al 1979), Caucasians and South African Cape coloureds 
(Orren et al 1987) with over 100 cases published . It is 
likely that patients with SLE are more frequently 
investigated for complement deficiencies than other 
patient groups and healthy individuals since associations 
between SLE and deficiency of C2 and C4 are well 
established (review Sjoholm 1991, review Densen 1991 ) As 
yet there have been few reported large scale studies o f 
terminal complement component deficiencies in autoimmune 
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patients and healthy controls , thus it is difficul to 
conclude whether there is truly an increased incidence o f 
C6 deficiency in SLE patients. 
It remains unclear whether the terminal sequence 
affects earlier steps in complement activation. Lachmann 
et al (1978) report that the complement profile in 
deficient patients is in general normal for all the other 
components when individuals are healthy. In contrast 
Bhakdi et al (1988) report that the terminal complement 
complex exerts a regulatory effect on the formati on of the 
classical and alternative pathway C3 convertases and on 
the utilisation of CS by cell bound CS convertases. Thus 
a negative feedback function of the MAC may contribute to 
regulation of the complement system. Individuals with 
terminal component deficiencies generally do not have 
impaired complement-dependent opsonisation, however there 
are exceptions (Boyer et al 1975) . At present it is 
difficult to conclude whether absence of a functi onal MAC 
due to a deficiency , or non-functional, terminal 
complement component(s) has any wider effect than simply 
loss of MAC function . The vast majority of complement 
deficiencies essentially affect only a single component 
(Lachmann et al 1978). The cases of coexisting 
deficiencies of : C2 and C9 (Kaneco et al 1993); CS and C4 
(Gianella Borradori et al 1990) ; C6 and C2 (Delage et al 
1979, Orren et al 1987) and C7 and C4 (Chapel et al 1987, 
Lopez-Trascasa et al 1988, Wuillemin et al 1991) are rare 
and do not suggest that absence of one component causes 
loss of another . These compound deficiencies appear to be 
the result of independent mutations (Wurzner et al 1992a). 
A further explanation for the reported association 
involves the heterogenous nature of SLE. SLE is an 
extremely variable disease (St einberg 1985) and it is 
becoming apparent that it consists of several subgroups 
(Arnett 1987, Jacob et al 1990). Fronek et al (1990) 
report that a clinical subset of SLE patients (those with 
nephritis) show an increase in the normally rare DR2 
associated DQ~1*0601 allele, and a decrease in DR4 
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frequency, compared with SLE patients lacking kidney 
disease and controls . This suggests that there may be 
different genetic backgrounds and therefore causes of SLE 
in different subsets of patients. It is possible hat a 
small subset of SLE patients do have associated deficiency 
of C6 and, given the variability in diagnosis of the 
disease, this group may have been under-represented in the 
present study . 
This study also examined the association between C6 
protein and Taq I RFLP alleles. No absolute correlation 
between protein and Taq I RFLP alleles was found 
demonstrating that C6 Taq I RFLP analysis cannot replace 
the IEF method of C6 allotyping. As a consequence of 
random genetic drift, selection, gene flow, non-random 
mating or common ancestry, alleles at separate loci may 
not associate at random (Lewontin 1988). This association 
is often thought to be a result of linkage, however non-
linked genes may also temporarily or permanently be held 
in a non-random association . Many attempts have been made 
over the years, to measure this association , o r 
disequilibrium . It is expected that for two randomly 
associated loci : A and B, the frequency of the different 
gametes or haplotypes will be equal . The standard 
equation to examine this property is ; 
D = (freq AlBl) (freq A2B2) - (freq AlB2) (freq A2Bl) (1 . ) 
where D = 0 implies no association (Lewontin and Kojima 
1960) . Thus Dis often used as a measure of the degree of 
non-random association . The value of Din this equation 
is dictated by the allele frequencies and Lewontin (1988) 
believes this disqualifies Das a general measure of 
association . Numerous researchers have proposed measures 
to normalise D for allelic frequencies (Lewontin 1964, 
Hill 1975, Ohta 1980, Maruyama 1982) . Hedrick (1987) 
examined six different measures of disequilibrium and 
showed them all to be dependent upon allelic frequencies 
despite four of them being normalised in some way . 
Lewontin (1988) concludes that there are no gene frequency 
independent measures of association, or disequilibrium, 
between loci and this idea of association is a very poorly 
defined concept. 
Despite the arguments above many researchers believe 
that measures of disequilbrium are valid . Numerous 
different methods for calculating this figure have been 
proposed and utilised (Weir and Wilson 1986, Haber 1984, 
Chakravarti et al 1984, Maiste and Weir 1992). In the 
present study three different methods were used and 
results compared . 
In order to examine the possibility of an association 
between the protein allele determining loci and the Taq I 
RFLP site it was first necessary to determine which 
alleles were inherited together. The present study lacked 
any family data so determining which alleles were 
inherited together was problematic where samples showed 
double heterozygosity. In this situation haplotypes are 
not able to be determined and a problem then arises as to 
what to do with these samples . Some researchers advocate 
discarding them (Prof J Edwards, Oxford, M Hobart, 
Cambridge) which is thought to be reliable but 
inefficient, while others use the individual allele 
frequencies to calculate expected distribution of the 
haplotypes (Thompson et al 1988). Further studies utilise 
a method which examines both possible haplotypes f or the 
double heterozygotes (Prof S Serjeantson, X Gao, 
Canberra) . The present study used all three methods in 
order to compare the differences. No statistically 
significant difference was found between the three 
methods, however discarding the double heterozygotes gave 
somewhat different haplotype frequencies and the x2 value 
was higher for comparisons between this and the latter two 
methods. 
The simplest method of calculating linkage 
disequilibrium, (1.) resulted in D values of 0 . 075, 0 . 035 , 
and 0 . 038 (Chapter 3, Table 3 . 5) for the three haplotype 
distribution methods. The largest D value was for the 
method of discarding double heterozygotes and could be 
regarded as evidence for a non-random association of these 
two DNA sites. A second method of calculating linkage was 
that of Baur and Danilovs (1980) . This estimate was 
calculated using a computer program which inco rporated 
double-counting of heterozygotes. Thus it was only 
possible to analyse the data with exclusion of double 
heterozygotes and double counting o f heterozygotes. 
Results for both of these anlyses showed significant 
linkage disequilibrium for protein type A and Taq I RFLP 
allele 8.0 as well as for protein type Band Taq I RFLP 
allele 7 . 0. Therefore the two methods of dealing with 
double heterozygotes yield equivalent results for this 
method of linkage disequilibrium estimation . A further 
linkage estimation method employed log-linear calculations 
of the data (Weir and Wilson 1986). The computer program 
for this model discards double heterozygotes and the 
results showed a significant deviation from linkage 
equilibrium. 
The present study employed three methods of -dealing 
with double heterozygotes as well as three estimates of an 
association between two DNA sites . The overall conclusion 
of these analyses was that these two sites are not 
associated at random . However , it still remains 
debateable as to whether any of these estimates of 
association are truly valid, since some workers believe an 
allelic frequency-independent measurement is difficult, if 
not impossible to obtain (Lewontin 1988, Hedrick 1987) . 
It is thought that C6 is selectively neutral (Hobart 
et al 1975) since gene frequencies for the common alleles 
are very similar in different racial groups, alleles are 
always found in Hardy-Weinberg equilibrium and people 
deficient in this protein are often healthy . Neither the 
common C6 protein allele determining site (exon three) nor 
the Taq I RFLP site are thought to affect the function of 
the protein . Thus should selection for functi onal C6 
protein be operating it would not affect these allele 
frequencies unless these sites were linked to a 
functionally critical site. Additionally, there is at 
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least a 60 kb distance between the two DNA sites and thus 
recombination events could occur between them. As yet no 
reports of recombination within the C6 gene or between the 
C6 and nearby C7 gene have appeared. However until 
recently (Fernie et al 1993) only two polymorphic DNA 
markers (Coto et al 1991a and b) for the C6 gene were 
available for study and few groups had specifically 
examined this aspect of the C6 gene . The possibility of 
recombination events and the apparent neutral selection 
for these two DNA sites would suggest they should 
associate at random. 
Interestingly Setien et al (1993) report a significant 
association between another C6 RFLP, involving a 
polymorphic Msp I site (Coto et al 1991b), and the C6 
Taq I RFLP . Fernie et al (in preparation) localise the 
polymorphic Msp I site to intron three, approximately 
three kb from exon three. This places the Msp I 
recognition sequence very close to the C6 protein allele 
determining site in exon three . Thus Setien and 
coworkers 1 (1993) results show equivalent findings to 
those in the present study , however the validity of 
measurements of association still remain controversial. 
It is possible that the exon three common protein 
allele determining and Taq I RFLP sites are of very 
different ages . The C6 protein allelism is known in 
rhesus monkeys (Hall and Alper 1977), rabbits (Kunstman 
and Mauff 1980, Goldman et al 1982, Rother 1986), rats 
(Granadose et al 1984) and pigs (Shibata et al 1993) thus 
it appears to be an ancient polymorphism. No data are 
available for the Taq I RFLP in other organisms so it is 
impossible to conclude whether this polymorphism is recent 
or of great antiquity . It is possible that the Taq I RFLP 
site is a recent sequence change and as yet insufficient 
time has passed for random association of these alleles. 
The amount of time, or number of generations, needed to 
produce random assorcment of alleles is determined by the 
rate of recombination and ~~e initial level of 
disequilibrium between two .on-linked sites. Bodrner and 
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Bodmer (1978) estimate that in a random mating population, 
if disequilibrium is present it would decline at a rate of 
(1-r) per generation, where r = the recombination 
fraction. Thus however close together the loci are, 
linkage disequilibrium, in the absence of selection, will 
eventually reach zero, but the rate at which this occurs 
depends on the recombination fraction. Given the 
available data for the C6 gene the rate of recombination 
cannot be accurately estimated but it appears that 
insufficient time has passed to produce a random 
association. 
Further investigation of the isssue of selection for 
C6 suggests that non-selection for C6 is not as clear as 
was indicated above. Results in Chapter 5 show that the 
C6 protein determining site and a further DNA plymorphism 
occur in chimpanzees. Additionally, C6 protein allele 
frequencies similar to those found in Caucasians, are 
found in rhesus monkeys (Hall and Alper 1977). These 
findings suggest that some form of selection is either; 1. 
maintaining these polymorphisms in the populations over 
great lengths of time, or 2. driving the independent 
establishment of these polymorphisms in different species. 
Chimpanzees are thought to have diverged from humans four 
to six million years ago while rhesus monkeys diverged 
a round 26 million years ago (Bulmer 1991). For 
polymorphisms to be preserved over such a length of time 
some selective advantage must arise from them (Fisher 
et al 1939, Takahata and Nei 1990, Golding 1992). 
Similarly, for several different species to establish 
identical polymorphisms independently, some form of 
selection must be operating. 
A review by Wurzner et al (1992a) includes a good 
discussion of possible beneficial effects of terminal 
complement deficiencies. It is postulated that terminal 
complement deficiencies may be beneficial in cases of 
autoimmune disease. The inability to generate the 
membrane attack complex, and therefore produce cell lysis 
through this pathway, may prevent destruction of many 
autologous cells. Wurzner et al (1992a) also suggests 
that sublytic functions of the MAC may play a role in 
disease pathogenesis, the example given is the affect of 
MAC-induced release of toxic reactive oxygen metabolites 
in the synovial fluid of rheumatoid arthritis patien s 
(Morgan et al 1988). Deficiency of any one of the 
terminal components would prevent the induction of these 
inflammatory mediators and hence limit the severity of 
disease . 
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Individuals with a deficiency in terminal complement 
components appear to have an increased susceptibility to 
meningococcal disease (review Wurzner et al 1992a), 
however there is some evidence that terminal component 
deficient individuals suffer a less severe form of the 
infection compared with complement sufficient persons 
(Ross and Densen 1984) . The mechanism for this proposed 
outcome is through a lower degree of tissue damage induced 
by activation of complement by endotoxin. Further studies 
(Lehner et al 1992) demonstrate that E. coli endotoxin 
release is induced in complement sufficient but not C6 
deficient indivi duals . Interesting findings are also 
reported for C6 deficiency in the Cape region of South 
Africa (Orren et al 1987) . In this population a higher 
than expected proportion of homozygous C6 deficient 
individuals was found in families that had experienced 
recurrent meningococcal infection. The suggested 
explanation for this is a selective advantage for terminal 
component deficiency in this population (Orren et al 
19 8 7 ) . 
Studies in rats and rabbits suggest that C6 deficiency 
may have a protective role in experimental autoimmune 
myasthenia gravis (Biesecker and Gomez 1989), Heymann 
nephritis, an experimental counterpart to human membranous 
glomerulonephritis (Groggel et al 1983) and experimental 
autoimmune thyroiditis (Inoue et al 1993). 
Thus it appears that some form of selection for C6 
deficiency may exist . C6 deficiency is not thought to 
have an absolute advantage, however there may be some form 
of heterozygote advantage under some environmental 
conditions . It is possible to postulate then that some 
selective force may operate on C6 polymorphisms tha alcer 
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protein phenotype. Perhaps particular changes in protein 
sequence confer some, as yet undetected, advantage to the 
individual. It is conceivable that DNA polymorphisms 
resulting in amino acid changes alter the binding 
efficiency of C6 to CSb or C7. The cluster of 
polymorphisms, located between exons 10 and 13, found in 
the present study, are very near the CSb binding domain of 
the C6 protein. Nakano et al (1991) localise the CSb 
binding domain to the latter two SCRs, encoded for by 
exons 12 to 14 (Hobart et al 1993a). Therefore it is 
possible that these DNA changes result in altered 
conformation of the protein in this region consequently 
changing the C6-C5b binding efficiency . A lower binding 
efficiency may be an advantage in some situations, for 
example autoirrrrnune diseases, as this may reduce tissue 
damage by the MAC . Alternatively these polymorphisms 
might increase the efficiency of binding and hence 
facilitate MAC lysis. Under varying environmental 
conditions it may be advantageous to carry these 
polymorphisms. 
This possible selective advantage may not be presently 
as strong as in the past, possibly because of better 
health-care facilities, hygiene and diet. However the 
past existence of such selection could explain both the 
trans-species polymorphisms of Chapter 5 as well as the 
linkage disequilibrium suggested for the protein 
determining and Taq I RFLP sites. 
Screening the 2802 bp coding region of C6 for 
polymorphisms identified eight sequence changes while a 
further sequence change was found in non-coding DNA. In 
total nine DNA sequences changes were identified and two 
further changes were implied . These 11 changes occurred 
over a region of 3820 bp, inferring a nucleotide 
divergence rate of 0.29 percent . Interestingly these 
changes were not randomly distributed throughout the gene, 
but were distinctly clustered. Four of these changes 
occurred in exon 11 and nine o f the 11 polymorphisms found 
were located between exons 10 and 13. Of the eight 
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sequence changes identified in the C6 coding r e gi on only 
two were silent, with the remaining six resulting in bo th 
amino acid and charge changes in the protein. Pro tein 
data has shown C6 to be highly polymorphic with a large 
number of alleles distinguished by their charge . Only two 
of the detected sequence change s found in the present 
study related to a protein phenotype, indicating that C6 
protein polymorphisms clearly underestimate DNA sequence 
changes . 
Effects of amino acid changes on protein conformati on 
are not well understood and predictions about the result 
of polymorphisms are not simple. From the present study 
it appears that some amino acid changes, which also al er 
the charge of the overall prote in molecule, do not greatly 
affect the conformation and thus migrati on of a protein 
through a gel matrix . This study identified four amino 
acid and charge - altering changes which were not evident 
from isoelectric focusing. This would seem unusual, 
however the location of these changes may be more 
important for conformation of the protein then the charge-
change alone . 
Li and Sadler (1991) have estimated the amount o f 
nucleotide diversity in humans fr om studies of publi s hed 
cDNA and genomic sequences that have been carefully 
checked for sequencing accuracy . The measure of 
variability was defined as the number of nucleotide 
differences between two sequences o f one gene . In over 75 
kb, from 49 genes , a nucleot ide diversity ranging from 
0 . 03 to 0 . 11 percent was f ound . Li and Saddlers (1991 ) 
study also demonstrated that the nucleotide differenc e s 
were not distributed evenly throughout the gene . Most o f 
the sequence pairs were identical whereas a number o f bas e 
pairs showed multiple differences. They conclude that 
this non-random distribution could be partly due t o 1 ) 
mutation rate variation, 2) sequence errors in the data, 
3) differences in sequence length and 4) statistical 
fluctuations . While this estimate of nucleotide diver s ity 
is useful it may not be truly accurate because the genes 
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examined are perhaps no t a r a ndom sampl e s i nce they were 
sequenced for their bio l ogical o r medi c al import a nce . 
The level of polymorphism found in the C6 gene i s 
high, approximately 0 . 29 percent, compared with Li and 
Sadlers' (1991) estimate and can not be easily explained 
by functional advantages. MHC genes show extraordinary 
levels of polymorphism (review Klein 1986) whi c h many 
researchers believe is convincingly ac counted f o r by the 
function of the protein (Parham et al 1989 ) . The MHC 
molecules are peptide-binding molecules which trap a 
diversity of peptides derived from the degradation of 
various proteins (Babbitt et al 1985, Bjorkman et al 1987a 
and b). An ability to bind a large number of peptides is 
seen as a selective advantage for the individual, thus the 
level of polymorphism seen in these genes and its 
advantage seem clear (Doherty et al 1975, Parnham et al 
1989) . 
Unlike theories for the MHC, the function of C6 does 
not easily explain this level of polymorphism because as 
yet there appears to be no obvious functional advantage to 
possessing such diversity in DNA sequence . This study 
presents no evidence to show whether these changes affect 
the function o f the C6 protein and therefore it is 
difficult to give a reason for their occurrence, or t o 
explain the maintenance of this diversity. It is 
theoretically possible that the chance effect of random 
drift during hominid evolution could account for the C6 
polymorphisms. 
A possible explanation for the amount and c lustering 
of DNA polymorphisms found in this gene is through gene 
conversion . High levels and non-random distributi o n o f 
polymorphisms are sometimes c onsidered evidence f o r s u ch 
an event (Stephens 1985, Sawyer 1989, Satta 1 992 ) . Gene 
conversion is a controversial topic and its existence in 
mammalian systems is not universally accepted . It was 
first recognised as a genetic mechanism in fungi (Lingre n 
1949) and has since been demonstrated in a number o f 
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eukaryotes. The evidence for this phenomenon has been i 
abberrant segregation of meiotic products. Instances in 
which one allele apparently increases in copy number while 
another decreases, have been observed in Drosophila, 
Saccharomyces and Sordania (Kitani 1962, Fogel and 
Mortimer 1969, review Wysocki and Gefter 1989). The 
mechanism of gene conversion has been the subject o f much 
attention (review Radding 1978). One explanati o n f o r gene 
conversion is that it is the result o f DNA repair 
following intragenic crossing-over (Holliday 1964) 
Crossing over produces DNA heteroduplexes, these a re 
molecules that contain one strand from one chromatid and 
the other from the homologous chromatid. As the site o f 
exchange migrates along the gene, it reaches the position 
where the two alleles differ in their sequence, leaving 
the non-complementary nucleotides unpaired. The unpaired 
region is then recognised by proof-reading enzymes which 
remove one of the nucleotides and replace it with a 
nucleotide complementary to that on the other strand . 
Since the nucleotide that is excised is chosen at random , 
different ratios of wild-type to mutant alleles result 
(Klein 1986) . 
The term gene conversion has been used for geneti c 
exchanges in higher eukaryotic organisms in which 
formation of heteroduplex, or hybrid, DNA is thought to be 
involved . Strictly, the term should only refer t o 
nonreciprocal exchanges of homologous genetic info rmati on . 
In mammals the four products of meiosis do not stay 
together and therefore the relationship of the haploid 
gametes to the original diploid germ cell can n ot be 
determined. For this reason,in mammals, it is not 
possible to identify whether meiotic recomb ination is 
reciprocal or nonreciprocal. In mammals the term is often 
used to describe incompletely-defined genetic exchanges . 
The first evidence that gene conversion occurred in 
mammals was in the fetal globin genes (Sl ight a m et al 
1980) . The conclusion for occurrence o f this mechanism 
was based on two equivalent introns in genes on the same 
166 
chromosome having a segment more similar to each other 
than to their alleli c counterpart . Since th i s first 
report o f gene conversion in mammals many examples of DNA 
transfer between member s o f mammalian multigene families 
have been reported (Mellor et al 1983, Pease et al 1983, 
Rechavi et al 1983, Gorski and Ma ch 1986, Liu et al 1987 , 
Gally and Edelman 1992 ) . 
Findings which are thought to suggest gene conversion 
are variable, ranging from almost identical segments of 
DNA between two homologous genes (Ga lly and Edelman 1992) 
to high levels and nonuniform distribution o f 
polymorphisms in a particular gene (Stephens 1985, Sawyer 
1989 , Satta 1992) . Evidence in mammals is thus far 
circumstantial and therefore cannot be conclusively 
established . 
Gene conversion is often associated with duplicated 
genes, for example C4 (Partanen and Campbell 1989, Braun 
et al 1990) and 2lhydroxylase (Urabe et al 1990, Kinoshita 
et al 1991 , Collier et al 1993 ) as well as multigene 
families (Griffiths and Watterson 199 0 , Moore et al 1992) 
Fernie et al (in preparation) suggest that the C6 gene 
arose through early duplication, and there has since been 
a collapse of the duplicated system. This hypothesis has 
been proposed as an explanation for the distribution and 
maintenance of the C6 protein allelism . Evi dence f or such 
an event is difficult to establish, however some of the 
present findings in the C6 gene could be evidence for 
this . The strongest finding suggestive o f this 
possibility is in the identification of three different 
bases at one site in exon 11 of one SLE patient . Athough 
this finding may be a result of PCR error o r 
contamination, the possibility that it is real st il l 
exists . If proven real this finding could represent 
evidence for duplicati on o f this exon, possibly as part of 
an incomplete collapse o f the duplicated system in this 
individual . Additionally it may be that the entire gene 
is duplicated and the two genes are too similar to be 
easily distinguished . This patient also possessed hree 
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proven polymorphisms in exon 11. As discussed above his 
level of sequence variation over 172 bp is surprisingly 
high but would appear less unusual if this exon was 
duplicated . Unfortunately no further time, or DNA from 
this patient were available and thus further studies could 
not be pursued. 
Additional evidence for gene duplication comes from 
chimpanzee studies by M Hobart (personal communications). 
In that study 30 chimpanzee samples were examined at the 
protein determining site in exon three, and all 30 showed 
an AB genotype . This result is not in agreement with 
Hardy-Weinberg expectations and therefore requires 
explanation. It seems unlikely that 30 samples could have 
been analysed incorrectly, however contamination of the 
PCR primers with an AB DNA sample is a simple possibility. 
Alternatively these findings may indeed be real and gene 
duplication could explain the result. However further 
evidence is needed before this hypothesis could be 
accepted . 
The components of the membrane attack system (C6 , C7 , 
C8 and C9) are thought to have a common ancestor (Discipio 
and Hugli 1989 , Setien et al 1993 , Hobart et al 1993a). 
This hypothesis is based on the similarites at both the 
protein and DNA level . The similarites in amino acid 
sequence are shown in Table 6.1 and nucleotide sequence 
comparisons are in Table 6 . 2 . Examination of the genomic 
organisation of these components presents further evidence 
for their common ancestry as the intron / exon boundaries 
are remarkably well conserved across all components 
(Hobart et al 1993a, Kaufmann et al 1993). Comparison of 
the amino acid sequences for these proteins shows that the 
region of amino acid sequence which aligns with the C6 
exon 11 is more highly conserved across all of the 
proteins than any other single region. This could 
indicate that exon 11 has been involved in gene conversion 
or duplication events among the MAC components. 
Conversion events and duplications can facilitate the 
production of polymorphisms as mismatching and unequal 
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Table 6. 1 Amino acid sequence identily of '= h e memb1 ane ar t a(·k (_'( l ll lp] PX proLP1.ns . Reqions 
c1nn n o acid sequence aJiqn with C6 amino a ci rls encoded f or by ( ' (-, P >': n r 1 ;--; . 
% Identitya for Amino acids 
Component Regionb 
Comparisons 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
C6-C 7 36 44 32 28 5 36 17 27 45 54 22 3 1 7.4 7 8 
C6-C8 A 22 20 49 28 6 32 2 40 ]7 56 
C6-C8 B 24 27 40 25 13 33 7 31 3] 47 
C6-C9 18 33 45 28 16 30 7 20 29 10 c 
0 % identity calculated using the method of Myers and Miller ( 1 988) and PC/Gene package 
h Using amino acid sequence alignments from Haefliger et al (1989) 
c Only nine amino acids of C9 correspond to this region of the C6 gene. 
C6-C 7 
C6-C8A 
C6-C8B 
C6-C9 
Total Amino Acid Sequence 
This study 
% Identity 
27 . 5 
28.4 
25 . 6 
21 . 3 
Haefliger et al (L989) 
% Identity % Conserved 
33.5 56.1 
30 . l 46.2 
28 . 4 48. 3 
26 . 6 47. 2 
n f 
17 
24 
-- '\ 
w 
~ 
Table 6 . 2 Nucleot j_de sequence identity f o r the merr~rane attack complex pro teins . Regi o ns 
refer to sections of DNA sequ e n ce t h at align with C6 exons . 
Component 6 
C6-C7 59.4 
C6-C 8A 50 . 0 
C6-C 8B 49 . 5 
C6-C9 51 . 3 
7 
55 . 2 
54 . 4 
57 . 7 
47 . 2 
8 
50 . 5 
52 . 9 
48.0 
53 . 3 
Regions 
9 
4 9 . 7 
63 . 3 
55 . 6 
55 . 5 
% Identitya 
Total 
10 11 12 13 DNA sequence 
57 . 3 61.6 55 . 7 52 . 3 54. 7 
5 4 . 2 59.5 - - 63.9 
55 . 5 56.5 - - 69.1 
55 .5 67.9 - - 61 . 8 
a% Identity cal c ulated using t h e met h od o f Myers a nd Mill er (198 8) and the compu ter pac kage 
PC / Gene 
crossing over event s can occur more easily (Petes and Fink 
1982) . Additionally these findings could suggest that 
this region of the protein is critical for the common 
function, or association, of these components. In 
contrast regions six and eight show much lower levels of 
identity across the different proteins. Thi s may suggest 
a lack of duplication / conversion events in these regions 
and possibly a less critical functional role, o r a role 
specific for each component and therefore not conserved 
across these proteins . 
Comparison of the nucleotide sequences of the genes 
for these components shows a similar trend for region 11, 
although this is not as marked as for the amino acid 
sequence . The percentage identity for region 11 is 
greater then the percentage identity for the total DNA 
sequence for C6 - C7 and C6 - C9 only , indicating that the DNA 
sequence for t hi s reg i on is not as highly conserved as is 
the amino acid sequence . This analysis shows that the 
conservation of the C6 protein and gene is not uniform 
throughout and suggests that the well conserved areas are 
functionally i mportant regions for interaction of the 
proteins . Additionally the similarites of specific areas 
could suggest that they arose from a common ancestor, 
through duplication or conversion. 
The non-random distribution of polymorphisms in the 
C6 gene can also be interpreted as evidence for mutati on 
generating mechanisms . Differential rates o f mutation 
across a gene could result in clusters of polymorphisms. 
Wolfe et al (1989) provide evidence for significant 
variation in mutation rate among regions of the mammalian 
genome . They show that the rate of some substitutions 
varies among genes and is correlated with the base 
composition of genes and their flanking DNA. Also 
proposed is that these differences in mutati on rate arise 
because mutation patterns vary with the timing of 
replication of different regions in the germline . 
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DNA mechanisms involving templated mutagenesis als o 
give rise to non-random distribution o f polymorphisms. 
Ripley (1982) suggests two models for this mechanism both 
of which involve quasi-palindromic sequences. The basic 
idea is that palindromic sequences in double-stranded DNA 
molecules have an inherent property of self-
complementarity within each single-strand of DNA . This 
complementarity permits these sequences to form uniquely 
paired DNA structures . A classical example of self -
complementarity is the formation of hairpin structures . 
In quasi-palindromic sequences where this complementarity 
is imperfect, the formation of unusual DNA structures is 
still possible. The imperfect base-pairing in these 
structures provides the potential to generate mutations in 
a templated and therefore predictable manner . 
Examination of the DNA sequences surrounding the 
polymorphisms f ound in exon 11 of the C6 gene showed there 
to be a short stretch of palindromic sequence (GCAGTAGACG) 
around the site for two identified mutations (cDNA ; 1752 
and 1753, amino acid 544). Ripley (1982) does not 
indicate a minimal number of bases required for the 
palindrome, thus it is difficult to assess whether what is 
seen in the C6 gene is sufficient for this mutational 
mechanism to occur . Several other DNA sites found to be 
polymorphic were also examined but no further palindromic 
sequences were identified. However, several sites (cDNA 
1845, Mnl I site and cDNA 1675 , Bsm I site) appeared to be 
located within regions of repetitive sequence suggesting 
mutations could arise through slippage of paired DNA 
sequences . It is possible that specific regions of a gene 
are more likely to contain polymorphisms because of the 
repetitive or palindromic nature of the surrounding DNA 
sequence. 
Although it has not been proven that any of these 
mutation-creating DNA mechanisms occur in the C6 gene it 
is evident that this non-random distribution of DNA 
polymorphisms is a phenomenon seen in other genes within 
......... 
the human genome. The significance and mechanisms for 
this occurrence however, remain to be established. 
The present study of the complement component six 
gene highlights the value of molecular analysis in studies 
of human genes. Fine level examination of DNA sequences 
is a very useful tool for understanding the structure-
function relationship of proteins, identification of 
mutations resulting in human diseases as well as studies 
of human population groups and evolution. The information 
gained from this study, in conjunction with broader 
functional analysis , significantly contributes to the 
understanding of this gene . 
Appendix 
Appendix 
Nucleotide and amino acid sequence of t he 
complement component six gene 
The numbering of the cDNA and amino acids corresponds 
to the numbering system o f Dis c ipio and Hugli (1989) in 
which the first amino acid (Cys teine ) after the 21 amino 
acid signal peptide sequence is des i gnated 1 . 
Intron / exon b oundary informati on i s from Hobart et al 
(1993a) and intron sequence data is as yet incomplete and 
is from MJ Hobart (Cambridge, UK ) . 
Key; 
Known intron sequence - ACTGTCTGA 
Exon sequence - ACTGTCATGC 
Amino acid - MetAlaArg 
Amino acid numbering is above the line and cDNA sequence 
numbering is at the end of the line 
* - polymorphic sites 
Primer position - ACGTCTGAGTG 
C6 EXON 1 
TTGA-TTGCCTTAAGG.l\.AGGCAGAA.~~l\ - GCA.A.ATATTTTCT.Z\AAATCACATTTGAATCT 
CTGACTCAGGATG ACTTGTGA.l\GGTTTACCTCAA.AAA.AGCATTTGATAT--GT ATGTAT 
-21 
-15 
* MetAlaArgArgServa ::.. LeuTyr?he 
TCTTTCATTTTAGGGCCTGGAGGCTCTCAAGGC 2:.TGGCC.?:i,GACGCTC C-::TC ':"'TGTACTTC 
- 10 -5 1 5 
174 
84 
Il e LeuLe uAs nAl a Leu I1eAs nLysG1y G1nA 1a Cys PheCysAspHis~·rA aTrp 
ATCCTGCTGA,ATGCTCTGATCAACAAGGGCC AAGCCTGCTTCTGTGATCACTATGC ATGG 144 
1 0 1 5 20 25 
Ty rGlnTrpThr SerCysSe rLys ThrCys AsnSe r GlyThrGlnS2rArgHisAr (g l 
ACTCAGmGGACCAGCTGCTCAJ\,"t,AJ\CTTGC ."A.AT CTGGA~Z\CCCAG.l:. GC.!..G.:\C."D..C,~GGTGG 2 0 G 
GTGrr.cAGCTTTGTGGCTTTTCTTTGTGTCCTGG.~l\GG.~CTCAAGGATGl'-.AGTC AGC .AJ:,,.CA 
TCAGGAGTGC A_l\CACTAAGC A .. "A.TGGG.i\J\C ATAT.l\T.rl..TATC lL~l\GT.~l\G;z.,._!!_CTrr:AC.l\J!._"A.mT 
TGG~TGA..~l\TTTG.Z\AGTCTCTCTCTTATGA~GTTGA..~l\GGA.~-TCTA - GTTTGT C~TTC 
TAC.Z\AGAACGAGGGGTTTCA.~l\GA.~~-TT.Z\ATTAAGAA- CTG- GC AACACTTTCAGTTGA 
A-ATTTAA-T-GCTTAGA.l\- CACTACCCA.l\GCTTTTTTCAA- CAGC ATACA.l\ --T-GCTT 
GCCTATAGTTAGTGAGTTAATTATAGAGA."A.--TTCTACTCA-TAAA- CGAGTCTAACAGG 
ACCTCAG 
C6 EXON 2 
C-GAAAATTTTCTTTCTTTTCTATTTATTGTAGTT.l\.ATGCTCA..l\TGA.TAC:TTTGATTATG 
,0 
L, 0 
(Ar ) gG _r 
GAGCAGGATATATGGTG.l\.ATACACTCATTCTAAGCA.l\CTTCTTCTTCATGGTTACAGACA 203 
30 3 5 4 0 4 5 
IleVa1Va1AspLysTyrTyrGlnGluAs nPheCysGluGlnI1eCysSer~ysG1rG:u 
A.l\TAGTAGTAGAT.Z\AGTACT.l\CCAGGA..~Z\ACTTTTGTG.Z\ACAGATTTGCAGC.l\ AGCAGG.l\ 2 6 3 
50 55 60 
ThrArgGluCysAsnTrpGlnArgCysPro lleAs n Cys LeuLeuGlyAspPheGlyPro 
GACTAGAGAATGTA.l\CTGGCA.~l\GATGCCCCATCAACTGCCTCCTGGGAGATT'I'TGGACC 323 
70 75 7 9 
TrpSerAspCysAspPheCyslleGluLysGln 
ATGGTCAGACTGTGACCCTTGTATTGA.li....Z\AACAGGTAGGC.l\.ACCATGGGC.l\-TTCC.l\GGh 3 58 
ATATGAATCACAATAGAGGGCTCTGA-TCCCTGAC.l\GGCTTAACAGCATAGTAATGCTG 
AATT.l:..CTTCAA-TTCTGA.AAATC.l\ACTGTCTCAGCTTCC.l\TTGAGGGJ._i~~~TTCCA-TTA 
GCAC--TTGTG ~GGGGAAGA~GGGGTTTA--TT~TGTATTT ACTG_CTTA 
C6 EXON 3 
CATTAGTA..AAAA-A-?.AGA.AATATTACCATAGGA..~.AAATCAC-GTTGTGATTGAGGAGCC 
CAGTTTTCTTAGGTACA-TTTG.2\CCTTGACCC TGCCTCAGAGTTA TA TCTTTC'TCTTCTT 
80 85 90 95 
SerLysVa l .. 'A..rgSer·:a l LeuArg PheSerG 1 n PheG lyG lyG l n ?heCys 
175 
TCCI'TTCAGTCT&A.AGTTAGATCTGTCTTGCGTCCC AGTC __ "l,,.-TTTGGGGGAC.Z\GCC .. "A.TGC -1 08 
* 100 105 110 115 
ThrG1uProLeuVa1AlaPheG_nProCys ileProSerLysLeuC~·sLysI1eGluGlu 
ACTGAGCCT CTGGTAGCCTTT,... AACCATGCATTCC ATCT,A.AGCT CTGC ,l,.!.~ll .. lc..TTG,;..-::i..c.~c: 4 6 9 
120 :25 1 ') r, ,._,o 
A.laAspCysLysAsnLysPhehrgCysAspSerG ( ly ) 
GCTGACTGCA.~GAJl.TA.A .. "A.T'T'TCGCTGTGACAGTGGTh...~TGTATTTTTG!'GA_A__4I'GTTCA G 5(; --1 
TCCCCACT AA'A..]\ATAGCTTGACT_;__i\ATCA..A...A.GTT- CTcc..;__A. TTGACT_;__Z\c -GTAGAA 
C6 EXON 4 
TTTACGCTCCAGTTTTTGTGTGCTCCCTAAP.ACTCTATC.l\A..;__I;.ACAGTG .. ~GACTTGCCT 
TC .. 4AC'I'TTACCTTGAAATTTAA.AGCATTTGAGTTTCA..l:vl.TTA..A.TA..;__~TACTTTCTAAGAT 
130 
( ly ) ArgCys il e AlaArgLys 
GATA..~TTTGTTGCATTGATTTTGTTTGCTTTTCTTGACTAGGCCGCTGCATTGCCAGAAA 523 
135 14 0 145 150 
LeuGluCysAsnGlyGluAsnAspCysGlyAspAsnS~rAspGl uArgAspCysGlyArg 
GTTAGAATGCA..A.TGGAGA.;__A.ATGACTGTGGAGACAATTCAGATGAAAGGGACTGTGGGAG 581 
155 160 165 17 0 
ThrLysAlaValCysThrArgLysTyrAsnProileProSerValGlnLeuMetGlyAsn 
GAC- .. A.-GGCAGTATGCAC.lc..CGG.~AGTATAATCCf'ATCC'.:::TAGTGT .. Z\CAGTTGATGG':";C.4.A 
175 
641 
Gl (y) 
TGGGI'ATGTAACATCTTT'I'TATCATCTTGGGGAGA..Z\CAGGTATCAGA..Z\CAP.ATGAGTCAG 644 
AGGGAGC--TGAG-TAC-TCATTGTCCATCTTCCTCATTAAA 
C6 EXON 5 
AGTAATGGAATAGGAGACCTA..~TAGAGCCAGAGA.AGCTGATTTGGC-TTCCAGCTTCCTT 
GCATGCCTCACCATGGACTAGGA..~~2\A..~~~Z\GCGGAGG-GTGGGGGA -TCCTTCA..Z\GTCA 
TT-GTCTTGAGGCAA..~~~GGTTTAGA..Z\GAGGA --TCCTTTCATATAA-T.~GGTl\AATTT 
17 6 
176 
(G l ) yPheHisPh2 
TAAAGATTGTTCTACATCTGTTGAATTCCTGAAlJl.TTACTTTGTTTCTAGGTmTCATTT~ 6~· 4 
180 185 19 0 195 
LeuAl aGlyGluProA~gG-yGluValLeuAspAsnSerPheThrG:yG yileCysLys 
CTGGC AGGAGAGC CC .Z\GAGGAG.l,..Z..GTCCTTGAT k..Z\CTCTTTCACTGGAGGAA T.~ T1~T.~A.P. 1 .._. 
200 205 210 215 
ThrVa 1 Ly sS2r S,::rl,.rgThrSer .~snPrcT'y r.Z..r9·\;a l ProAl '"=i. A sr :;:.,"?uC 1 uAsnVa. l 
220 
GlyPheGlu 
GGCTTTGAGGT.Z\ TGAC A GCCTAGC A TGGI'GGCA..Z\CTCCA..Z\CACCGTCAGTGATTAT AAGC 7 8 3 
TAAATTTCT 
C6 EXON 6 
CAGCGGCCGCCG-TCAGCCCGCCCGCC ACCGTCAGC ACC ACTGC-TCl\A--TCACAGAC-
TGCTA.A.A.AJi._TAACCTTCATTGTTTATCACCCTGTTAAGTCTCAGCTTAGGTGGCTTTTCC 
TTGAGGGAGGGTTTCCTGATATTGCCTCTCAGGGTCTTATATTTCCTGTGGGATTCC ACT 
GGTCACACAGTACTTACCTC-TTA.AGTGTTGGTG-TTATCTTTCTCTCTA..A.CTA.AACTAT 
TA.ACCCCTCAGTGCAGGA.A-TAACACTATTCTTTGTTCTCTAGCAA--TGTGTCCTCAAT 
AAATACTGGCTGAGTGC-TAA-TAAATA.A-TCATCATTTC-TTAGATATCCACAAGTCGC 
22 2 22 5 
Va lGlnTh rAl a 
TCCCACTATTTCCT_~CTTATATTTTATTTTACATGGATTTTCTCC AGGTACAAACTGC - 7~5 
230 235 24 0 2 45 
Gl uAspAspLeuLysThr AspPheTyrLysAspLeuThrSerLeuGlyH i sl\.snGl uAs n 
GAAGA TGACTTGAAAACl~,GA rnTTCTAC."l\AGGATTT.~CTTCTCTTGGAC .2:1.CA..Z\TG.~V.-AT 8 ::, ': 
25 0 255 26 0 2 65 
GlnGlnG lySer Pl-12Se rSe rG 1 nGlyG ly Se rSer PheS>?rVa 1 Pro I 1 e PheT-}'rSer 
CA}\CAAGGCTCATTCTr A..A.GTCAGGGGGGGAGCTCTTTCAGTGTACCA/,TTTTTTATTCC 9 15 
270 275 280 285 
SerLysArgSerGluAsnileAsnHisAsnSerAlaPheLysGlnAlaileGlnAlaSer 
TCAAAGAGAAGTGA.~~ATATC,i,.ACCATA-TTCTGCCTTCA.~ACAAGCC ATTCAAGCCTCT 97 5 
288 
Hi sLysLys 
CACA..~~.AAGGTATCAA4AATGGTTTCC~CCTTTTATTCTTTCTTGA..A.AATTAACAGTA- 98 4 
-TCCAGTA.ATCA-GCAATA..~GAAGGGGAGA-TTTTGATATTGTACCA.AGTATGACTTCTA 
ATACAGAT'!'TAAGTAG 
C6 EX ON 7 
TTTTTTGATCACTG-TTTCTTCTTTCTTAGAGAACACGTGCCCCCATTAC-CA-TTTAC-
TTATTGAG-TAATCTTACTGTTTTGCAC-TTGGAC-TTGGTAmTGG.Z\AAGCA.~~Z\TGAAA 
ATTATAATTTTGTACGTGAGAACATGCA.Z\TAGAGAGTGAGAATTATTGTAATTCTGTGGT 
GGGAATGA.A.ACTAATGATA..~"A.TC,~"A..TGAC-TTTA..MTGCTAGGTAC'I'TCAAC::TTmC-TT 
290 295 
AspSerS2rPheileArgil~H13 
1 ~ 8 
ACCTTTAATC.Zl..TCTTTTTACTTCTTTCTTCCATmTAGG.;TTCTAGTTTT."A.TTAGGP~TC".:' .Z-\ l O o-
300 305 315 
LysVa1MecLysValueuAsnPheI1eThrLysA1aLysAspLeuHisLeuSerAspVa~ 
TA.~Z\GTGATG,;_A.A~TCTTA..~Z\CTTCACAACGAA - GCTA.~Z\GATCTGC-C - TTTCTGATGT 1 06 7 
325 330 335 
PheLeuuysAla.;_JeuAsnH i sLeuProLeuG 1 uTyr AsnSer AlaLeuT-_1rSer .Z\rg I l ~ 
CTTTTTG.~l:),_Zl..GC ACTTAACCATCTGCCTCTAG.~Zl.. TAC.l:),_Z\CTCTGCTTTGTl-\CAGC:::: '~_ll,NT " 2 7 
3 4 0 345 35G 355 
PheAspli.sp PheGlyThrH i sTyr PheThrSerGlySerLeuGlyG lyVa l 'Iyr .~s pLeu 
ATTCGATGACTTTGGGACTCATTACTTCACCTCTGGCTCCCTGGGAGGCGTGTATGA:~T ~lo-
3 60 365 
LeuTyrGlnPheSerSerGluGluLeuLysAsnSerG ( ly ) 
TCTCTATCAGTTTAGCAGTGAGGA.Zl..CTA.~Z\GAACTCAGGT.MCTTTCTTCAGTCCTCACT 1~25 
CTTTTT A.Z\CTGGTA TGATAGCA TGCAA TACATTTTTCTCmTACTCTA TC .l\ T'I'TT .l\Jl.. TT.Z\ T 
TCTGCTTTGACTTTATTTAGATCCTGCTTTATTTCCAAA.Z\TGATATGA.Z\GAATGATA.~l:),_~ 
AATACACATTCAAAT.Z\AATA.~A.AC."A.A..~A.ATAGA.Z\AACTli.AGACCA.~~l\Jl..ATA..Z\AGA..~~~-
TAAGTATGCTTAACCACTGTGATTTTAGGCATCATATTTGTCTCTA..~Z\TTTCCTA.Z\C.~T 
CTGGGA.Z\CATCAT.A.AGCTTACACAGTAGTGGTTACCCAAAGAGGA.~~A-GCA-GCC A.l\TA 
TCTCA.AGGGAA.ACCAA-TTT 
C6 EXON 8 
ATGGGAAGGGCCAA--TGGCTC -T-TGTGCTTCTGAGGGTCAGTGCTGA.~~GGGGAGAr:G 
ATGGGCACTCACGGGACTCCTGTTCAGGATCATCTCTGGGCCCATGCAGGATTGA .. A.TCTA 
TAGGTAAAACTAACTTGAGCTGTCACTT.ZI.AGATTATGGGGACTGGGGAAGAGAGGGGCTA 
ATATAAAGTATCTGTAGATCCGAA-TGACCAG-GCACCATGTrnCCTCTTTGAATTG CA.~ 
370 375 
(G) lyLeuThrGluGluGluAla 
TGGTGC-TTCTCAGTGGTTTCTGTTTGTACTTCATCTCCT.?i..GGrnTTAA1CG.~GGJ::._A.G."t..."!:..G 
380 38 5 390 39~ 
LysHisCys a, Arg::!:leGluTr.rLysLys.l..rgVa_LeuPheJi. aLysL~·sThrL::'s·/a. 
4 00 4 0 5 4l 0 
GluHisArgCysThrThrAsnLysLeuSerGluLysHisGluG ( ly , 
CTTAGC AGCTT n TC C AGrnGTGC C CTGAGCCTGGCTGTC A TTT AC AGAC CA r: A TTGG .;TGT 
GACTGTGCTATrnTTTAGCTTTTCATTTATTTCATTTCTCrnTCCTCAGA.ACCCTGTGTG~T 
GGAATAGGGGATACA.~A.TA.A.AATAGCATTAGCATTACCTA..~~~~A.GGA.~.~TGrnTA.~GGT 
TTTCTTTATCTCATACTTAGGCTGTTTA.A.TGAAT.~-TTATTGA~TTT:::;CTCATGG.--.CA:::; 
AA 
j 
C6 EXON 9 
TGT A.."!\ TTGG AAC TTTC N::C A TG AC AG TC .i...."A. TTG AC TGGC ~-~TC AG A..;....~ CC ."!\ TG TG ,.c T A 
TCTTATTCTGGGC-CCCA..~-AC -TATGCTrL"l\C-TA..~"l\TCAGAA CAG~GCGGTTGAC-T~ 
AAAGAGTAAGGGGCAGAGTAGTCAAGGAC G GCTATATTTGC- CCTA~Tcc~GTC CT 
TAGTA.."A.CCA TGTGTTCCAGG.--.C - .-.P.TTACTTTCGGCTTCP-_"4 TGmT?."!... ~ r\.."A. T.ll....\~)\CC ':'.:\C 
TTCTCAGGGTTGTCATGAGA.."!\TTATATA..~GATGTGTGTA.."!\AGTGCCTGGCATCTACCAGA 
TGCTTAATA..~TGGTAGCTGTTAGTACTGTTAT~ATTATTTCTATTATTA..l\..~CTCCCTAC 
AGGGAGGAGGAGTGTTC.:,.,.,CTTGCTTTTTC ACTT J..SCTTTC'?T AATGG.~GCT .--.C .\ TACTGT 
ACCATCTACTTCTCCC T'TCTG'!' ACµ_l;A TA _y(] T,.,..,~TGTTTGTT,.,.,GTTrnTAG.ll...."A.":'AG~.~-z:,.. T 
41 1 41S 
42 0 425 4 3 C 
A aGluLysSerI~eserLe I eArgG _yG l ~· .2•.rgS~rG l uT-yrG ly _"?., __ ..,.p,._: ctLJe 
.'A. ~C ,'!\G."A.G.~3..J-. me:= .~ T .'?\ T C C C' TG.~. ~TCG l\GGTGG.~_; -rG.~GTG ."A~. T .~ TGG AGC .~GC T7·~GC 
44 0 445 45 0 455 
TrpGluLJysGl~·SerSerGlyLeuGluG uLysThr?heSe~GluTrpue GluSerVal 
.~TGGGAGAA .• A.GGGAGCTCTGGTCTGGAGGAG.;.?\ ~ ,"A.Ca ':'':'':'TC:TGAGTGGTTAGA."t..TC AGT 4 8 4 
460 4 r C:: 0...J 
LysG1uAsnProA1aVa1IleAspPheG1u 
G.AAGG,?:...AP.ATC Tr;CTGTGATTGACTTTr;AGGTA.."A.GA\JmA..ll....l\.."!\ATTAT~CCAGG~A,.'\:;AG 515 
ATCTAAAGTAGTTCTCTAGCAGCCCA--TTGCACATCACACAATTTATTTTCCATT,.,.,TCT 
TCTCAGACAATGA..~~GAAATGCCTTTCTTTAGTATTCATGCACA..~TG ACCTTTTTTT."!\A 
ATGTTAAATI'GCAT 
C6 EXON 10 
TCCTGGTCACTGCAAGCATACTGGCACTfa.AGAAGGTCA - - - CAGTCTGGAGGTTTTACTG 
AGGTAATGGTTAP-~GGTGAGCACGTGATTTA-ATTAGCCTATTAGTTTGTTACGTGT.~ 
GTTCTTCCATTCATCCTACTGGCA.AGTTTATTTCTTCATTTTCTCCCACTCCACA-TTTC 
TCATCT.~CTCCAACA.Z\JI.AGCCA..l\.AAC- GTCCTGGAA~~~~A.Gfa.ACATGGA..~l\GCTTCTC 
TTATCCTCTCTA.AATTTTTTGCTGCTTGAATCA.~l\TTTAATGAGGTTTCAGTAGAGCAGG 
A.AAGAGTTGCCTAACTCTTGGTCACCTATCTCAGTGCTTTGATGCATGCATAGAATACTT 
A.ATA.~l\TAACATGATATATAACC.~GTA..l\GCAACACCTCCCATGCTTCCTTCACAGTAAA 
ATTGTAGGGAAGGTA..l\GTGCCATATACATCACACCTGTCCACAGGTAGA.l\GGCTTTTGCC 
TACTGGTTCA.l\CAGGTGCAATACTATATTCTGC.A.AT.~.TCCCTTTGA..AGTGTA..~~;TTTT 
CAGGCTTTCCCTCTCATTTCAGAGA.ACTGGGCAGT.l._ATGGCA..l\CCTATTACCA.AAGGGGA 
4 66 470 
LeuhlaPr0IleValAspL2uVal Arg 
TGTGACTGGACCTCCTC~CTCCCATTITCTCCTAG '.:TTGCCCCCATCGTGG.l\CTTC.~G'T' . .\..L. 
475 4 8 0 485 4 '.? 0 
.Asn I l 2 ProCys Alc..-/a l TbrLys.;rgAsn.l..snL2uArgLys.AlaL-:: uG l nG l uT-
1
·r."t.la 
4 95 500 5 0 5 S10 
AlaLysPheAspProCysGlnCys Ala ProCysProAsnAsnGlyArgProThrLeuSe~ 
CAGCCAAGTTCGATCCTTGCC AGTGTGCTCCATGC1CT.~ATAATGGCCGACCCACCCTCT 
515 * 520 525 530 
GlyThrGl uCysLeuCysVa l CysG lnS-?rG lyThr'I\1 rGlyG l ul>.s:1Cy sG 1 uLysG 1 r. 
CAGGGACTGA.ATGTCTGTGTGTGTGTCAGAGTGGCAC'.:TATGGTGAGA.;CTGTGAGJ....~~C 
535 54 0 
SerProAspTyrLysSerA ( sn ) 
AGTCTCCAGATTATA.A.ATCCAGTAAGTATCAGGAATCTATTGTGAGGTAGATA..AGTTTTC 
1 
1659 
17 42 
C6 EXONS 11 and 12 
CCCTCCAAAGAGTATTCTA..4GTTGGTCAATTA..ZI.A.l\AGA..A....~CAAAACTTCTATTAGCAACC 
TCCACCTTGTACAGGCTCAG.Z\GGG ."l\A.G."A..TAA.li.CCTGC.?:i.....°A.l>-.AAGTGTGAGTCTC."A..GCTGTA 
ACCTACC AACTATGTG ."A..GC::TTGGG.?\.A....Z\GTTACCCAGCTTCCCTATGCCTC"l\A. TCTGTTC A 
TCCATAAAATGAGG.--,.TA..4CACCA TATCTA CTAAGG.l\ATATGA..Z\TAT.~TTATATGCGTA 
TTTATATATCAAGAATACATATACAATGCTCATA.ACATTA.."A..GCCACAACCA..l\AG~TTTCA 
TACAGGACTAAGTATGTTCATAGTTACCTCA..4A.TCCTCCTTAGAAACAGGGT."l\A.GGCATG 
GGAGTP.AGAATGTATACTACTTCCTTTA..ZI.A.~GTGTAATTTAATATGCATTCTGTTA..l\GAA 
GATGTTTATATTTATACACATATGAGTGCACATTTTT.l\AA.AGGCCTCC .lV>AGCC .ZV-G.L...~T 
ACAGAGGTTTCTTA.."A..CAGTTGAAAATAATTCATA..~TGATTGCCATTTGTTGCCATTTTAT 
TTAGGCTTATGGGAAC::AAAGTCTAA.?:i.....~GGA..?:i.....~TCAGGCAATGTGTCAGGCCCCTTGCACA 
GGTAATTTCTTTTA.ATCCTTAGAAGAACCCTATCATATCCCACA.."l\A.GGA..~GTTACTGAGC 
T.l\AAAAGTGAGG.lV,.ACC AGGTTGGCCTCACTTCC A..A....~CCC.l\AATTCAGCTGCACCATGAT 
542 ** * 55 0 
(A , snAlaValAspGly~lnT~pGlyCysTrpSer 
555 560 565 s-:-o 
SerTrpSerThrCysAspA~aThrfyr L'i-· s Ar _ S >?r .l...rgmh ~ .:::..rg~ l :::ys Asn.~sn Pro 
TTCCTGGAGTACCTGTGATGCTACTTATA..~GAGATCGAGA..~C~:::GAGAATGC AA .l\.Ji.TCC 
* 58 0 585 59 0 
AlaPr oGlnArgGlyGlyLysArgCysGluGlyGluwysArgGlnGluGluAspCys Thr 
TGCCCCCCAACGA~GAGGGAAACGCTGTGAGGGGGAGAAGC~ACAAGAGGk;GACTGCAC 
595 598 
18:; 2 
1892 
PheSerileMetGluAsnAs(n) 
AT'T'TTCAATCATGGA.~~~CAAGTAAGGCCGGGTAAcr__cAA.._~"A..GA..~TGGGTCATTTTGCCC:: 1914 
TAACTCTC.l\AT.l\ACATTGAGAGTTCA..l\ATGGTTATTAGTCTACTGCTk..~GTAAAGA..l._p.TA 
ATTAGAACTTTACCTATGCCAACACAGA..~TATTA..~TGAGCCACTGGGTCTACTG C::CGTGC 
CTTTTTCTGTGTGT.A....l\TGTTTTCTATTTAATACATATATGTATGC.l\ATGTGTACACATGT 
ATACACATAAGCATATACACACATGTAAATGTGTGTACATACATACATATACACACATAT 
600 605 610 
(As ) nGlyGlnProCysileAsnAspAspGluGluMecLysG·uval 
TTATGTTTCCCTTTTAGTGGAC.l\ACCATGTATCA..~TGATGATG.~ G~?:i.....~TG A..?:i.....~GAGGTC 
615 620 625 * 
AspLeuProGluI1eGluAlaAspSerGlyCysProGlnProVa1Pro ProG1uAsnG Y 
GATCTTCCTGAGATAG.l\AGCAGATTCCGGGTGTCCTCAGCCAGTTCCTCCAGA..?:i.....:V..TGGA 
635 
PheI lel,rg 
TTTATCCGGGTCAGCATCCTAAACCTCACTTTTGGTTT-TAGTTTTAAA.?:i.....~CCTCGA-ZI.A.~ 
GT.~TA 
2016 
2 02 5 
C6 EXONS 13 and 14 
GCCTTAAAGAGTTTAGAGAGTGTATTCATAGCATTAATAAGTTTCTGGTTTCTGCTTrA..Zl. 
6 4 0 6 45 650 
AsnG 1 uLysGlnLeuTyrLeuVa lG lyG 1 uG l nVa lGl u I 1 eSe r Cys L'?uThrG 11,-
TTAAGA.A.TG."l:\A"A.AGC AACT."A. ACTT~GT GGACAAGATGTTG.l\..~~TTTCA.TGrCTTACTG 
655 660 665 670 
PheG 1 uThr\,·a lG ly'I'"yrG 1 n'I'"yr PheArgCys LeuPro AspG lyThrT1·pJi.rgG 1 nG 1~, 
GCTTTGA,i\.ACTGTTGGATACCAGTACTTC .Zl.GATGCTTACCAGACCGGAC'C T~GAG.~C."t..AG 
675 * 
AspValGluCysGlnA (rg ) 
:_ 3 
GGGATGTGGAATGCC.~ll.CG'!'GAGA.ACTGGGCAA.ACA"ATTTTGCTTGACTACTTTACAG.l\.."A. 2 ::_ 5 9 
TGAATGTGCCCAATATAAAAACAGTA..h...A.ATCACATCCTTAGATCA..Zl.TACATTTTACTAGT 
TTTTAGTAACTCTGGTGA.AAGATTTTGTGA.Ji.GCAGAA..~"ATA..l\.."ATAGA.AG~GCTCATTTGC 
TAA.A.ACTGGATTTCCAGATTATCTCC ATATTTCAGTGTCCTGCTCCTACCTATTACTGTC 
AC.~CACAT.:i.GGACTGTG.l\..!..GT.Zl.TGCAC:TTC."l._l._l.._~GA..A...'A.TCC .:'.\GG .l..J,.GTCTGC A_'A.GCTGT.;; 
TCT ."A.AC C AC AG AC A TC TGC T'1 '7GC CC .A..."A TG TTC A.."AA -TGACGC AJ-..AA TGC TG AG 'I'C TC A..Zl. 
GAAGATGATATTTACACTCTTTATGTAACAGAAATGGGAAGTTGTGTA.."AGATGGGA ~TTT 
GTGTAAGACGTAGTTTTCGCC AAGACACTACTCCTTGGTTCATGTTCACATTCTTTACTG 
AGA-2\.AGAGTGA.."AmGAGCTTTAGGCTCTGCACATATCTGTGCTAGAGT A.AAGTGAA.AJ,._Zl.CA 
AGATTCAA.."ATAAGGCTTGAATGGGAGTCCA.."A.AGACTTATTGTGGGAGACC ATGAAGCAGA 
GTTGAGACCAGTGTCAATTAG?.ATGCCCATCACTCTGCATCAGTCATAGTGTGGTAACTT 
GCATTTGGAGA.AATCC ATTAGGGATAAGAGA.AA.."AG."AA.'A.GTGTTTCTTGA.AAGG."AA.~"AGGT 
CCCAATGATTTCATA..~"AAGTTGGATGTGTCTGGAGCCAGTTCTTTAGCA.."AGGGA- TCTCA 
GATAATGA.."A.ACTA..~"AGGGA.."ATTTTTCAATGA.."AGGGTCTGAGGG.~-.AAGCCC AGGATTCTTA 
TCCCCCAGGTTTTCTGATCAA..~"AGGAGGCACC.~.AGCTGAACAGATGCAGTl\AATCTCAT 
CAAA.AATCACCTCTTTGGTTGCACAAAATTTGCCT."AAATTTGTTGTTTATTCTGCTCCAC 
681 685 
(A) rgThrGluCy sileLysProValVa _Gln 
TA.AACACAT."A.TGAA.l!TGTTGCTCTCTTGC.."AGGG~ACGGAGTGCATCA..Z..GCC AGTTGTGCAG 
690 695 700 70 5 
GluValLeuThrileThrProPheGlnArgLeuTyrArglleGlyGluSe rileGluLeu 
GA.AGTCCTGACAATTACACCATTTCAGAGATTGTATAGA.ATTGGTGAATCC ATTGAGCTA 
710 715 720 725 
ThrCysPheLysGlyPheValValAlaGlyProSerArgTyrThrCysGlnGlyAsnSer 
ACTTGCCCCA.AAGGCTTTGTTGTTGCTGGGCCATCAAGGTACACATGCCAGGGGAATTCC 
730 735 740 
2 , ..., ~ .l.0 I 
22 47 
23 07 
TrpThrProProileSerAsnSerLeuThrCysGluLysA (sp ) 
TGGACACCACCC.?..TTTCA.AACTCTCTCACCTGTG.?..AA.."AAGGTGAGTAGCAGCTCAGTGT'T 2 3 4 7 
CTGGGGTCTGATAAGGTGGTGCACCCTGAGATTCGTAGTATAGCCTCTATAGCCATTATA 
TTTCTTAAGCACTGAGAGGCT."AA.~l\.."A.AGA-GCAAGTTTAGACAGTGTGGGTCAAACCGGA 
ACTATGCAATAGCTCTGCT."A.ATTCCCTAAGCTCATTGCCATCCTGCGTCCTTTATTCTCT 
TCTGGGCTTTTATAACGTGTG."AAAGA."AAGGGAG."AA."AGTTAACCTTTTGAATAACCTTA..~Z.. 
TAAAATTATCAGTAA.."AGCGATCTCATGG."AA.?..TTAGTGAGAACTTCAGGTTT."A.AGTATTGT 
GTCTTGGTTTCACTAGACTCCTGATCATAATAATA.AP.TTAC."A.AGGAATGTAAGTGTCAG~ 
GGAATGAATGTATGTGGA_?..GCCATAGACTTCAG.~"AAGTT."AGGATCTTTAJi..GACACTGTAG 
GCAGTATCCTCATAA-
C6 EXONS 15 and 16 
ATTTAGGTTGGA.A.AATGACACCTCATGTGCACTGGAAAGGACCTTTCAGGTGGAATATTT 
AATGACAATGTATTTAGAGAAGCCA.~l\ATG .. l\ATGATCTAACTCC .. l\AGAGATA.l\ATATGAA 
TCCTTTACCACTGCCTCTTCTCTGAATTCAAGCTTATCACTTAGAATCCATGCTGTGC AC 
745 750 
(A) spThrLeuThrLysLeuLysGlyHisCys 
GTTCTTTTCTCCTTTTTTCTTTTGTTTCAGA TA CT CTl-i.A CA!>.J., A TT .~.A .. A..AGGCC J:.. TTGT 
755 760 765 77 0 
GlnLeuGlyGlnLysGlnSerGlySerGluCysileCysMetSerProGluGluAspCys 
CAGCTGGGACAGA.l\ACAATCAGGATCTGAATGCATTTGTATGTCTCCAGA.AGAAr-ACTCT 
Se (r ) 
ACXTA . ."A.GAGATAC CCTACAGACTGTGTCTGGA...A.-TTGGGAAA...A.CCAGTCTAGTGTA..l\CC ."t,. 
l\ATTTGATGGA.;GAGCTGAGCT~TTGAAGC ACAGACATGA.i\..A.TA.A.TG.Z.....;TTTTCC ACATA 
ACTGATJ. .. TTCCTGTGCTCTGCTG .. i\..:\TTCCTCCTTCCCCATTGGGTAGC A .. A.GTTTC"'T .. "4.."t,.T 
TATCTCTCAGCCCAGTTCCCTGTTTA...i\..i\..A.TGAGATTGTTCATTATJ\..ACAGTCTCl-.TTTTG 
GTTTTAAAGACTTA..~CTTCTGCACATGTAAAA.A.CTTTAAACTCAGTTATATCAACACTTT 
CCTGTTCCTCTCACTCAAGCCC.A.GGGCTTGGAGTGGGGTGGGGA.~J\C .. A.GGCl\J.._A. . ."t>..G.?:-....t~"t.. 
ACTGGTTGGTGAGTGA.A.CACACTACATTGGCTACGTGCCCCCTGTTTTTTTCTGATCTTC 
775 78 0 
(Se ) rHisHisSerGluAspLeuCysVa _Phe 
ATATAGJ.J._A.TGC'ITGCTTTCC'I'CTCTTGGGCAGCC .. A.TCATTCAGAAGATCTCTGTGTG~':' 
785 790 795 800 
AspThrAspSerAsnAspTyrPheThrSerProAlaCysLysPheLeuAlaGluLysCys 
TGACACAGACTCCAACGATTACTTTACTTCACCCGCTTGTA.A.GTTTTTGGCTGAGA..~.TG 
805 810 815 820 
LeuAsnAsnGlnGlnLeuHisPheLeuHisileGlySerCysGlnAspGiyArgGln~eu 
TTTAAAT.l\ATCAGCAACTCCATTTTCTACATATTGGTTCCTGCCJ..AGACGGCCGCCAGTT 
825 830 835 840 
GluTrpGlyLeuGluArgThrArgLeuSerSerAsnSerThrLysLysGluSerCysGly 
AGAATGGGGTCTTGAAAGGACAAGACTTTCATCCAACAGCAC A.A.AG .. i\..i\..A.GJ.. .. ATCCTGTGG 
845 850 854 
TyrAspThrCysTyrAspTrpGluLysCysSerA (la) 
l 
2376 
2426 
2 4 38 
2 4 ,S 6 
2 ~,2 6 
2586 
2646 
CTATGACACCTGCTATGACTGGGAA..A.AATGTTCAGGTAAGTTCCA.ATGG'DSACCATACTA 2679 
AATGCTCTCACTTA.A.CCTTCATCTCAGCTAGTAC-TCATCTTTCTTA.i\..i\..i\..A.T.:V,. .. CCT~TC 
CTTAATCAA..A.ATAATTCCTTTTCATTGTA 
C6 EXON 17 
CGCC-CCCCTGGGG- TGATTTAGATAJI.AGCCAA-CCCTAATGT-CTGTGGTA.~-TC-C--
855 860 865 
(A)laSerThrSerLysCysValCysLeuLeuProProGln 
TGTCTCTCTCTCTCTC-TTACAGCCTCCACTTCCAAATGTGTCTGCCTAT'TGCCCCCACA 
870 875 880 
CysPhe LysGlyGlyAsnGlnLeuTy r CysValLysMetGly·SerSerThrSerGluLys 
GTGCTTCAAGGGTGCA.~ACC AACTCTACTGTGTCAA.~,TGGGATCATCAAC ~ ~GTGAG~~ 
890 895 900 905 
Th rLeuAs nI 1eCysGluVa1GlyTh ri leArgCys A1aAsnArgLysMetGluI1eLeu 
A.h.CATTGAACATCTGTGA,AGTGGGAACTATAAGATGTGC AA/:." AGG."l:._"f..GATGG.A A.?, TACT 
910 913 
HisPr oGlyLysCysLeuA l aSTOP 
GC ATCCTGGA..~AGTGTTTGGCCTAGC ACA.~TTACTGCTAGGCCC AGC ACAATGA~CAGAT 
TTACC ATCCCGAl\GAACCM CTCCTACA/i.,.'f\TGAG.2\.ATTCTTGC ACAJ:-.,'Z\CAGC AGACTGGC 
ATGCTCAAAGTTA(TGACAAP.AATT.ATTTTCTGTTAGTTTGAGATCATTATTCTCCCCTG 
ACTCTCCTGTTTGGGCATGTCTTATTCAGTTCCAGCTCATGACGCCCTGTAGC ATACCCC 
TAGGTACC A.A.CTTCCACAGCAGTCTCGTA..Zl.ATTCTCCTGTTCACATTGTACA.A.AA..-...TAAT 
GTGACTTCTGAGGCCCTTATGTAGCCTGTGACATTAAGCATTCTCGC A.~TTAGA.Zl.ATAAG 
AATAAAACCCATAATTTTCTTCAATGAGTTAATA..Zl.ACAGAAATCTCC AGAACCTCTGA..A!, 
CACATTCTTGAAGCCCAGCTTTCATATCTTCATTCAACAAAT,Zl.ATTTCTGAGTGTGTATA 
CAGGATGTCAAGTACTGACCAAAGTCCTGAGAACTCGGCAGATAATAAAACAGACAAA.AG 
CCTT'I'GCCTTCATGAAGCATACATTCATTCAGGGGTAGACACACA..~~~-TGA.~AT.liJI..AC 
AGGTAAATATGTAGCA-GTTTGATGGTGATAAT-G- - TTGGAGAA..~ATACA.ACACGGAAG 
GGTGAGTCCCATCCTTAATTATCATCTTA-GCAAGGAA.ATA-TCCATAACfa..AT.Zl.AACATC 
GCTGTAAGGATGATT 
185 
2717 
2837 
2 8 9 '7 
2957 
3017 
3077 
3197 
3257 
3317 
3427 
3 4 44 
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